EP3950674A1 - Pyrrole amide compound and use thereof - Google Patents
Pyrrole amide compound and use thereof Download PDFInfo
- Publication number
- EP3950674A1 EP3950674A1 EP20878312.6A EP20878312A EP3950674A1 EP 3950674 A1 EP3950674 A1 EP 3950674A1 EP 20878312 A EP20878312 A EP 20878312A EP 3950674 A1 EP3950674 A1 EP 3950674A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- alkyl
- methyl
- butyl
- phenyl
- independently
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 Pyrrole amide compound Chemical class 0.000 title claims abstract description 92
- KAESVJOAVNADME-UHFFFAOYSA-N 1H-pyrrole Natural products C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 title claims abstract description 18
- 150000001875 compounds Chemical class 0.000 claims abstract description 254
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 42
- 229940083712 aldosterone antagonist Drugs 0.000 claims abstract description 10
- 229910052794 bromium Inorganic materials 0.000 claims description 50
- 229910052801 chlorine Inorganic materials 0.000 claims description 49
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 49
- 229910052731 fluorine Inorganic materials 0.000 claims description 48
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 47
- 229910052805 deuterium Inorganic materials 0.000 claims description 45
- 125000000623 heterocyclic group Chemical group 0.000 claims description 44
- 239000003814 drug Substances 0.000 claims description 41
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 38
- 125000000217 alkyl group Chemical group 0.000 claims description 37
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 claims description 36
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 36
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 36
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 36
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 34
- 150000003839 salts Chemical class 0.000 claims description 33
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 32
- 229910052739 hydrogen Inorganic materials 0.000 claims description 30
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 30
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 30
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 28
- 125000001424 substituent group Chemical group 0.000 claims description 28
- 125000004778 2,2-difluoroethyl group Chemical group [H]C([H])(*)C([H])(F)F 0.000 claims description 26
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims description 25
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 25
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 24
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 24
- 125000002393 azetidinyl group Chemical group 0.000 claims description 24
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 24
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 24
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 24
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims description 24
- 125000002757 morpholinyl group Chemical group 0.000 claims description 24
- 125000003566 oxetanyl group Chemical group 0.000 claims description 24
- 125000000466 oxiranyl group Chemical group 0.000 claims description 24
- 125000003386 piperidinyl group Chemical group 0.000 claims description 24
- 125000004076 pyridyl group Chemical group 0.000 claims description 24
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 24
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 24
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 24
- 201000010099 disease Diseases 0.000 claims description 23
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 23
- 239000000651 prodrug Substances 0.000 claims description 22
- 229940002612 prodrug Drugs 0.000 claims description 22
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 21
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 21
- 150000002148 esters Chemical class 0.000 claims description 20
- 125000001072 heteroaryl group Chemical group 0.000 claims description 20
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 19
- 150000001204 N-oxides Chemical class 0.000 claims description 19
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims description 19
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims description 19
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 19
- 229920002554 vinyl polymer Polymers 0.000 claims description 19
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 18
- 125000003118 aryl group Chemical group 0.000 claims description 18
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 18
- 125000001624 naphthyl group Chemical group 0.000 claims description 17
- 201000009395 primary hyperaldosteronism Diseases 0.000 claims description 17
- 206010020571 Hyperaldosteronism Diseases 0.000 claims description 16
- 239000004480 active ingredient Substances 0.000 claims description 16
- 239000002207 metabolite Substances 0.000 claims description 16
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 16
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 16
- 239000012453 solvate Substances 0.000 claims description 16
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 15
- 206010020772 Hypertension Diseases 0.000 claims description 15
- 125000004432 carbon atom Chemical group C* 0.000 claims description 15
- 229910052799 carbon Inorganic materials 0.000 claims description 14
- HGCIXCUEYOPUTN-UHFFFAOYSA-N cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 claims description 14
- LPIQUOYDBNQMRZ-UHFFFAOYSA-N cyclopentene Chemical compound C1CC=CC1 LPIQUOYDBNQMRZ-UHFFFAOYSA-N 0.000 claims description 14
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 14
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 13
- 238000004519 manufacturing process Methods 0.000 claims description 13
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims description 12
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims description 12
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 claims description 12
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims description 10
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims description 10
- 125000002837 carbocyclic group Chemical group 0.000 claims description 10
- 239000003937 drug carrier Substances 0.000 claims description 10
- 208000010125 myocardial infarction Diseases 0.000 claims description 10
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims description 9
- 206010007558 Cardiac failure chronic Diseases 0.000 claims description 9
- 208000020832 chronic kidney disease Diseases 0.000 claims description 9
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 9
- RGSFGYAAUTVSQA-UHFFFAOYSA-N pentamethylene Natural products C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 claims description 9
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 8
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims description 8
- 208000006011 Stroke Diseases 0.000 claims description 8
- 208000033679 diabetic kidney disease Diseases 0.000 claims description 8
- 201000002793 renal fibrosis Diseases 0.000 claims description 8
- ZABMHLDQFJHDSC-UHFFFAOYSA-N 2,3-dihydro-1,3-oxazole Chemical compound C1NC=CO1 ZABMHLDQFJHDSC-UHFFFAOYSA-N 0.000 claims description 7
- OYJGEOAXBALSMM-UHFFFAOYSA-N 2,3-dihydro-1,3-thiazole Chemical compound C1NC=CS1 OYJGEOAXBALSMM-UHFFFAOYSA-N 0.000 claims description 7
- LWTIGYSPAXKMDG-UHFFFAOYSA-N 2,3-dihydro-1h-imidazole Chemical compound C1NC=CN1 LWTIGYSPAXKMDG-UHFFFAOYSA-N 0.000 claims description 7
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 7
- 208000001647 Renal Insufficiency Diseases 0.000 claims description 7
- 239000002671 adjuvant Substances 0.000 claims description 7
- 239000003085 diluting agent Substances 0.000 claims description 7
- 230000004761 fibrosis Effects 0.000 claims description 7
- 201000006370 kidney failure Diseases 0.000 claims description 7
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 7
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims description 7
- 239000003981 vehicle Substances 0.000 claims description 7
- KEQTWHPMSVAFDA-UHFFFAOYSA-N 2,3-dihydro-1h-pyrazole Chemical compound C1NNC=C1 KEQTWHPMSVAFDA-UHFFFAOYSA-N 0.000 claims description 6
- JKTCBAGSMQIFNL-UHFFFAOYSA-N 2,3-dihydrofuran Chemical compound C1CC=CO1 JKTCBAGSMQIFNL-UHFFFAOYSA-N 0.000 claims description 6
- VSWICNJIUPRZIK-UHFFFAOYSA-N 2-piperideine Chemical compound C1CNC=CC1 VSWICNJIUPRZIK-UHFFFAOYSA-N 0.000 claims description 6
- RSEBUVRVKCANEP-UHFFFAOYSA-N 2-pyrroline Chemical compound C1CC=CN1 RSEBUVRVKCANEP-UHFFFAOYSA-N 0.000 claims description 6
- CFBGXYDUODCMNS-UHFFFAOYSA-N cyclobutene Chemical compound C1CC=C1 CFBGXYDUODCMNS-UHFFFAOYSA-N 0.000 claims description 6
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 6
- 239000003146 anticoagulant agent Substances 0.000 claims description 5
- 239000002934 diuretic Substances 0.000 claims description 5
- 239000005541 ACE inhibitor Substances 0.000 claims description 4
- 229940127291 Calcium channel antagonist Drugs 0.000 claims description 4
- 229940122434 Calcium sensitizer Drugs 0.000 claims description 4
- 229910002651 NO3 Inorganic materials 0.000 claims description 4
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims description 4
- 239000002333 angiotensin II receptor antagonist Substances 0.000 claims description 4
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims description 4
- 239000002876 beta blocker Substances 0.000 claims description 4
- 230000001882 diuretic effect Effects 0.000 claims description 4
- 239000002461 renin inhibitor Substances 0.000 claims description 4
- 229940086526 renin-inhibitors Drugs 0.000 claims description 4
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 claims description 3
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims description 3
- 229940126317 angiotensin II receptor antagonist Drugs 0.000 claims description 3
- 229960004676 antithrombotic agent Drugs 0.000 claims description 3
- 239000000480 calcium channel blocker Substances 0.000 claims description 3
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 3
- 241000208011 Digitalis Species 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 167
- 239000000203 mixture Substances 0.000 description 114
- 239000000243 solution Substances 0.000 description 73
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 56
- 235000019439 ethyl acetate Nutrition 0.000 description 56
- 238000006243 chemical reaction Methods 0.000 description 54
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 47
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 47
- 239000007787 solid Substances 0.000 description 41
- 239000002904 solvent Substances 0.000 description 39
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 37
- 239000000460 chlorine Substances 0.000 description 37
- 150000002500 ions Chemical class 0.000 description 37
- 238000000034 method Methods 0.000 description 37
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 36
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 34
- 230000002829 reductive effect Effects 0.000 description 33
- 235000002639 sodium chloride Nutrition 0.000 description 32
- 108090000375 Mineralocorticoid Receptors Proteins 0.000 description 29
- 239000003208 petroleum Substances 0.000 description 28
- 238000010898 silica gel chromatography Methods 0.000 description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 27
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 26
- 102100021316 Mineralocorticoid receptor Human genes 0.000 description 25
- 238000012360 testing method Methods 0.000 description 25
- 229910001868 water Inorganic materials 0.000 description 24
- 239000012074 organic phase Substances 0.000 description 23
- 229940079593 drug Drugs 0.000 description 22
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 21
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 21
- 229960002478 aldosterone Drugs 0.000 description 21
- 239000000126 substance Substances 0.000 description 21
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 20
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 20
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- 230000000694 effects Effects 0.000 description 17
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 17
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 16
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 15
- 239000003153 chemical reaction reagent Substances 0.000 description 15
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 14
- 238000005160 1H NMR spectroscopy Methods 0.000 description 13
- 235000019441 ethanol Nutrition 0.000 description 13
- 238000009472 formulation Methods 0.000 description 13
- 210000004369 blood Anatomy 0.000 description 12
- 239000008280 blood Substances 0.000 description 12
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 12
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 12
- 230000000670 limiting effect Effects 0.000 description 12
- 229910052757 nitrogen Inorganic materials 0.000 description 12
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 12
- 238000011282 treatment Methods 0.000 description 12
- 208000035475 disorder Diseases 0.000 description 11
- 239000000706 filtrate Substances 0.000 description 11
- 206010019280 Heart failures Diseases 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 10
- 239000012065 filter cake Substances 0.000 description 10
- 238000010348 incorporation Methods 0.000 description 10
- 239000000543 intermediate Substances 0.000 description 10
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- 239000003826 tablet Substances 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 9
- 206010034972 Photosensitivity reaction Diseases 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 239000002552 dosage form Substances 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 229910052760 oxygen Inorganic materials 0.000 description 9
- 208000007578 phototoxic dermatitis Diseases 0.000 description 9
- 231100000018 phototoxicity Toxicity 0.000 description 9
- 238000002390 rotary evaporation Methods 0.000 description 9
- 229910052717 sulfur Inorganic materials 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 9
- WSARYNAINPBAEY-UHFFFAOYSA-N 3-fluoro-4-methylsulfonylaniline Chemical compound CS(=O)(=O)C1=CC=C(N)C=C1F WSARYNAINPBAEY-UHFFFAOYSA-N 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- NOSNHVJANRODGR-UHFFFAOYSA-N 1-(2-hydroxyethyl)-4-methyl-n-(4-methylsulfonylphenyl)-5-[2-(trifluoromethyl)phenyl]pyrrole-3-carboxamide Chemical compound CC=1C(C(=O)NC=2C=CC(=CC=2)S(C)(=O)=O)=CN(CCO)C=1C1=CC=CC=C1C(F)(F)F NOSNHVJANRODGR-UHFFFAOYSA-N 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 7
- HWWVQLHLORPEPX-UHFFFAOYSA-N CC=1C(=CNC=1C1=C(C=CC=C1)C(F)(F)F)C(=O)OCC Chemical compound CC=1C(=CNC=1C1=C(C=CC=C1)C(F)(F)F)C(=O)OCC HWWVQLHLORPEPX-UHFFFAOYSA-N 0.000 description 7
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 7
- 150000001721 carbon Chemical group 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 239000003112 inhibitor Substances 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 210000003734 kidney Anatomy 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 238000004293 19F NMR spectroscopy Methods 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 6
- 229910019142 PO4 Inorganic materials 0.000 description 6
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 6
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 125000004429 atom Chemical group 0.000 description 6
- 125000000753 cycloalkyl group Chemical group 0.000 description 6
- 239000000839 emulsion Substances 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- 235000021317 phosphate Nutrition 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 125000006413 ring segment Chemical group 0.000 description 6
- 229920006395 saturated elastomer Polymers 0.000 description 6
- 239000012312 sodium hydride Substances 0.000 description 6
- 229910000104 sodium hydride Inorganic materials 0.000 description 6
- 238000006467 substitution reaction Methods 0.000 description 6
- 238000003419 tautomerization reaction Methods 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 208000024172 Cardiovascular disease Diseases 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 5
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 5
- 125000002619 bicyclic group Chemical group 0.000 description 5
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 239000008298 dragée Substances 0.000 description 5
- 125000005842 heteroatom Chemical group 0.000 description 5
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 5
- 125000002950 monocyclic group Chemical group 0.000 description 5
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 5
- 229910052700 potassium Inorganic materials 0.000 description 5
- 239000011591 potassium Substances 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 239000000829 suppository Substances 0.000 description 5
- 208000011580 syndromic disease Diseases 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 description 4
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 description 4
- LRWRUOYIDMUSSU-UHFFFAOYSA-N CC1=C(N(C=C1C(=O)NC2=CC(=C(C=C2)S(=O)(=O)C)F)C3=CN=CC=C3)C4=CC=CC=C4C(F)(F)F Chemical compound CC1=C(N(C=C1C(=O)NC2=CC(=C(C=C2)S(=O)(=O)C)F)C3=CN=CC=C3)C4=CC=CC=C4C(F)(F)F LRWRUOYIDMUSSU-UHFFFAOYSA-N 0.000 description 4
- YICDFCBKWVSFQV-UHFFFAOYSA-N CC1=C(N(C=C1C(=O)NC2=CC(=C(C=C2)S(=O)(=O)C)F)CCO)C3=CC=CC=C3C(F)(F)F Chemical compound CC1=C(N(C=C1C(=O)NC2=CC(=C(C=C2)S(=O)(=O)C)F)CCO)C3=CC=CC=C3C(F)(F)F YICDFCBKWVSFQV-UHFFFAOYSA-N 0.000 description 4
- YQIFJPHFERILNX-UHFFFAOYSA-N CC1=C(N(C=C1C(=O)NC2=CC(=C3C(=C2)SC(=O)N3C)F)CCO)C4=CC=CC=C4C(F)(F)F Chemical compound CC1=C(N(C=C1C(=O)NC2=CC(=C3C(=C2)SC(=O)N3C)F)CCO)C4=CC=CC=C4C(F)(F)F YQIFJPHFERILNX-UHFFFAOYSA-N 0.000 description 4
- IQELJQVFQJBFRY-UHFFFAOYSA-N CC1=C(NC=C1C(=O)OCC2=CC=CC=C2)C3=CC=CC=C3C(F)(F)F Chemical compound CC1=C(NC=C1C(=O)OCC2=CC=CC=C2)C3=CC=CC=C3C(F)(F)F IQELJQVFQJBFRY-UHFFFAOYSA-N 0.000 description 4
- 241000282472 Canis lupus familiaris Species 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 108090000331 Firefly luciferases Proteins 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- 241000282567 Macaca fascicularis Species 0.000 description 4
- 102000003979 Mineralocorticoid Receptors Human genes 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 108010052090 Renilla Luciferases Proteins 0.000 description 4
- 125000003282 alkyl amino group Chemical group 0.000 description 4
- 230000003042 antagnostic effect Effects 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 4
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 4
- 229910000024 caesium carbonate Inorganic materials 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 238000013270 controlled release Methods 0.000 description 4
- 125000004122 cyclic group Chemical group 0.000 description 4
- 239000006196 drop Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 235000019253 formic acid Nutrition 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 239000003862 glucocorticoid Substances 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 230000000155 isotopic effect Effects 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 238000004806 packaging method and process Methods 0.000 description 4
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000008327 renal blood flow Effects 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 238000013268 sustained release Methods 0.000 description 4
- 239000012730 sustained-release form Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
- YXZFGWCFNVDAFY-UHFFFAOYSA-N CC1=C(N(C=C1C(=O)NC2=CC(=C(C=C2)S(=O)(=O)C)F)C3CCC3)C4=CC=CC=C4C(F)(F)F Chemical compound CC1=C(N(C=C1C(=O)NC2=CC(=C(C=C2)S(=O)(=O)C)F)C3CCC3)C4=CC=CC=C4C(F)(F)F YXZFGWCFNVDAFY-UHFFFAOYSA-N 0.000 description 3
- SPPHWTZFIILDTE-UHFFFAOYSA-N CC1=C(N(C=C1C(=O)NC2=CC(=C(C=C2)S(=O)(=O)C)F)CC3(CC3)O)C4=CC=CC=C4C(F)(F)F Chemical compound CC1=C(N(C=C1C(=O)NC2=CC(=C(C=C2)S(=O)(=O)C)F)CC3(CC3)O)C4=CC=CC=C4C(F)(F)F SPPHWTZFIILDTE-UHFFFAOYSA-N 0.000 description 3
- RLDDEVPQRMMSGL-UHFFFAOYSA-N CC1=C(N(C=C1C(=O)NC2=CC(=C(C=C2)S(=O)(=O)C)F)CC3CCO3)C4=CC=CC=C4C(F)(F)F Chemical compound CC1=C(N(C=C1C(=O)NC2=CC(=C(C=C2)S(=O)(=O)C)F)CC3CCO3)C4=CC=CC=C4C(F)(F)F RLDDEVPQRMMSGL-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 206010049418 Sudden Cardiac Death Diseases 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 230000009102 absorption Effects 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 125000004452 carbocyclyl group Chemical group 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 239000008121 dextrose Substances 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 230000029142 excretion Effects 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 239000007887 hard shell capsule Substances 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- 239000005414 inactive ingredient Substances 0.000 description 3
- 208000017169 kidney disease Diseases 0.000 description 3
- 125000005647 linker group Chemical group 0.000 description 3
- 231100000053 low toxicity Toxicity 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 239000002394 mineralocorticoid antagonist Substances 0.000 description 3
- PGSADBUBUOPOJS-UHFFFAOYSA-N neutral red Chemical compound Cl.C1=C(C)C(N)=CC2=NC3=CC(N(C)C)=CC=C3N=C21 PGSADBUBUOPOJS-UHFFFAOYSA-N 0.000 description 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 125000000160 oxazolidinyl group Chemical group 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 238000007127 saponification reaction Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000007886 soft shell capsule Substances 0.000 description 3
- 230000003595 spectral effect Effects 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000011593 sulfur Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 231100001274 therapeutic index Toxicity 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- SVBJXMHQSLTSDV-UHFFFAOYSA-N (1-phenylmethoxycyclopropyl)methanol Chemical compound C(C1=CC=CC=C1)OC1(CC1)CO SVBJXMHQSLTSDV-UHFFFAOYSA-N 0.000 description 2
- CKWAKBVQKSSTOD-UHFFFAOYSA-N (1-phenylmethoxycyclopropyl)methyl methanesulfonate Chemical compound CS(OCC1(CC1)OCC1=CC=CC=C1)(=O)=O CKWAKBVQKSSTOD-UHFFFAOYSA-N 0.000 description 2
- CUKWUWBLQQDQAC-VEQWQPCFSA-N (3s)-3-amino-4-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s,3s)-1-[[(2s)-1-[(2s)-2-[[(1s)-1-carboxyethyl]carbamoyl]pyrrolidin-1-yl]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-ox Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 CUKWUWBLQQDQAC-VEQWQPCFSA-N 0.000 description 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 2
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 description 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 2
- 0 *c1c(-c2c(*)c(*)c(*)c(*)c2*)[n](*)c(*)c1C(N(*)c1c(*)c(F)c(*)c(*)c1*)=O Chemical compound *c1c(-c2c(*)c(*)c(*)c(*)c2*)[n](*)c(*)c1C(N(*)c1c(*)c(F)c(*)c(*)c1*)=O 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- HEFXTBTYIGBJDA-UHFFFAOYSA-N 2-bromo-1-[2-(trifluoromethyl)phenyl]propan-1-one Chemical compound CC(Br)C(=O)C1=CC=CC=C1C(F)(F)F HEFXTBTYIGBJDA-UHFFFAOYSA-N 0.000 description 2
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 2
- KBEIFKMKVCDETC-UHFFFAOYSA-N 3-iodooxetane Chemical compound IC1COC1 KBEIFKMKVCDETC-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- GCNTZFIIOFTKIY-UHFFFAOYSA-N 4-hydroxypyridine Chemical compound OC1=CC=NC=C1 GCNTZFIIOFTKIY-UHFFFAOYSA-N 0.000 description 2
- QLNABVZSBDRZPF-UHFFFAOYSA-N 4-methyl-5-[2-(trifluoromethyl)phenyl]-1h-pyrrole-3-carboxylic acid Chemical compound OC(=O)C1=CNC(C=2C(=CC=CC=2)C(F)(F)F)=C1C QLNABVZSBDRZPF-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 102400000345 Angiotensin-2 Human genes 0.000 description 2
- 101800000733 Angiotensin-2 Proteins 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- 101800001288 Atrial natriuretic factor Proteins 0.000 description 2
- 102400001282 Atrial natriuretic peptide Human genes 0.000 description 2
- 101800001890 Atrial natriuretic peptide Proteins 0.000 description 2
- 102400000667 Brain natriuretic peptide 32 Human genes 0.000 description 2
- 101800002247 Brain natriuretic peptide 45 Proteins 0.000 description 2
- HELONCRAXULTEB-UHFFFAOYSA-N C(#N)C(C(=O)OCC)C(C(C1=C(C=CC=C1)C(F)(F)F)=O)C Chemical compound C(#N)C(C(=O)OCC)C(C(C1=C(C=CC=C1)C(F)(F)F)=O)C HELONCRAXULTEB-UHFFFAOYSA-N 0.000 description 2
- 102000012421 C-Type Natriuretic Peptide Human genes 0.000 description 2
- 101800000060 C-type natriuretic peptide Proteins 0.000 description 2
- UBYLNKPVZDMMSO-UHFFFAOYSA-N C1=C(C=C2C(=C1F)NC(=O)S2)[N+](=O)[O-] Chemical compound C1=C(C=C2C(=C1F)NC(=O)S2)[N+](=O)[O-] UBYLNKPVZDMMSO-UHFFFAOYSA-N 0.000 description 2
- UNWUULFVMQZDRC-UHFFFAOYSA-N CC1=C(N(C=C1C(=O)Cl)C2=CN=CC=C2)C3=CC=CC=C3C(F)(F)F Chemical compound CC1=C(N(C=C1C(=O)Cl)C2=CN=CC=C2)C3=CC=CC=C3C(F)(F)F UNWUULFVMQZDRC-UHFFFAOYSA-N 0.000 description 2
- QWOMHNJDEZMECC-UHFFFAOYSA-N CC1=C(N(C=C1C(=O)Cl)C2CCC2)C3=CC=CC=C3C(F)(F)F Chemical compound CC1=C(N(C=C1C(=O)Cl)C2CCC2)C3=CC=CC=C3C(F)(F)F QWOMHNJDEZMECC-UHFFFAOYSA-N 0.000 description 2
- NXVHKWDOYLWANX-UHFFFAOYSA-N CC1=C(N(C=C1C(=O)NC2=CC(=C(C=C2)S(=O)(=O)C)F)CCOCC3=CC=CC=C3)C4=CC=CC=C4C(F)(F)F Chemical compound CC1=C(N(C=C1C(=O)NC2=CC(=C(C=C2)S(=O)(=O)C)F)CCOCC3=CC=CC=C3)C4=CC=CC=C4C(F)(F)F NXVHKWDOYLWANX-UHFFFAOYSA-N 0.000 description 2
- ZFXYQONVTMUXOU-UHFFFAOYSA-N CC1=C(N(C=C1C(=O)O)C2=CN=CC=C2)C3=CC=CC=C3C(F)(F)F Chemical compound CC1=C(N(C=C1C(=O)O)C2=CN=CC=C2)C3=CC=CC=C3C(F)(F)F ZFXYQONVTMUXOU-UHFFFAOYSA-N 0.000 description 2
- OURMOEPXUKUBEV-UHFFFAOYSA-N CC1=C(N(C=C1C(=O)O)C2CCC2)C3=CC=CC=C3C(F)(F)F Chemical compound CC1=C(N(C=C1C(=O)O)C2CCC2)C3=CC=CC=C3C(F)(F)F OURMOEPXUKUBEV-UHFFFAOYSA-N 0.000 description 2
- OOPFFRBTSLXNDZ-UHFFFAOYSA-N CC1=C(N(C=C1C(=O)O)C2COC2)C3=CC=CC=C3C(F)(F)F Chemical compound CC1=C(N(C=C1C(=O)O)C2COC2)C3=CC=CC=C3C(F)(F)F OOPFFRBTSLXNDZ-UHFFFAOYSA-N 0.000 description 2
- PDCRHJQZESNSSB-UHFFFAOYSA-N CC1=C(N(C=C1C(=O)O)CC2(CC2)OCC3=CC=CC=C3)C4=CC=CC=C4C(F)(F)F Chemical compound CC1=C(N(C=C1C(=O)O)CC2(CC2)OCC3=CC=CC=C3)C4=CC=CC=C4C(F)(F)F PDCRHJQZESNSSB-UHFFFAOYSA-N 0.000 description 2
- AUHDSHMAUDSUCZ-UHFFFAOYSA-N CC1=C(N(C=C1C(=O)OCC2=CC=CC=C2)C3=CN=CC=C3)C4=CC=CC=C4C(F)(F)F Chemical compound CC1=C(N(C=C1C(=O)OCC2=CC=CC=C2)C3=CN=CC=C3)C4=CC=CC=C4C(F)(F)F AUHDSHMAUDSUCZ-UHFFFAOYSA-N 0.000 description 2
- DEIBVNPNDHCHPJ-UHFFFAOYSA-N CC1=C(N(C=C1C(=O)OCC2=CC=CC=C2)C3CCC3)C4=CC=CC=C4C(F)(F)F Chemical compound CC1=C(N(C=C1C(=O)OCC2=CC=CC=C2)C3CCC3)C4=CC=CC=C4C(F)(F)F DEIBVNPNDHCHPJ-UHFFFAOYSA-N 0.000 description 2
- YWSGNLDBXHUTGN-UHFFFAOYSA-N CC1=C(N(C=C1C(=O)OCC2=CC=CC=C2)CC3CCO3)C4=CC=CC=C4C(F)(F)F Chemical compound CC1=C(N(C=C1C(=O)OCC2=CC=CC=C2)CC3CCO3)C4=CC=CC=C4C(F)(F)F YWSGNLDBXHUTGN-UHFFFAOYSA-N 0.000 description 2
- AXXLZBCOHJPKAM-UHFFFAOYSA-N CCOC(=O)C1=CN(C(=C1C)C2=CC=CC=C2C(F)(F)F)C3COC3 Chemical compound CCOC(=O)C1=CN(C(=C1C)C2=CC=CC=C2C(F)(F)F)C3COC3 AXXLZBCOHJPKAM-UHFFFAOYSA-N 0.000 description 2
- VFOZTJRCGYZHFY-UHFFFAOYSA-N CCOC(=O)C1=CN(C(=C1C)C2=CC=CC=C2C(F)(F)F)CCOCC3=CC=CC=C3 Chemical compound CCOC(=O)C1=CN(C(=C1C)C2=CC=CC=C2C(F)(F)F)CCOCC3=CC=CC=C3 VFOZTJRCGYZHFY-UHFFFAOYSA-N 0.000 description 2
- JOLRNMSMQLRMGS-UHFFFAOYSA-N CN1C2=C(C=C(C=C2SC1=O)N)F Chemical compound CN1C2=C(C=C(C=C2SC1=O)N)F JOLRNMSMQLRMGS-UHFFFAOYSA-N 0.000 description 2
- UFKGDHTXQBIYLD-UHFFFAOYSA-N CN1C2=C(C=C(C=C2SC1=O)[N+](=O)[O-])F Chemical compound CN1C2=C(C=C(C=C2SC1=O)[N+](=O)[O-])F UFKGDHTXQBIYLD-UHFFFAOYSA-N 0.000 description 2
- 208000031229 Cardiomyopathies Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- AWZGZPIZDSPBRT-UHFFFAOYSA-N ClC=1NC(=C(C=1C(=O)OCC)C)C1=C(C=CC=C1)C(F)(F)F Chemical compound ClC=1NC(=C(C=1C(=O)OCC)C)C1=C(C=CC=C1)C(F)(F)F AWZGZPIZDSPBRT-UHFFFAOYSA-N 0.000 description 2
- 208000008448 Congenital adrenal hyperplasia Diseases 0.000 description 2
- 208000016998 Conn syndrome Diseases 0.000 description 2
- 102400000739 Corticotropin Human genes 0.000 description 2
- 101800000414 Corticotropin Proteins 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 240000001879 Digitalis lutea Species 0.000 description 2
- 208000007530 Essential hypertension Diseases 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- 108010001515 Galectin 4 Proteins 0.000 description 2
- 102100039556 Galectin-4 Human genes 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 101000851058 Homo sapiens Neutrophil elastase Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 208000009525 Myocarditis Diseases 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 2
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 235000019483 Peanut oil Nutrition 0.000 description 2
- YNPNZTXNASCQKK-UHFFFAOYSA-N Phenanthrene Natural products C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 2
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 2
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 108090000783 Renin Proteins 0.000 description 2
- 108700008625 Reporter Genes Proteins 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 206010041277 Sodium retention Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 206010042957 Systolic hypertension Diseases 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-WFGJKAKNSA-N acetone d6 Chemical compound [2H]C([2H])([2H])C(=O)C([2H])([2H])[2H] CSCPPACGZOOCGX-WFGJKAKNSA-N 0.000 description 2
- YRKCREAYFQTBPV-UHFFFAOYSA-N acetylacetone Chemical compound CC(=O)CC(C)=O YRKCREAYFQTBPV-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 238000005917 acylation reaction Methods 0.000 description 2
- 210000004404 adrenal cortex Anatomy 0.000 description 2
- 208000024447 adrenal gland neoplasm Diseases 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 150000001342 alkaline earth metals Chemical class 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 150000001412 amines Chemical group 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000002399 angioplasty Methods 0.000 description 2
- 229950006323 angiotensin ii Drugs 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 229920000249 biocompatible polymer Polymers 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000007887 coronary angioplasty Methods 0.000 description 2
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 2
- 229960000258 corticotropin Drugs 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- ZSWFCLXCOIISFI-UHFFFAOYSA-N cyclopentadiene Chemical compound C1C=CC=C1 ZSWFCLXCOIISFI-UHFFFAOYSA-N 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 150000001975 deuterium Chemical group 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 229920001971 elastomer Polymers 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- 229950006558 esaxerenone Drugs 0.000 description 2
- ZIUSEGSNTOUIPT-UHFFFAOYSA-N ethyl 2-cyanoacetate Chemical compound CCOC(=O)CC#N ZIUSEGSNTOUIPT-UHFFFAOYSA-N 0.000 description 2
- CUKUDVGMDUOWMG-UHFFFAOYSA-N ethyl 5-bromo-4-methyl-1h-pyrrole-3-carboxylate Chemical compound CCOC(=O)C1=CNC(Br)=C1C CUKUDVGMDUOWMG-UHFFFAOYSA-N 0.000 description 2
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 229940014259 gelatin Drugs 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 125000005456 glyceride group Chemical group 0.000 description 2
- 229960005150 glycerol Drugs 0.000 description 2
- 239000003119 guanylate cyclase activator Substances 0.000 description 2
- 150000003278 haem Chemical class 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 102000052502 human ELANE Human genes 0.000 description 2
- 150000002431 hydrogen Chemical group 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 125000002632 imidazolidinyl group Chemical group 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 108020001756 ligand binding domains Proteins 0.000 description 2
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 229960001855 mannitol Drugs 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- WGQINZCNAVXCGR-UHFFFAOYSA-N methyl 1-phenylmethoxycyclopropane-1-carboxylate Chemical compound C=1C=CC=CC=1COC1(C(=O)OC)CC1 WGQINZCNAVXCGR-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- HPNRHPKXQZSDFX-OAQDCNSJSA-N nesiritide Chemical compound C([C@H]1C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1N=CNC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 HPNRHPKXQZSDFX-OAQDCNSJSA-N 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 231100001085 no phototoxicity Toxicity 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000006408 oxalic acid Nutrition 0.000 description 2
- 239000000312 peanut oil Substances 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 125000004193 piperazinyl group Chemical group 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000002600 positron emission tomography Methods 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 208000013846 primary aldosteronism Diseases 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- 150000003233 pyrroles Chemical class 0.000 description 2
- 238000005956 quaternization reaction Methods 0.000 description 2
- 230000009103 reabsorption Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 208000037803 restenosis Diseases 0.000 description 2
- 238000009666 routine test Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 238000002603 single-photon emission computed tomography Methods 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 229940037128 systemic glucocorticoids Drugs 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 2
- 239000003451 thiazide diuretic agent Substances 0.000 description 2
- 125000001984 thiazolidinyl group Chemical group 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 230000003966 vascular damage Effects 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- WRIYPTGFYKBSFU-UHFFFAOYSA-N ()-Conen Chemical compound CCCCOP(=O)(SCC)SCC1=CC=CC=C1 WRIYPTGFYKBSFU-UHFFFAOYSA-N 0.000 description 1
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- PUSBIOFSWWHNDD-UHFFFAOYSA-N 1-[2-(trifluoromethyl)phenyl]propan-1-one Chemical compound CCC(=O)C1=CC=CC=C1C(F)(F)F PUSBIOFSWWHNDD-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- QJARBNAXWFCCKX-UHFFFAOYSA-N 2,3-dichlorobenzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC(Cl)=C1Cl QJARBNAXWFCCKX-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- GXUWICFDIIONCH-UHFFFAOYSA-N 2-(bromomethyl)-1,3-oxazole Chemical compound BrCC1=NC=CO1 GXUWICFDIIONCH-UHFFFAOYSA-N 0.000 description 1
- FWOHDAGPWDEWIB-UHFFFAOYSA-N 2-bromoethoxymethylbenzene Chemical compound BrCCOCC1=CC=CC=C1 FWOHDAGPWDEWIB-UHFFFAOYSA-N 0.000 description 1
- JIVPVXMEBJLZRO-CQSZACIVSA-N 2-chloro-5-[(1r)-1-hydroxy-3-oxo-2h-isoindol-1-yl]benzenesulfonamide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC([C@@]2(O)C3=CC=CC=C3C(=O)N2)=C1 JIVPVXMEBJLZRO-CQSZACIVSA-N 0.000 description 1
- 125000001340 2-chloroethyl group Chemical group [H]C([H])(Cl)C([H])([H])* 0.000 description 1
- 125000004398 2-methyl-2-butyl group Chemical group CC(C)(CC)* 0.000 description 1
- 125000004918 2-methyl-2-pentyl group Chemical group CC(C)(CCC)* 0.000 description 1
- 125000004922 2-methyl-3-pentyl group Chemical group CC(C)C(CC)* 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- AKUVRZKNLXYTJX-UHFFFAOYSA-N 3-benzylazetidine Chemical compound C=1C=CC=CC=1CC1CNC1 AKUVRZKNLXYTJX-UHFFFAOYSA-N 0.000 description 1
- CELKOWQJPVJKIL-UHFFFAOYSA-N 3-fluoropyridine Chemical compound FC1=CC=CN=C1 CELKOWQJPVJKIL-UHFFFAOYSA-N 0.000 description 1
- 125000004917 3-methyl-2-butyl group Chemical group CC(C(C)*)C 0.000 description 1
- 125000004919 3-methyl-2-pentyl group Chemical group CC(C(C)*)CC 0.000 description 1
- 125000004921 3-methyl-3-pentyl group Chemical group CC(CC)(CC)* 0.000 description 1
- NCGICGYLBXGBGN-UHFFFAOYSA-N 3-morpholin-4-yl-1-oxa-3-azonia-2-azanidacyclopent-3-en-5-imine;hydrochloride Chemical compound Cl.[N-]1OC(=N)C=[N+]1N1CCOCC1 NCGICGYLBXGBGN-UHFFFAOYSA-N 0.000 description 1
- POILWHVDKZOXJZ-UHFFFAOYSA-N 4-hydroxypent-3-en-2-one Chemical compound CC(O)=CC(C)=O POILWHVDKZOXJZ-UHFFFAOYSA-N 0.000 description 1
- 125000004920 4-methyl-2-pentyl group Chemical group CC(CC(C)*)C 0.000 description 1
- 101150059573 AGTR1 gene Proteins 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 208000003200 Adenoma Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010001935 American trypanosomiasis Diseases 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 208000031295 Animal disease Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 102100040214 Apolipoprotein(a) Human genes 0.000 description 1
- 206010003130 Arrhythmia supraventricular Diseases 0.000 description 1
- 208000031104 Arterial Occlusive disease Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 208000033386 Buerger disease Diseases 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- KYVLHGIMPHGMNC-UHFFFAOYSA-N CC1=C(C2=C(C(F)(F)F)C=CC=C2)N(C(CO)CCl)C=C1C(NC(C=C1)=CC(F)=C1S(C)(=O)=O)=O Chemical compound CC1=C(C2=C(C(F)(F)F)C=CC=C2)N(C(CO)CCl)C=C1C(NC(C=C1)=CC(F)=C1S(C)(=O)=O)=O KYVLHGIMPHGMNC-UHFFFAOYSA-N 0.000 description 1
- YYMVHXHJLHJOBJ-UHFFFAOYSA-N CC1=C(N(C=C1C(=O)Cl)CC2(CC2)OCC3=CC=CC=C3)C4=CC=CC=C4C(F)(F)F Chemical compound CC1=C(N(C=C1C(=O)Cl)CC2(CC2)OCC3=CC=CC=C3)C4=CC=CC=C4C(F)(F)F YYMVHXHJLHJOBJ-UHFFFAOYSA-N 0.000 description 1
- IFIZSNMLRPZSPE-UHFFFAOYSA-N CC1=C(N(C=C1C(=O)Cl)CCOCC2=CC=CC=C2)C3=CC=CC=C3C(F)(F)F Chemical compound CC1=C(N(C=C1C(=O)Cl)CCOCC2=CC=CC=C2)C3=CC=CC=C3C(F)(F)F IFIZSNMLRPZSPE-UHFFFAOYSA-N 0.000 description 1
- OURGCDRNVYFABR-UHFFFAOYSA-N CC1=C(N(C=C1C(=O)NC2=CC(=C(C=C2)S(=O)(=O)C)F)CC3(CC3)OCC4=CC=CC=C4)C5=CC=CC=C5C(F)(F)F Chemical compound CC1=C(N(C=C1C(=O)NC2=CC(=C(C=C2)S(=O)(=O)C)F)CC3(CC3)OCC4=CC=CC=C4)C5=CC=CC=C5C(F)(F)F OURGCDRNVYFABR-UHFFFAOYSA-N 0.000 description 1
- NMNHJJLDODISEF-UHFFFAOYSA-N CC1=C(N(C=C1C(=O)NC2=CC(=C3C(=C2)SC(=O)N3C)F)CCOCC4=CC=CC=C4)C5=CC=CC=C5C(F)(F)F Chemical compound CC1=C(N(C=C1C(=O)NC2=CC(=C3C(=C2)SC(=O)N3C)F)CCOCC4=CC=CC=C4)C5=CC=CC=C5C(F)(F)F NMNHJJLDODISEF-UHFFFAOYSA-N 0.000 description 1
- OIENSHDZULRHCH-UHFFFAOYSA-N CC1=C(N(C=C1C(=O)O)CC2CCO2)C3=CC=CC=C3C(F)(F)F Chemical compound CC1=C(N(C=C1C(=O)O)CC2CCO2)C3=CC=CC=C3C(F)(F)F OIENSHDZULRHCH-UHFFFAOYSA-N 0.000 description 1
- KXBXNTLLSCZNNI-UHFFFAOYSA-N CC1=C(N(C=C1C(=O)O)CCOCC2=CC=CC=C2)C3=CC=CC=C3C(F)(F)F Chemical compound CC1=C(N(C=C1C(=O)O)CCOCC2=CC=CC=C2)C3=CC=CC=C3C(F)(F)F KXBXNTLLSCZNNI-UHFFFAOYSA-N 0.000 description 1
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 1
- WGGIGEUJARDGHS-UHFFFAOYSA-N CCOC(=O)C1=CN(C(=C1C)C2=CC=CC=C2C(F)(F)F)CC3(CC3)OCC4=CC=CC=C4 Chemical compound CCOC(=O)C1=CN(C(=C1C)C2=CC=CC=C2C(F)(F)F)CC3(CC3)OCC4=CC=CC=C4 WGGIGEUJARDGHS-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010007556 Cardiac failure acute Diseases 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
- 208000006029 Cardiomegaly Diseases 0.000 description 1
- 208000024699 Chagas disease Diseases 0.000 description 1
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 1
- 229940127328 Cholesterol Synthesis Inhibitors Drugs 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010056370 Congestive cardiomyopathy Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 1
- 208000014311 Cushing syndrome Diseases 0.000 description 1
- PMPVIKIVABFJJI-UHFFFAOYSA-N Cyclobutane Chemical compound C1CCC1 PMPVIKIVABFJJI-UHFFFAOYSA-N 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- GSNUFIFRDBKVIE-UHFFFAOYSA-N DMF Natural products CC1=CC=C(C)O1 GSNUFIFRDBKVIE-UHFFFAOYSA-N 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 206010012758 Diastolic hypertension Diseases 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 1
- 201000010046 Dilated cardiomyopathy Diseases 0.000 description 1
- JRWZLRBJNMZMFE-UHFFFAOYSA-N Dobutamine Chemical compound C=1C=C(O)C(O)=CC=1CCNC(C)CCC1=CC=C(O)C=C1 JRWZLRBJNMZMFE-UHFFFAOYSA-N 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 206010048554 Endothelial dysfunction Diseases 0.000 description 1
- 102000002045 Endothelin Human genes 0.000 description 1
- 108050009340 Endothelin Proteins 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- XLYOFNOQVPJJNP-ZSJDYOACSA-N Heavy water Chemical compound [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- 208000029422 Hypernatremia Diseases 0.000 description 1
- 206010055171 Hypertensive nephropathy Diseases 0.000 description 1
- 208000019025 Hypokalemia Diseases 0.000 description 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 1
- 206010022562 Intermittent claudication Diseases 0.000 description 1
- KLDXJTOLSGUMSJ-JGWLITMVSA-N Isosorbide Chemical compound O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 KLDXJTOLSGUMSJ-JGWLITMVSA-N 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
- 241000254158 Lampyridae Species 0.000 description 1
- 229940127470 Lipase Inhibitors Drugs 0.000 description 1
- 108010033266 Lipoprotein(a) Proteins 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- 206010027525 Microalbuminuria Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 229920000715 Mucilage Polymers 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 206010028594 Myocardial fibrosis Diseases 0.000 description 1
- XKLMZUWKNUAPSZ-UHFFFAOYSA-N N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide Chemical compound COC1=CC=CC=C1OCC(O)CN1CCN(CC(=O)NC=2C(=CC=CC=2C)C)CC1 XKLMZUWKNUAPSZ-UHFFFAOYSA-N 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- 108020001621 Natriuretic Peptide Proteins 0.000 description 1
- 102000004571 Natriuretic peptide Human genes 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- MHABMANUFPZXEB-UHFFFAOYSA-N O-demethyl-aloesaponarin I Natural products O=C1C2=CC=CC(O)=C2C(=O)C2=C1C=C(O)C(C(O)=O)=C2C MHABMANUFPZXEB-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 108010016731 PPAR gamma Proteins 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- SCKXCAADGDQQCS-UHFFFAOYSA-N Performic acid Chemical compound OOC=O SCKXCAADGDQQCS-UHFFFAOYSA-N 0.000 description 1
- 206010034464 Periarthritis Diseases 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 102100038831 Peroxisome proliferator-activated receptor alpha Human genes 0.000 description 1
- 102100038824 Peroxisome proliferator-activated receptor delta Human genes 0.000 description 1
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 1
- 229940123263 Phosphodiesterase 3 inhibitor Drugs 0.000 description 1
- 229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- 208000010067 Pituitary ACTH Hypersecretion Diseases 0.000 description 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
- 208000020627 Pituitary-dependent Cushing syndrome Diseases 0.000 description 1
- 208000002151 Pleural effusion Diseases 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 206010036030 Polyarthritis Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 206010037423 Pulmonary oedema Diseases 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 208000003782 Raynaud disease Diseases 0.000 description 1
- 208000012322 Raynaud phenomenon Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 102100028255 Renin Human genes 0.000 description 1
- 206010038563 Reocclusion Diseases 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 201000004239 Secondary hypertension Diseases 0.000 description 1
- 239000004280 Sodium formate Substances 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 241000589970 Spirochaetales Species 0.000 description 1
- 208000007718 Stable Angina Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 206010043540 Thromboangiitis obliterans Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- NGBFQHCMQULJNZ-UHFFFAOYSA-N Torsemide Chemical compound CC(C)NC(=O)NS(=O)(=O)C1=CN=CC=C1NC1=CC=CC(C)=C1 NGBFQHCMQULJNZ-UHFFFAOYSA-N 0.000 description 1
- FNYLWPVRPXGIIP-UHFFFAOYSA-N Triamterene Chemical compound NC1=NC2=NC(N)=NC(N)=C2N=C1C1=CC=CC=C1 FNYLWPVRPXGIIP-UHFFFAOYSA-N 0.000 description 1
- UHWVSEOVJBQKBE-UHFFFAOYSA-N Trimetazidine Chemical compound COC1=C(OC)C(OC)=CC=C1CN1CCNCC1 UHWVSEOVJBQKBE-UHFFFAOYSA-N 0.000 description 1
- 241000223109 Trypanosoma cruzi Species 0.000 description 1
- 208000007814 Unstable Angina Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 206010047281 Ventricular arrhythmia Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000004097 X-ray Buerger Methods 0.000 description 1
- JNSBEPKGFVENFS-UHFFFAOYSA-N [2-(trifluoromethyl)phenyl]boronic acid Chemical compound OB(O)C1=CC=CC=C1C(F)(F)F JNSBEPKGFVENFS-UHFFFAOYSA-N 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- BZKPWHYZMXOIDC-UHFFFAOYSA-N acetazolamide Chemical compound CC(=O)NC1=NN=C(S(N)(=O)=O)S1 BZKPWHYZMXOIDC-UHFFFAOYSA-N 0.000 description 1
- 229960000571 acetazolamide Drugs 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 125000005042 acyloxymethyl group Chemical group 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229950006790 adenosine phosphate Drugs 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 206010001323 adrenal adenoma Diseases 0.000 description 1
- 208000015234 adrenal cortex adenoma Diseases 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 201000005188 adrenal gland cancer Diseases 0.000 description 1
- 239000000808 adrenergic beta-agonist Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 239000002170 aldosterone antagonist Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 229940061720 alpha hydroxy acid Drugs 0.000 description 1
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- XSDQTOBWRPYKKA-UHFFFAOYSA-N amiloride Chemical compound NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N XSDQTOBWRPYKKA-UHFFFAOYSA-N 0.000 description 1
- 229960002576 amiloride Drugs 0.000 description 1
- PBSXKCQOTWYLMQ-LWECRCKRSA-N anaritide Chemical compound C([C@@H](C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@H](CS)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CCCNC(N)=N)C1=CC=CC=C1 PBSXKCQOTWYLMQ-LWECRCKRSA-N 0.000 description 1
- 108010005565 anaritide Proteins 0.000 description 1
- 229950004772 anaritide Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000000181 anti-adherent effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 239000003911 antiadherent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 150000004982 aromatic amines Chemical class 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 125000005228 aryl sulfonate group Chemical group 0.000 description 1
- 125000000732 arylene group Chemical group 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000001746 atrial effect Effects 0.000 description 1
- 125000004069 aziridinyl group Chemical group 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- KXVUSQIDCZRUKF-UHFFFAOYSA-N bromocyclobutane Chemical compound BrC1CCC1 KXVUSQIDCZRUKF-UHFFFAOYSA-N 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 229960004064 bumetanide Drugs 0.000 description 1
- MAEIEVLCKWDQJH-UHFFFAOYSA-N bumetanide Chemical compound CCCCNC1=CC(C(O)=O)=CC(S(N)(=O)=O)=C1OC1=CC=CC=C1 MAEIEVLCKWDQJH-UHFFFAOYSA-N 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 229940097217 cardiac glycoside Drugs 0.000 description 1
- 239000002368 cardiac glycoside Substances 0.000 description 1
- NSQLIUXCMFBZME-MPVJKSABSA-N carperitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 NSQLIUXCMFBZME-MPVJKSABSA-N 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 229940023913 cation exchange resins Drugs 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 229910052729 chemical element Inorganic materials 0.000 description 1
- 229960001657 chlorpromazine hydrochloride Drugs 0.000 description 1
- 229960001523 chlortalidone Drugs 0.000 description 1
- 230000001906 cholesterol absorption Effects 0.000 description 1
- 239000003354 cholesterol ester transfer protein inhibitor Substances 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000002517 constrictor effect Effects 0.000 description 1
- 230000008094 contradictory effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000006240 deamidation Effects 0.000 description 1
- 238000006298 dechlorination reaction Methods 0.000 description 1
- 238000007257 deesterification reaction Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- CARVNSROHCBVAO-BUGJESOBSA-N depelestat Chemical compound O=C([C@H](C(C)C)NC(=O)CNC(=O)[C@@H]1CSSC[C@@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N2CCC[C@H]2C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H]2C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC=3C=CC=CC=3)C(=O)N[C@@H](CC=3C=CC=CC=3)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=3C4=CC=CC=C4NC=3)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=3C=CC=CC=3)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@H]3CSSC[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=4C=CC(O)=CC=4)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC=4C=CC(O)=CC=4)NC(=O)[C@H]4N(CCC4)C(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC3=O)C(C)C)CSSC2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(C)C)[C@@H](C)CC)C(C)C)=O)[C@@H](C)CC)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(O)=O)N1CCC[C@H]1C(O)=O CARVNSROHCBVAO-BUGJESOBSA-N 0.000 description 1
- 108010077021 depelestat Proteins 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 229940120124 dichloroacetate Drugs 0.000 description 1
- JXTHNDFMNIQAHM-UHFFFAOYSA-N dichloroacetic acid Chemical compound OC(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 1
- 229960005156 digoxin Drugs 0.000 description 1
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 1
- HXITXNWTGFUOAU-UHFFFAOYSA-N dihydroxy-phenylborane Natural products OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 1
- FSBVERYRVPGNGG-UHFFFAOYSA-N dimagnesium dioxido-bis[[oxido(oxo)silyl]oxy]silane hydrate Chemical compound O.[Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O FSBVERYRVPGNGG-UHFFFAOYSA-N 0.000 description 1
- GPAYUJZHTULNBE-UHFFFAOYSA-N diphenylphosphine Chemical compound C=1C=CC=CC=1PC1=CC=CC=C1 GPAYUJZHTULNBE-UHFFFAOYSA-N 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- SPBWMYPZWNFWES-UHFFFAOYSA-N disodium;azanylidyneoxidanium;iron(2+);pentacyanide;dihydrate Chemical compound O.O.[Na+].[Na+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].[O+]#N SPBWMYPZWNFWES-UHFFFAOYSA-N 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 229960001089 dobutamine Drugs 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 229940052760 dopamine agonists Drugs 0.000 description 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 210000000613 ear canal Anatomy 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000008694 endothelial dysfunction Effects 0.000 description 1
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- 229960001433 erlotinib Drugs 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- MMDOYVVZUVZLHQ-UHFFFAOYSA-N ethyl 4-methyl-1h-pyrrole-3-carboxylate Chemical compound CCOC(=O)C1=CNC=C1C MMDOYVVZUVZLHQ-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- KTWOOEGAPBSYNW-UHFFFAOYSA-N ferrocene Chemical compound [Fe+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 KTWOOEGAPBSYNW-UHFFFAOYSA-N 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012847 fine chemical Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- ANSXAPJVJOKRDJ-UHFFFAOYSA-N furo[3,4-f][2]benzofuran-1,3,5,7-tetrone Chemical compound C1=C2C(=O)OC(=O)C2=CC2=C1C(=O)OC2=O ANSXAPJVJOKRDJ-UHFFFAOYSA-N 0.000 description 1
- 229960003883 furosemide Drugs 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 229960004275 glycolic acid Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 229940126514 guanylate cyclase activator Drugs 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 125000004438 haloalkoxy group Chemical group 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 1
- 150000002390 heteroarenes Chemical class 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical group [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 229960002003 hydrochlorothiazide Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- RCCPEORTSYDPMB-UHFFFAOYSA-N hydroxy benzenecarboximidothioate Chemical compound OSC(=N)C1=CC=CC=C1 RCCPEORTSYDPMB-UHFFFAOYSA-N 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 208000015210 hypertensive heart disease Diseases 0.000 description 1
- 230000004179 hypothalamic–pituitary–adrenal axis Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
- 229960002411 imatinib Drugs 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- NDDAHWYSQHTHNT-UHFFFAOYSA-N indapamide Chemical compound CC1CC2=CC=CC=C2N1NC(=O)C1=CC=C(Cl)C(S(N)(=O)=O)=C1 NDDAHWYSQHTHNT-UHFFFAOYSA-N 0.000 description 1
- 229960004569 indapamide Drugs 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 208000021156 intermittent vascular claudication Diseases 0.000 description 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 201000007170 intrinsic cardiomyopathy Diseases 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- OCVXZQOKBHXGRU-UHFFFAOYSA-N iodine(1+) Chemical compound [I+] OCVXZQOKBHXGRU-UHFFFAOYSA-N 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 230000019948 ion homeostasis Effects 0.000 description 1
- 150000008040 ionic compounds Chemical class 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- 229940039009 isoproterenol Drugs 0.000 description 1
- 229960002479 isosorbide Drugs 0.000 description 1
- MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 description 1
- 229960000201 isosorbide dinitrate Drugs 0.000 description 1
- YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical compound [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 description 1
- 229960003827 isosorbide mononitrate Drugs 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- WHXMKTBCFHIYNQ-SECBINFHSA-N levosimendan Chemical compound C[C@@H]1CC(=O)NN=C1C1=CC=C(NN=C(C#N)C#N)C=C1 WHXMKTBCFHIYNQ-SECBINFHSA-N 0.000 description 1
- 229960000692 levosimendan Drugs 0.000 description 1
- 230000001795 light effect Effects 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000002171 loop diuretic Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229960001708 magnesium carbonate Drugs 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 229940037627 magnesium lauryl sulfate Drugs 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- HBNDBUATLJAUQM-UHFFFAOYSA-L magnesium;dodecyl sulfate Chemical compound [Mg+2].CCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCOS([O-])(=O)=O HBNDBUATLJAUQM-UHFFFAOYSA-L 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- FLOSMHQXBMRNHR-DAXSKMNVSA-N methazolamide Chemical compound CC(=O)\N=C1/SC(S(N)(=O)=O)=NN1C FLOSMHQXBMRNHR-DAXSKMNVSA-N 0.000 description 1
- 229960004083 methazolamide Drugs 0.000 description 1
- KPJWVJURYXOHOO-UHFFFAOYSA-N methyl 1-hydroxycyclopropane-1-carboxylate Chemical compound COC(=O)C1(O)CC1 KPJWVJURYXOHOO-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- AQCHWTWZEMGIFD-UHFFFAOYSA-N metolazone Chemical compound CC1NC2=CC(Cl)=C(S(N)(=O)=O)C=C2C(=O)N1C1=CC=CC=C1C AQCHWTWZEMGIFD-UHFFFAOYSA-N 0.000 description 1
- 229960002817 metolazone Drugs 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 230000003228 microsomal effect Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- PZRHRDRVRGEVNW-UHFFFAOYSA-N milrinone Chemical compound N1C(=O)C(C#N)=CC(C=2C=CN=CC=2)=C1C PZRHRDRVRGEVNW-UHFFFAOYSA-N 0.000 description 1
- 229960003574 milrinone Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003506 n-propoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 239000000692 natriuretic peptide Substances 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000009125 negative feedback regulation Effects 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 230000002988 nephrogenic effect Effects 0.000 description 1
- 201000009925 nephrosclerosis Diseases 0.000 description 1
- 229960001267 nesiritide Drugs 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000008587 neuronal excitability Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 231100000905 neutral red uptake (NRU) test Toxicity 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- 108020004017 nuclear receptors Proteins 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 208000001797 obstructive sleep apnea Diseases 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 229940082615 organic nitrates used in cardiac disease Drugs 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229940116315 oxalic acid Drugs 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 description 1
- 108091008765 peroxisome proliferator-activated receptors β/δ Proteins 0.000 description 1
- 150000004965 peroxy acids Chemical class 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002570 phosphodiesterase III inhibitor Substances 0.000 description 1
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 description 1
- 231100000760 phototoxic Toxicity 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 208000010916 pituitary tumor Diseases 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 208000030428 polyarticular arthritis Diseases 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 230000009090 positive inotropic effect Effects 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 208000024896 potassium deficiency disease Diseases 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 239000003286 potassium sparing diuretic agent Substances 0.000 description 1
- 229940097241 potassium-sparing diuretic Drugs 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 201000001474 proteinuria Diseases 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 208000005333 pulmonary edema Diseases 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 208000002815 pulmonary hypertension Diseases 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 229960000213 ranolazine Drugs 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000036454 renin-angiotensin system Effects 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000003590 rho kinase inhibitor Substances 0.000 description 1
- WXXSNCNJFUAIDG-UHFFFAOYSA-N riociguat Chemical compound N1=C(N)C(N(C)C(=O)OC)=C(N)N=C1C(C1=CC=CN=C11)=NN1CC1=CC=CC=C1F WXXSNCNJFUAIDG-UHFFFAOYSA-N 0.000 description 1
- 229960000529 riociguat Drugs 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000010956 selective crystallization Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 229960003310 sildenafil Drugs 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical class O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- HLBBKKJFGFRGMU-UHFFFAOYSA-M sodium formate Chemical compound [Na+].[O-]C=O HLBBKKJFGFRGMU-UHFFFAOYSA-M 0.000 description 1
- 235000019254 sodium formate Nutrition 0.000 description 1
- 229940083618 sodium nitroprusside Drugs 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- RSIJVJUOQBWMIM-UHFFFAOYSA-L sodium sulfate decahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].[O-]S([O-])(=O)=O RSIJVJUOQBWMIM-UHFFFAOYSA-L 0.000 description 1
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical class [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 229960003787 sorafenib Drugs 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229930002534 steroid glycoside Natural products 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 150000008143 steroidal glycosides Chemical class 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical compound [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- IEHKWSGCTWLXFU-IIBYNOLFSA-N tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C([C]4C=CC=CC4=N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 IEHKWSGCTWLXFU-IIBYNOLFSA-N 0.000 description 1
- 229960000835 tadalafil Drugs 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 230000009424 thromboembolic effect Effects 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 108090000721 thyroid hormone receptors Proteins 0.000 description 1
- 102000004217 thyroid hormone receptors Human genes 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 238000003354 tissue distribution assay Methods 0.000 description 1
- 229960005461 torasemide Drugs 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 229960001288 triamterene Drugs 0.000 description 1
- 125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- 229960001177 trimetazidine Drugs 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Definitions
- the present invention belongs to the field of pharmaceuticals, and specifically relates to a pyrrole amide compound and the use thereof. It further relates to a pharmaceutical composition comprising the compound.
- the compound or the pharmaceutical composition can be used as a mineralocorticoid receptor antagonist.
- MR Mineralocorticoid Receptor
- aldosterone is a nuclear hormone receptor activated by aldosterone, which regulates the expression of many genes involved in electrolyte homeostasis and cardiovascular diseases.
- the increase in circulating aldosterone increases blood pressure through its effect on urinary sodium excretion, and potentially affects the brain, heart, and vascular system at the same time.
- hyperaldosteronism is related to many physiological processes that lead to kidney and cardiovascular diseases.
- hyperaldosteronism is usually caused by aldosterone-producing adenomas, patients with refractory hypertension often have elevated aldosterone levels, commonly referred to as "aldosterone escape", which is due to increased serum potassium levels or residual AT1R activity. Hyperaldosteronism and aldosterone escape typically lead to increased MR activity. It has been proven that MR antagonists can be effective antihypertensive agents and can also be effective in the treatment of heart failure and primary aldoster
- Aldosterone is a steroid hormone formed in the adrenal cortex. Its production greatly depends on renal blood flow and is indirectly regulated. Any reduction in renal blood flow causes the enzyme renin in the kidney to be released and enter the circulating blood. This in turn activates the formation of angiotensin II, which on the one hand has a constrictive effect on arterial blood vessels, but on the other hand also stimulates the formation of aldosterone in the adrenal cortex.
- the kidney is used as a blood pressure sensor in the blood circulation, and thus indirectly as a volume sensor, and the serious loss of volume is offset by the renin-angiotensin-aldosterone system. This is achieved on the one hand by increasing blood pressure (angiotensin II effect), on the other hand by increasing the reabsorption of sodium and water in the kidney to rebalance the filling state of the vascular system (aldosterone effect).
- the control system can be damaged in various ways. For example, a chronic decrease in renal blood flow (eg, due to heart failure and the resulting blood blockage in the venous system) results in chronic excess release of aldosterone. This is followed by the expansion of blood volume and thereby increasing the weakness of the heart by increasing the supply of blood volume to the heart. The obstruction of blood in the lungs, along with shortness of breath and the formation of edema of the limbs, and ascites and pleural effusion may result from this; renal blood flow decreases further. In addition, excessive aldosterone leads to a decrease in the potassium concentration in the blood and extracellular fluid. In myocardium that has been damaged in other ways before, if there is a deviation below the critical minimum level, it may induce fatal cardiac arrhythmia. This is likely to be one of the main causes of sudden cardiac death that often occurs in patients with heart failure.
- aldosterone determines many of the myocardial remodeling processes that are typically observed in heart failure.
- hyperaldosteronism is a decisive component of the pathogenesis and prognosis of heart failure, which can be initially induced by various types of injury, such as myocardial infarction, myocardial inflammation, or hypertension.
- This hypothesis is supported by the fact that in an extensive clinical study of patients with chronic heart failure and post-acute myocardial infarction through the use of aldosterone antagonists, overall mortality was significantly reduced ( B. Pitt, F. Zannad, WJ Remme et al., N. Engl. J. Med. ML 709-717 (1999 ); B. Pitt, W. Remme, F. Zannad et al., N. Engl. J. Med 1309-1321 (2003 )).
- MR MR regulates sodium retention, potassium excretion, and water balance in response to aldosterone.
- the expression of MR in the brain also seems to play a role in controlling neuronal excitability, negative feedback regulation of the hypothalamic-pituitary adrenal axis, and cognitive aspects of behavioral performance ( Castren et al., J. of Neuroendocrinology, 3, 461-66 (1993 )).
- Increased levels of aldosterone or excessive stimulation of mineralocorticoid receptors are related to some physiological disorders or pathological conditions, including Conen's syndrome, primary and secondary hyperaldosteronism, and increased sodium retention, increased excretion of magnesium and potassium (polyuria), increased water retention, hypertension (isolated systolic hypertension and combined systolic/diastolic hypertension), arrhythmia, myocardial fibrosis, myocardial infarction, Bart's syndrome, and disorders related to excessive catecholamine levels ( Hadley, ME, ENDOCRINOLOGY, 2nd Ed., pp366-81, (1988 ); and Brilla et al., Journal of Molecular and Cellular Cardiology, 25(5), pp563-75 (1993 )).
- Compounds and/or pharmaceutical compositions with MR antagonism have therapeutic value for any of the above-mentioned conditions.
- the present invention addresses those needs by providing compounds and compositions that can be used to treat or prevent hypertension, heart failure, other cardiovascular disorders, and other aldosterone disorders.
- the present invention provides a pyrrole amide compound with mineralocorticoid receptor (MR) antagonism and a pharmaceutical composition thereof, as well as the use of the compound or the pharmaceutical composition in the manufacture of a medicament for treating, preventing or alleviating hyperaldosteronism, hypertension, chronic heart failure, sequelae of myocardial infarction, liver cirrhosis, non-alcoholic steatohepatitis, chronic kidney disease, diabetic nephropathy, renal failure, fibrosis and/or stroke, and the like in patients.
- MR mineralocorticoid receptor
- each of R 2 and R 3 is independently H, D, F, Cl, Br, OH, NH 2 , SH, CN, NO 2 , methyl, ethyl, n -propyl, isopropyl, trifluoromethyl or difluoromethyl;
- the compound having Formula (I) provided herein is preferably a compound having Formula (Ia) or a stereoisomer, a geometric isomer, a tautomer, an atropisomer, an N -oxide, a hydrate, a solvate, a metabolite, an ester, a pharmaceutically acceptable salt or a prodrug thereof, wherein, R 1 , R 2a , R 2b , R 2c , R 2d and R 2e have the meanings described in the present invention.
- the compound having Formula (I) provided herein is preferably a compound having Formula (IIa) or a stereoisomer, a geometric isomer, a tautomer, an atropisomer, an N -oxide, a hydrate, a solvate, a metabolite, an ester, a pharmaceutically acceptable salt or a prodrug thereof, wherein, R 1 has the meaning described in the present invention.
- R 1 is C 1-4 alkyl, C 3-6 cycloalkyl, phenyl, 3-6 membered heterocyclyl or 5-6 membered heteroaryl, wherein the C 1-4 alkyl, C 3-6 cycloalkyl, phenyl, 3-6 membered heterocyclyl and the 5-6 membered heteroaryl are independently and optionally substituted by 1, 2, 3 or 4 R a ; each R a is independently D, F, Cl, Br, OH, NH 2 , SH, CN, NO 2 , methyl, ethyl, n -propyl, isopropyl, n -butyl, tert -butyl, vinyl, ethynyl, methoxy, ethoxy, isopropoxy, tert -butoxy, trifluoromethyl, difluoromethyl, monofluoromethyl, 2,2-difluoroethyl, cyclopropyl, cyclobutoxy, triflu
- R 1 is methyl, ethyl, n -propyl, isopropyl, n -butyl, tert -butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, oxiranyl, azetidinyl, oxetanyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, morpholinyl, pyrrolyl, pyridyl or pyrimidine, wherein the methyl, ethyl, n -propyl, isopropyl, n -butyl, tert -butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, oxiranyl, azetidinyl, oxetanyl, t
- the present invention relates to a pharmaceutical composition
- a pharmaceutical composition comprising the compound of the present invention; optionally, the pharmaceutical composition further comprises at least one of pharmaceutically acceptable carriers, excipients, diluents, adjuvants and vehicles.
- the pharmaceutical composition provided herein further comprises one or more other active ingredients, and the other active ingredient is an ACE inhibitor, a renin inhibitor, an angiotensin II receptor antagonist, a ⁇ -receptor blocker, acetylsalicylic acid, a diuretic, a calcium antagonist, a statin, a digitalis derivative, a calcium sensitizer, a nitrate or an antithrombotic agent.
- the other active ingredient is an ACE inhibitor, a renin inhibitor, an angiotensin II receptor antagonist, a ⁇ -receptor blocker, acetylsalicylic acid, a diuretic, a calcium antagonist, a statin, a digitalis derivative, a calcium sensitizer, a nitrate or an antithrombotic agent.
- the present invention relates to the use of the compound or the pharmaceutical composition in the manufacture of a medicament for treating, preventing or alleviating the following diseases in patients: hyperaldosteronism, hypertension, chronic heart failure, sequelae of myocardial infarction, liver cirrhosis, non-alcoholic steatohepatitis, chronic kidney disease, diabetic nephropathy, renal failure, fibrosis and/or stroke.
- the present invention relates to the use of the compound or the pharmaceutical composition in the manufacture of a medicament, wherein the medicament is used as a mineralocorticoid receptor antagonist.
- grammatical articles "a”, “an” and “the”, as used herein, are intended to include “at least one” or “one or more” unless otherwise indicated herein or clearly contradicted by the context.
- the articles used herein refer to one or more than one (i.e. at least one) articles of the grammatical objects.
- a component means one or more components, and thus, possibly, more than one component is contemplated and may be employed or used in an implementation of the described embodiments.
- patient refers to a human (including adults and children) or other animal. In some embodiments, “patient” refers to a human.
- Stereoisomers refers to compounds which have identical chemical constitution, but differ with regard to the arrangement of the atoms or groups in space. Stereoisomers include enantiomer, diastereomers, conformer (rotamer), geometric (cis/trans) isomer, atropisomer, etc.
- Enantiomers refers to two stereoisomers of a compound which are non-superimposable mirror images of one another.
- Diastereomer refers to a stereoisomer with two or more centers of chirality and whose molecules are not mirror images of one another. Diastereomers have different physical properties, e.g ., melting points, boling points, spectral properties or biological activities. Mixture of diastereomers may separate under high resolution analytical procedures such as electrophoresis and chromatography such as HPLC.
- “Atropisomers” refer to structural isomers based on axial or planar chirality due to restricted intramolecular rotation.
- the compound of the present invention has two atropisomers.
- the compound having formula (II) has two atropisomers, which is resulting from the axial chirality derived from the restriction of the rotation due to steric hindrance of the bond between the phenyl substituted by trifluoromethyl at the ortho position and the substituted pyrrole ring.
- the "atropisomer" of the present invention is any one of the two atropisomers of the compound provided herein.
- an atropisomer having more excellent pharmacological activity, stability, in vivo kinetic properties, safety, etc., and thus having advantageous properties as a drug is preferred.
- the separation of atropisomers can be accomplished by chiral resolution techniques, such as selective crystallization or high performance liquid chromatography.
- any asymmetric atom (e.g., carbon or the like) of the compound(s) disclosed herein can be present in racemic or enantiomerically enriched, for example the ( R )-, ( S )- or ( R , S )-configuration.
- each asymmetric atom has at least 50 % enantiomeric excess, at least 60 % enantiomeric excess, at least 70 % enantiomeric excess, at least 80 % enantiomeric excess, at least 90 % enantiomeric excess, at least 95 % enantiomeric excess, or at least 99 % enantiomeric excess in the ( R )- or ( S )- configuration.
- Any resulting mixtures of stereoisomers can be separated on the basis of the physicochemical differences of the constituents, into the pure or substantially pure geometric isomers, enantiomers, diastereomers, for example, by chromatography and/or fractional crystallization.
- Cis and trans isomers are diastereomer.
- tautomer or "tautomeric form” refers to structural isomers of different energies which are interconvertible via a low energy barrier. Where tautomerization is possible (e.g. in solution), a chemical equilibrium of tautomers can be reached.
- protontautomers also known as prototropic tautomers
- Valence tautomers include interconversions by reorganization of some of the bonding electrons.
- keto-enol tautomerization is the interconversion of pentane-2,4-dione and 4-hydroxypent-3-en-2-one tautomers.
- tautomerization is phenol-keto tautomerization.
- the specific example of phenol-keto tautomerisms is pyridin-4-ol and pyridin-4(1 H )-one tautomerism. Unless otherwise stated, all tautomeric forms of the compounds disclosed herein are within the scope of the invention.
- compounds disclosed herein may optionally be substituted with one or more substituents, such as are illustrated generally below, or as exemplified by particular classes, subclasses, and species of the invention.
- substitutes of compounds disclosed herein are disclosed in groups or in ranges. It is specifically intended that the invention includes each and every individual subcombination of the members of such groups and ranges.
- C 1 -C 6 alkyl or “C 1-6 alkyl” specifically refers to independently disclosed methyl, ethyl, C 3 alkyl, C 4 alkyl, C 5 alkyl and C 6 alkyl;
- C 1-4 alkyl specifically refers to independently disclosed methyl, ethyl, C 3 alkyl (i.e. propyl, including n -propyl and isopropyl) and C 4 alkyl (i.e. butyl, including n -butyl, isobutyl, sec -butyl and tert -butyl).
- linking substituents are described. Where the structure clearly requires a linking group, the Markush variables listed for that group are understood to be linking groups. For example, if the structure requires a linking group and the Markush group definition for that variable lists “alkyl” or “aryl” then it is understood that the “alkyl” or “aryl” represents a linking alkylene group or arylene group, respectively.
- alkyl refers to a saturated linear or branched-chain monovalent hydrocarbon group of 1-20 carbon atoms, wherein the alkyl group is optionally substituted with one or more substituents described herein.
- the alkyl group contains 1-12 carbon atoms.
- the alkyl group contains 1-6 carbon atoms, i.e. C 1-6 alkyl.
- the alkyl group contains 1-4 carbon atoms, i.e. C 1-4 alkyl.
- the alkyl group contains 1-3 carbon atoms, i.e. C 1-3 alkyl.
- the C 1-6 alkyl group described herein includes C 1-4 alkyl; in other embodiments, the C 1-6 alkyl described herein includes C 1-3 alkyl.
- alkyl group examples include methyl, ethyl, propyl (including n -propyl and isopropyl), butyl (including n -butyl, isobutyl, sec -butyl, tert -butyl), n -pentyl, 2-pentyl, 3-pentyl, 2-methyl-2-butyl, 3-methyl-2-butyl, 3-methyl-1-butyl, 2-methyl-1-butyl, n -hexyl, 2-hexyl, 3-hexyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 3-methyl-3-pentyl, 2-methyl- 3-pentyl, 2,3-dimethyl-2-butyl, 3,3-dimethyl-2-butyl, n -heptyl, n -octyl, etc.
- alkoxy refers to an alkyl group, as previously defined, attached to parent molecular moiety via an oxygen atom.
- alkoxy group include methoxy, ethoxy, propoxy (including 1-propoxy or 2-propoxy), butoxy (including n -butoxy, isobutoxy, sec -butoxy, tert -butoxy), etc.
- haloalkyl or “haloalkoxy” refer to an alkyl or alkoxy group is substituted by one or more halogen atoms. Some non-limiting examples of this include trifluoromethyl, difluoromethyl, monofluoromethyl, trifluoromethoxy, chloroethyl (for example, 2-chloroethyl), trifluoroethyl (including but not limited to, 2,2,2-trifluoroethyl), 2,2-difluoroethyl, 2-chloro-1-methylethyl, etc.
- amino refers to the group -NH 2 .
- carboxy refers to the group -COOH.
- hydroxyl refers to the group -COOH.
- hydroxyl refers to the group -COOH.
- cyano refers to the group -COOH.
- nitro refers to the groups -OH, -CN, -NO 2 , -SH, respectively.
- alkylamino refers to the group -NH 2 is substituted by one or two alkyl groups, wherein the alkyl group has the meaning as described herein. Some non-limiting examples of the alkyl group include methylamino, ethylamino, methylethylamino, dimethylamino, etc.
- carbocyclyl refers to a saturated or partially unsaturated ring having 3 to 14 ring carbon atoms as a monocyclic, bicyclic, or tricyclic ring system, which has one or more attachments attaching to the rest of the molecule, wherein the carbocyclyl is optionally substituted with the substituents described herein.
- carbocyclic ring can be used interchangeably with the term “carbocyclyl”.
- Some non-limiting examples of the carbocyclic ring include cyclopropane, cyclobutane, cyclopentane, cyclohexane, cyclopentene, cyclohexene, cyclopentadiene, etc.
- cycloalkyl refers to a saturated monocyclic, bicyclic or tricyclic ring system containing 3-12 ring carbon atoms.
- cycloalkyl contains 3-10 ring carbon atoms, such as C 3-10 cycloalkyl; in other embodiments, cycloalkyl contains 3-8 ring carbon atoms, such as C 3-8 cycloalkyl; in still other embodiments, the cycloalkyl contains 3-6 ring carbon atoms, such as C 3-6 cycloalkyl.
- cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, and the like.
- C 3-8 cycloalkyl includes C 3-6 cycloalkyl; the C 3-6 cycloalkyl includes cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
- the cycloalkyl group may be optionally substituted with one or more substituents disclosed herein.
- heterocyclic ring can be used interchangeably with the term “heterocyclic”.
- heterocyclic examples include oxiranyl, azetidinyl, oxetanyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydrothienyl, thiazolidinyl, pyrazolidinyl, oxazolidinyl, imidazolidinyl, isoxanyl oxazolidinyl, piperidinyl, piperazinyl or morpholinyl, etc.
- the heterocyclic can be composed of 3-8 members or 3-6 members, the members are optionally selected from C, N, O or S and at least one member is N, O or S.
- the 3-8 membered heterocyclyl includes a heterocyclyl composed of 3-6 members; the 3-6 membered heterocyclyl includes a heterocyclyl composed of 3-5 members.
- the 3-6 membered heterocyclyl includes, but is not limited to, oxiranyl( ), aziridinyl( ), azetidinyl( ), oxetanyl( ), pyrrolidinyl( ), tetrahydrofuranyl( ), tetrahydrothienyl( ), thiazolidinyl( ), dihydrothiazole(e.g.
- heterocyclyl group may be optionally substituted with one or more substituents disclosed herein.
- halogen refers to fluorine(F), chlorine(Cl), bromine(Br) or iodine(I).
- aryl refers to monocyclic, bicyclic and tricyclic carbocyclic ring systems having a total of 6 to 14 ring members, or 6 to 12 ring members, or 6 to 10 ring members, wherein at least one ring is aromatic and that has a single point or multipoint of attachment to the rest of the molecule.
- aryl and aromatic ring can be used interchangeably herein.
- Some non-limiting examples of the aryl group include phenyl, 2,3-dihydro-1 H -indenyl, naphthalenyl and anthracenyl.
- the aryl group may be optionally substituted with one or more substituents disclosed herein.
- the group “C 6-10 aryl” refers to an aryl group containing 6-10 ring carbon atoms.
- heteroaryl refers to monocyclic, bicyclic and tricyclic ring systems having a total of 5 to 12 ring members, 5 to 10 ring members, or 5 to 6 ring atoms, wherein at least one ring is aromatic, and in which at least one ring contains 1, 2, 3 or 4 ring heteroatoms selected from nitrogen, oxygen, and sulfur, and the heteroaryl has a single point or multipoint of attachment to the rest of the molecule.
- heteroaryl group may be connected to the rest of the molecule (such as the parent nucleus structure in the general formula) through any reasonable position (which may be C in CH or N in NH).
- heteroaryl and “heteroaromatic ring” or “heteroaromatic compound” can be used interchangeably herein.
- Some non-limiting examples of the heteroaryl include furyl, imidazolyl, pyrrolyl, pyrazolyl, pyridyl, pyrimidinyl, pyrazinyl, etc.
- the heteroaryl group may be optionally substituted with one or more substituents disclosed herein.
- the heteroaryl is composed of 5-10 members, which refers to the heteroaryl containing 1-9 ring carbon atoms and 1, 2, 3 or 4 ring heteroatoms selected from O, S and N. In some embodiments, the heteroaryl is composed of 5-6 members, which refers to the heteroaryl containing 1-5 ring carbon atoms and 1, 2, 3 or 4 ring heteroatoms selected from O, S and N.
- 5-6 membered heteroaryl examples include furyl, imidazolyl, isoxazolyl, oxazolyl, pyrrolyl, pyrazolyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, thienyl, thiazolyl, etc.
- j-k membered refers to the ring group consisted of j to k ring atoms, the ring atoms include carbon atom and/or heteroatoms such as O, N, S, P, and so on; the j and k are each independently any non-zero natural number, and k > j; the "j-k” includes j, k and any natural number between them.
- "3-8 membered”, “5-10 membered” or “5-6 membered” refers to the ring group consisted of 3-8, 5-10 or 5-6 ring atoms, the ring atoms include carbon atom and/or heteroatoms such as O, N, S, P, and so on.
- pharmaceutically acceptable refers to molecular entities and compositions that are physiologically tolerable and do not typically produce an allergic or similar untoward reaction, such as gastric upset, dizziness and the like, when administered to a human.
- pharmaceutically acceptable means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans.
- carrier refers to a diluent, adjuvant, excipient, or matrix with which the compound is administered.
- Such pharmaceutical carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like.
- Water and aqueous solutions e.g ., saline solution, dextrose solution, glycerol solution
- Suitable pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences” by E. W. Martin.
- prodrug refers to a compound that is transformed in vivo into a compound of Formula (I). Such a transformation can be affected, for example, by hydrolysis of the prodrug form in blood or enzymatic transformation to the parent form in blood or tissue.
- Prodrugs of the compounds disclosed herein may be, for example, esters. Some common esters which have been utilized as prodrugs are phenyl esters, aliphatic (C 1-24 ) esters, acyloxymethyl esters, carbonates, carbamates and amino acid esters. For example, a compound disclosed herein that contains a hydroxy group may be acylated at this position in its prodrug form.
- prodrug forms include phosphates, such as, those phosphate compounds are derived from the phosphonation of a hydroxy group on the parent compound.
- phosphates such as, those phosphate compounds are derived from the phosphonation of a hydroxy group on the parent compound.
- a thorough discussion of prodrugs is provided in T. Higuchi and V. Stella, Pro-drugs as Novel Delivery Systems, Vol. 14 of the A.C.S. Symposium Series, Edward B. Roche, ed., Bioreversible Carriers in Drug Design, American Pharmaceutical Association and Pergamon Press, 1987 , J. Rautio et al., Prodrugs: Design and Clinical Applications, Nature Review Drug Discovery, 2008, 7, 255-270 , and S. J. Hecker et al., Prodrugs of Phosphates and Phosphonates, Journal of Medicinal Chemistry, 2008, 51 , 2328-2345 , all of which are incorporated herein by reference in their entireties.
- a “metabolite” is a product produced through metabolism in the body of a specified compound or salt thereof.
- the metabolites of a compound may be identified using routine techniques known in the art and their activities determined using tests such as those described herein. Such products may result for example from oxidation, reduction, hydrolysis, amidation, deamidation, esterification, deesterification, enzyme cleavage, and the like, of the administered compound.
- the invention includes metabolites of compounds disclosed herein, including metabolites produced by contacting a compound disclosed herein with a mammal for a sufficient time period.
- a “pharmaceutically acceptable salts” refers to organic or inorganic salts of a compound disclosed herein.
- Pharmaceutically acceptable salts are well known in the art. For example, S. M. Berge et al., describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 1977, 66: 1-19 , which is incorporated herein by reference.
- Some non-limiting examples of pharmaceutically acceptable and nontoxic salts include salts formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid, malonic acid, etc.
- salts include those obtained by reacting with an appropriate base, including alkali metal, alkaline earth metal, ammonium and N + (C 1-4 alkyl) 4 salts.
- This invention also envisions the quaternization of any basic nitrogen-containing groups of the compounds disclosed herein. Water or oil soluble or dispersable products may be obtained by such quaternization.
- Alkali metals or alkaline earth metals that can form salts include sodium, lithium, potassium, calcium, magnesium, and the like.
- salts include appropriate and nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions, such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, C 1-8 sulfonate or aryl sulfonate.
- solvate refers to an association or complex of one or more solvent molecules and a compound disclosed herein.
- solvents that form solvates include, but are not limited to, water, isopropanol, ethanol, methanol, DMSO, ethyl acetate, acetic acid and ethanolamine.
- hydrate refers to the complex where the solvent molecule is water.
- esters refers to an in vivo hydrolysable ester of a compound containing a hydroxyl group or a carboxyl group. for example, a pharmaceutically acceptable ester which is hydrolysed in the human or animal body to produce the parent alcohol or acid.
- the compound having Formula (I) of the present invention contains carboxyl group, which can form a hydrolyzable ester in vivo with an appropriate group.
- groups include, but are not limited to, alkyl, arylalkyl and the like.
- N -oxide refers to one or more than one nitrogen atoms oxidised to form an N-oxide, where a compound contains several amine functions.
- Particular examples of N -oxides are the N -oxides of a tertiary amine or a nitrogen atom of a nitrogen-containing heterocycle.
- N -oxides can be formed by treatment of the corresponding amine with an oxidizing agent such as hydrogen peroxide or a per-acid (e.g., a peroxycarboxylic acid) (See, Advanced Organic Chemistiy, by Jerry March, 4th Edition, Wiley Interscience , pages). More particularly, N -oxides can be made by the procedure of L. W. Deady (Syn. Comm. 1977, 7, 509-514 ) in which the amine compound is reacted with m-chloroperoxybenzoic acid (MCPBA), for example, in an inert solvent such as dichloromethane.
- MCPBA m
- the term “treat”, “treating” or “treatment” of any disease or disorder refers in one embodiment, to ameliorating the disease or disorder (i.e., slowing or arresting or reducing the development of the disease or at least one of the clinical symptoms thereof).
- “treat”, “treating” or “treatment” refers to alleviating or ameliorating at least one physical parameter including those which may not be discernible by the patient.
- “treat”, “treating” or “treatment” refers to modulating the disease or disorder, either physically, ( e.g ., stabilization of a discernible symptom), physiologically, (e.g., stabilization of a physical parameter), or both.
- “treat”, “treating” or “treatment” refers to preventing or delaying the onset or development or progression of the disease or disorder.
- any formula given herein is also intended to represent isotopically unenriched forms as well as isotopically enriched forms of the compounds.
- Isotopically enriched compounds have the structure depicted by the general formula given herein, except that one or more atoms are replaced by the atom having a selected atomic mass or mass number.
- isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, and chlorine, such as 2 H (deuterium, D), 3 H, 11 C, 13 C, 14 C, 15 N, 17 O, 18 O, 18 F, 31 P, 32 P, 35 S, 36 Cl 125 I, respectively.
- the compounds of the invention include isotopically enriched compounds as defined herein, for example those into which radioactive isotopes, such as 3 H, 14 C and 18 F, or those into which non-radioactive isotopes, such as 2 H and 13 C are present.
- isotopically enriched compounds are useful in metabolic studies (with 14 C), reaction kinetic studies (with, for example 2 H or 3 H), detection or imaging techniques, such as positron emission tomography (PET) or single-photon emission computed tomography (SPECT) including drug or substrate tissue distribution assays, or in radioactive treatment of patients.
- PET positron emission tomography
- SPECT single-photon emission computed tomography
- an 18 F-enriched compound may be particularly desirable for PET or SPECT studies.
- Isotopically-enriched compounds of Formula (I) can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the accompanying Examples and Preparations using an appropriate isotopically-labeled reagent in place of the non-labeled reagent previously employed.
- isotopic enrichment factor means the ratio between the isotopic abundance and the natural abundance of a specified isotope.
- a substituent in a compound of this invention is denoted deuterium, such compound has an isotopic enrichment factor for each designated deuterium atom of at least 3500 (52.5% deuterium incorporation at each designated deuterium atom), at least 4000 (60% deuterium incorporation), at least 4500 (67.5% deuterium incorporation), at least 5000 (75% deuterium incorporation), at least 5500 (82.5% deuterium incorporation), at least 6000 (90% deuterium incorporation), at least 6333.3 (95% deuterium incorporation), at least 6466.7 (97% deuterium incorporation), at least 6600 (99% deuterium incorporation), or at least 6633.3 (99.5% deuterium incorporation).
- Pharmaceutically acceptable solvates in accordance with the invention include those wherein the solvent of crystallization may be isotopically substituted, e.g. D 2 O, d 6 -acetone, DMSO-d 6 .
- the present invention provides a pyrrole amide compound that can competitively antagonize the mineralocorticoid receptor (MR) and the use thereof, as well as a pharmaceutical composition containing the compound and the compound or the pharmaceutical composition in the manufacture of a medicament for treating, preventing or alleviating hyperaldosteronism, hypertension, chronic heart failure, sequelae of myocardial infarction, liver cirrhosis, non-alcoholic steatohepatitis, chronic kidney disease, diabetic nephropathy, renal failure, fibrosis and/or stroke, and the like in patients.
- MR mineralocorticoid receptor
- the change of the substitution position of F on the benzene ring connected to the amide has a greater impact on the properties of the compound; for example, when F is in the meta position of the acyl group, the activity of the compound (i.e., the compound provided herein) is the highest.
- the compound provided herein has excellent mineralocorticoid receptor antagonistic activity and excellent pharmacokinetic properties; furthermore, the compound has substantially no phototoxicity.
- each of R 2 and R 3 is independently H, D, F, Cl, Br, OH, NH 2 , SH, CN, NO 2 , C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl or C 1-6 haloalkyl.
- each of R 2 and R 3 is independently H, D, F, Cl, Br, OH, NH 2 , SH, CN, NO 2 , C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl or C 1-4 haloalkyl.
- each of R 2 and R 3 is independently H, D, F, Cl, Br, OH, NH 2 , SH, CN, NO 2 , methyl, ethyl, n -propyl, isopropyl, trifluoromethyl or difluoromethyl.
- each of R 8 , R b and R c is independently H, D, C 1-6 alkyl or C 1-6 haloalkyl. In some embodiments, each of R 8 , R b and R c is independently H, D, C 1-4 alkyl or C 1-4 haloalkyl.
- each of R 8 , R b and R c is independently H, D, methyl, ethyl, n -propyl, isopropyl, n -butyl, tert -butyl, trifluoromethyl, difluoromethyl, monofluoromethyl or 2,2-difluoroethyl.
- the compound having Formula (I) provided herein is preferably a compound having Formula (Ia) or a stereoisomer, a geometric isomer, a tautomer, an atropisomer, an N -oxide, a hydrate, a solvate, a metabolite, an ester, a pharmaceutically acceptable salt or a prodrug thereof, wherein, R 1 , R 2a , R 2b , R 2c , R 2d and R 2e have the meanings described in the present invention.
- the compound having Formula (I) provided herein is preferably a compound having Formula (II) or a stereoisomer, a geometric isomer, a tautomer, an atropisomer, an N -oxide, a hydrate, a solvate, a metabolite, an ester, a pharmaceutically acceptable salt or a prodrug thereof, wherein, R 1 has the meaning described in the present invention.
- the compound having Formula (I) provided herein is preferably a compound having Formula (IIa) or a stereoisomer, a geometric isomer, a tautomer, an atropisomer, an N-oxide, a hydrate, a solvate, a metabolite, an ester, a pharmaceutically acceptable salt or a prodrug thereof, wherein, R 1 has the meaning described in the present invention.
- R 1 is C 1-6 alkyl, C 3-6 cycloalkyl, C 6-10 aryl, 3-6 membered heterocyclyl or 5-10 membered heteroaryl, wherein the C 1-6 alkyl, C 3-6 cycloalkyl, C 6-10 aryl, 3-6 membered heterocyclyl or 5-10 membered heteroaryl are independently and optionally substituted with 1, 2, 3 or 4 R a ; wherein R a has the meaning described herein.
- R 1 is C 1-4 alkyl, C 3-6 cycloalkyl, phenyl, 3-6 membered heterocyclyl or 5-6 membered heteroaryl, wherein the C 1-4 alkyl, C 3-6 cycloalkyl, phenyl, 3-6 membered heterocyclyl and 5-6 membered heteroaryl are independently and optionally substituted with 1, 2, 3 or 4 R a ; wherein R a has the meaning described herein.
- R 1 is methyl, ethyl, n -propyl, isopropyl, n -butyl, tert -butyl , cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, oxiranyl, azetidinyl, oxetanyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, morpholinyl, pyrrolyl, pyridyl or pyrimidinyl, wherein the methyl, ethyl, n -propyl, isopropyl, n -butyl, tert -butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, oxiranyl, azetidinyl, oxetanyl, ox
- each R a is independently D, F, Cl, Br, OH, NH 2 , SH, CN, NO 2 , C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 3-6 cycloalkyl, C 6-10 aryl, 3-6 membered heterocyclyl or 5-10 membered heteroaryl; wherein, the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 3-6 cycloalkyl, C 6-10 aryl, 3-6 membered heterocyclyl and 5-10 membered heteroaryl are independently unsubstituted or substituted with 1, 2, 3 or 4 substituents independently selected from D, F, Cl, Br, OH, NH 2 , SH, CN, NO 2 , C 1-6 alkyl, C 2-6 alkenyl
- each R a is independently D, F, Cl, Br, OH, NH 2 , SH, CN, NO 2 , C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 1-4 alkoxy, C 1-4 haloalkyl, C 3-4 cycloalkyl, C 6-10 aryl, 3-6 membered heterocyclyl or 5-6 membered heteroaryl; wherein, the C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 1-4 alkoxy, C 1-4 haloalkyl, C 3-6 cycloalkyl, C 6-10 aryl, 3-6 membered heterocyclyl and 5-6 membered heteroaryl are independently unsubstituted or substituted with 1, 2, 3 or 4 substituents independently selected from D, F, Cl, Br, OH, NH 2 , SH, CN, NO 2 , C 1-4 alkyl, C 2-4 alkenyl
- each R a is independently D, F, Cl, Br, OH, NH 2 , SH, CN, NO 2 , methyl, ethyl, n -propyl, isopropyl, n -butyl, tert -butyl, vinyl, ethynyl, methoxy, ethoxy, isopropoxy, tert -butoxy, trifluoromethyl, difluoromethyl, monofluoromethyl, 2,2-difluoroethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, oxiranyl, azetidinyl, oxetanyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, morpholinyl, pyrrolyl, pyridyl, pyrimidinyl or quinoliny
- the compound provided herein having one of the following structures, or a stereoisomer, a geometric isomer, a tautomer, an atropisomer, an N -oxide, a hydrate, a solvate, a metabolite, an ester, a pharmaceutically acceptable salt or a prodrug thereof,
- composition comprising the compound disclosed herein.
- the pharmaceutical composition provided herein optionally comprises at least one of pharmaceutically acceptable carriers, excipients, diluents, adjuvants and vehicles.
- the pharmaceutical composition provided herein further comprises one or more other active ingredients, wherein the other active ingredient is a ACE inhibitor, a renin inhibitor, an angiotensin II receptor antagonist, a ⁇ -receptor blocker, acetylsalicylic acid, a diuretic, a calcium antagonist, a statin, a digitalis derivative, a calcium sensitizer, a nitrate and/or an antithrombotic agent.
- the other active ingredient is a ACE inhibitor, a renin inhibitor, an angiotensin II receptor antagonist, a ⁇ -receptor blocker, acetylsalicylic acid, a diuretic, a calcium antagonist, a statin, a digitalis derivative, a calcium sensitizer, a nitrate and/or an antithrombotic agent.
- provided herein is use of the compound or the pharmaceutical composition disclosed herein in the manufacture of a medicament for treating, preventing or alleviating the following diseases in patients: hyperaldosteronism, hypertension, chronic heart failure, sequelae of myocardial infarction, liver cirrhosis, non-alcoholic steatohepatitis, chronic kidney disease, diabetic nephropathy, renal failure, fibrosis or stroke.
- provided herein is use of the compound or the pharmaceutical composition disclosed herein in the manufacture of a medicament, wherein the medicament is used as a mineralocorticoid receptor antagonist.
- provided herein is the compound or the pharmaceutical composition disclosed herein for use in treating, preventing or alleviating the following diseases in patients: hyperaldosteronism, hypertension, chronic heart failure, sequelae of myocardial infarction, liver cirrhosis, non-alcoholic steatohepatitis, chronic kidney disease, diabetic nephropathy, renal failure, fibrosis or stroke.
- the compound or the pharmaceutical composition disclosed herein can be used as a mineralocorticoid receptor antagonist.
- provided herein is a method for treating, preventing or alleviating the following diseases in patients: hyperaldosteronism, hypertension, chronic heart failure, sequelae of myocardial infarction, liver cirrhosis, non-alcoholic steatohepatitis, chronic kidney disease, diabetic nephropathy, renal failure, fibrosis or stroke, comprising administering to the subject a therapeutically effective amount of the compound or the pharmaceutical composition disclosed herein.
- provided herein is a method for using the compound or pharmaceutical composition disclosed herein to antagonize the mineralocorticoid receptor, comprising contacting an organism (including in vivo or in vitro) with the compound or pharmaceutical composition disclosed herein in an effective dosage.
- the compounds or pharmaceutical compositions disclosed herein competitively antagonize the mineralocorticoid receptor (MR), and therefore they can be useful agents for treating and preventing conditions associated with increased aldosterone levels.
- MR mineralocorticoid receptor
- the compound or pharmaceutical composition disclosed herein can be used to treat or prevent aldosterone receptor-mediated diseases.
- the present invention also provides a method for treating or reducing aldosterone receptor-mediated diseases, or sensitiving to these diseases in a patient comprising administering to the patient a therapeutically effective amount of the compound or pharmaceutical composition disclosed herein.
- the present invention also comprises uses of the compound and pharmaceutically acceptable salts thereof in the manufacture of a medicine for treating mineralocorticoid receptor or aldosterone related diseases in patients, including those diseases described herein.
- the present invention provides a pharmaceutical composition comprising an effective therapeutic amount of the compound having Formula (I) required for combining with at least one pharmaceutically acceptable carrier, excipient, diluent, adjuvant, vehicle.
- the salt is a pharmaceutically acceptable salt.
- pharmaceutically acceptable refers to that the substance or composition must be compatible chemically and/or toxicologically, with the other ingredients comprising a formulation, and/or the mammal being treated therewith.
- the slats of the compounds disclosed herein also include salts of intermediates used for preparing and/or purifying compounds of Formula (I), or the salts of the isolated enantiomers of the compounds of Formula (I), but not necessarily pharmaceutically acceptable salts.
- the salts of the compounds disclosed herein may be prepared by any suitable method available in the art, for example, treatment of the free base with an inorganic acid, such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like.
- an inorganic acid such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like.
- an organic acid such as acetic acid, maleic acid, succinic acid, mandelic acid, fumaric acid, malonic acid, pyruvic acid, oxalic acid, glycolic acid and salicylic acid; a pyranosidyl acid, such as glucuronic acid and galacturonic acid; an alpha-hydroxy acid, such as citric acid and tartaric acid; an amino acid, such as aspartic acid and glutamic acid; an aromatic acid, such as benzoic acid and cinnamic acid; a sulfonic acid, such as p-toluenesulfonic acid, ethanesulfonic acid and the like.
- an organic acid such as acetic acid, maleic acid, succinic acid, mandelic acid, fumaric acid, malonic acid, pyruvic acid, oxalic acid, glycolic acid and salicylic acid
- a pyranosidyl acid such as glucuronic acid and galacturonic acid
- the biological activity of the compounds disclosed herein may be assessed by using any conventionally known methods. Appropriate detection methods are well known in the art. For example, the MR antagonistic activity, pharmacokinetic activity, and/or liver microsomal stability of the compounds disclosed herein can be tested by appropriate conventional methods.
- the detection method provided herein is presented only as an example and does not limit the present invention.
- the compounds disclosed herein have activity in at least one of the detection methods provided herein.
- the compounds disclosed herein have good antagonistic activity against mineralocorticoid receptors and good in vivo pharmacokinetic properties, such as better absorption and exposure, and high bioavailability; in another example, the compounds disclosed herein have low toxic side effects.
- the pharmaceutical composition of the invention comprises pyrrole amide compounds having Formula (I), Formula (Ia), Formula (II) or Formula (IIa), the compounds listed herein, or the compounds of Examples 1-8, and a pharmaceutically acceptable carrier, adjuvant, or excipient.
- the amount of the compound in the composition of the present invention can effectively treat or lessen mineralocorticoid receptor or aldosterone-related diseases in a subject.
- compositions disclosed herein further comprise a pharmaceutically acceptable carrier, an adjuvant, or a vehicle, which, as used herein, includes any and all solvents, diluents, or other liquid vehicle, dispersion or suspension aids, surface active agents, isotonic agents, thickening or emulsifying agents, preservatives, solid binders, lubricants and the like, as suited to the particular dosage form desired.
- a pharmaceutically acceptable carrier includes any and all solvents, diluents, or other liquid vehicle, dispersion or suspension aids, surface active agents, isotonic agents, thickening or emulsifying agents, preservatives, solid binders, lubricants and the like, as suited to the particular dosage form desired.
- Some non-limiting examples of materials which can serve as pharmaceutically acceptable carriers include ion exchangers; aluminium; aluminum stearate; lecithin; serum proteins such as human serum albumin; buffer substances such as phosphates; glycine; sorbic acid; potassium sorbate; partial glyceride mixtures of saturated vegetable fatty acids; water; salts or electrolytes such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride and zinc salts; colloidal silica; magnesium trisilicate; polyvinyl pyrrolidone; polyacrylates; waxes; polyethylene-polyoxypropylene-block polymers; wool fat; sugars such as lactose, glucose and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients such as
- the pharmaceutical composition of the present invention can be administered directly or in a pharmaceutical composition or pharmaceutical form along with a suitable carrier or excipient, which is well known in the art.
- the treatment method of the present invention may comprise administering an effective compound of the present invention to an individual in need.
- the individual is a mammalian individual, and in other preferred embodiments, the individual is a human individual.
- the effective amount of the compound, pharmaceutical composition or drug of the present invention can be easily determined by routine test, and the most effective and convenient route of administration and the most suitable formulation can also be determined by routine test.
- the pharmaceutical dosage form of the compound of the present invention can be provided in the form of an immediate release, controlled release, sustained release or target drug release system.
- commonly used dosage forms include solutions and suspensions, (micro) emulsions, ointments, gels and patches, liposomes, tablets, dragees, soft or hard shell capsules, suppositories, ovules, implants, amorphous or crystalline powder, aerosol and freeze-dried formulations.
- special devices may be required to administer the drug, such as syringes and needles, inhalers, pumps, injection pens, applicators or special flask.
- Pharmaceutical dosage forms often consist of drugs, excipients, and container/sealing systems.
- excipients also known as inactive ingredients
- the type of excipients added to the drugs may depend on various factors, such as the physical and chemical properties of the drugs, the route of administration, and the preparation steps.
- Pharmaceutical excipients exist in this field and include those listed in various pharmacopoeias. (Refer to U.S. Pharmacopeia (USP), Japanese Pharmacopoeia (JP), European Pharmacopoeia (EP) and British Pharmacopoeia (BP); publications of the Center for Drug Evaluation and Research (CEDR) of the U.S. Food and Drug Administration(www.fda.gov), such as Inactive Ingredient Guide, 1996; Handbook of Pharmaceutical Additives by Ash and Ash, 2002; Synapse Information Resources, Inc., Endicott NY ; etc. )
- the pharmaceutical dosage form of the compound of the present invention can be manufactured by any method well known in the art, for example, by conventional mixing, sieving, dissolving, melting, granulating, making sugar-coated pills, pressing, suspending, squeezing, spray drying, grinding, emulsification, (nano/micron) encapsulation, encapsulation or freeze-drying process.
- the composition of the present invention may include one or more physiologically acceptable inactive ingredients, which can promote the processing of active molecules into formulations for medical use.
- the composition can be formulated in an aqueous solution, if necessary, using physiologically compatible buffers, including, for example, phosphate, histidine or citrate used to adjust the pH of the formulation, and tonicity agents such as sodium chloride or dextrose.
- physiologically compatible buffers including, for example, phosphate, histidine or citrate used to adjust the pH of the formulation, and tonicity agents such as sodium chloride or dextrose.
- semi-solid, liquid preparations or patches may be preferred, and may contain penetration enhancers; such penetration enhancers are generally known in the art.
- the compounds can be formulated into liquid or solid dosage forms and used as immediate release or controlled release/sustained release formulations.
- Suitable dosage forms for oral administration by individuals include tablets, pills, dragees, hard and soft shell capsules, liquids, gels, syrups, ointments, suspensions and emulsions.
- the compounds also be formulated in rectal compositions such as suppositories or retention enemas, which, for example, contain conventional suppository matrix, such as cocoa butter or other glycerides.
- Solid oral dosage forms can be obtained by using excipients, which include fillers, disintegrants, binders (dry and wet), dissolution retardants, lubricants, glidants, anti-adherents, cation exchange resins, humectants, antioxidants, preservatives, coloring agents and flavoring agents.
- excipients include fillers, disintegrants, binders (dry and wet), dissolution retardants, lubricants, glidants, anti-adherents, cation exchange resins, humectants, antioxidants, preservatives, coloring agents and flavoring agents.
- excipients include fillers, disintegrants, binders (dry and wet), dissolution retardants, lubricants, glidants, anti-adherents, cation exchange resins, humectants, antioxidants, preservatives, coloring agents and flavoring agents.
- excipients can be synthetic or natural.
- excipients examples include cellulose derivatives, citric acid, dicalcium phosphate, gelatin, magnesium carbonate, magnesium lauryl sulfate/sodium lauryl sulfate, mannitol, polyethylene glycol, polyvinylpyrrolidone, silicic acid salt, silicon dioxide, sodium benzoate, sorbitol, starch, stearic acid or its salt, sugar (i.e. dextrose, sucrose, lactose, etc. ), talc, tragacanth mucilage, vegetable oil (hydrogenated) and wax. Ethanol and water can be used as granulation additives.
- the tablet it is necessary to coat the tablet with, for example, a taste-masked film, a gastric acid resistant film, or a delayed release film.
- Natural and synthetic polymers are usually combined with colorants, sugar and organic solvents or water to coat tablets to produce dragees.
- the capsule is superior to the tablet, the drug powder, suspension or solution can be delivered in a compatible hard-shell or soft-shell capsule form.
- compositions formulated for parenteral administration by injection are generally sterile and can be provided in unit dosage forms, such as ampoules, syringes, injection pens, or multi-dose containers.
- the latter usually contains a preservative.
- the composition can be the form of a suspension, solution or emulsion in an oily or aqueous carrier, and can contain preparation agents, such as buffers, tonicity agents, viscosity enhancers, surfactants, suspending and dispersing agents, antioxidants, biocompatible polymers, chelating agents and preservatives.
- the carrier may contain water, vegetable oils, and/or organic co-solvents.
- the controlled release or sustained release depot formulation of the compound of the present invention may include injectable suspensions of nano/micro particles or nano/micro or non-micronized crystals.
- Other well-known matrices in the art, polymers, such as poly (lactic acid), poly (glycolic acid) or copolymers thereof, can be used as a controlled release/sustained release matrix.
- Other depot delivery systems can be provided in the form of implants and pumps that require incisions.
- Suitable carriers for the compound of the present invention for intravenous injection are well known in the art and include water-based solutions containing alkalis (such as sodium hydroxide) for the formation of ionic compounds; sucrose or sodium chloride as tonicity agents; buffers containing phosphate or histidine.
- alkalis such as sodium hydroxide
- sucrose or sodium chloride as tonicity agents
- buffers containing phosphate or histidine Co-solvents of polyethylene glycol can be added.
- These water-based systems can effectively dissolve the compounds of the present invention and produce low toxicity after systemic administration. Without destroying the solubility and toxicity characteristics, the ratio of the components of the solution system can be greatly changed. In addition, the characteristics of the components can be changed.
- low-toxicity surfactants such as polysorbate or poloxamer can be used, polyethylene glycol or other co-solvents can also be used.
- Biocompatible polymer such as polyvinylpyrrolidone can be added, and dextrose can be
- the compounds of the invention can be used systemically and/or locally. They can be administered in a suitable manner, for example, oral administration, gastrointestinal administration, pulmonary administration, nasal administration, sublingual administration, translingual administration, buccal administration, rectal administration, dermal administration, transdermal administration, conjunctival administration, ear canal administration, or administration as a graft or stent.
- the compounds of the present invention are preferably administered orally or parenterally.
- Suitable administration manner for oral administration are as follows: according to the prior art, the manners of administration that release the compounds of the present invention by rapid release and/or modified methods include crystalline and/or amorphous and/or dissolved forms of the compounds, such as tablet (an uncoated tablet or a tablet coated with a gastric tolerant or delayed dissolution or insoluble coating that controls the release of the compounds), tablet or film/flake that quickly shatter in the mouth, film/lyophilized body, capsule (e.g., hard or soft capsule), sugar-coated tablet, granule, pill, powder, emulsion, suspension, aerosol or solution.
- tablet an uncoated tablet or a tablet coated with a gastric tolerant or delayed dissolution or insoluble coating that controls the release of the compounds
- tablet or film/flake that quickly shatter in the mouth
- film/lyophilized body e.g., hard or soft capsule
- sugar-coated tablet granule, pill, powder, emulsion, suspension, aerosol or solution.
- Parenteral administration can bypass the absorption step (e.g., intravenous, intraarterial, intracardia, intraspine, or lumbar) or include absorption (e.g ., intramuscular, subcutaneous, intradermal, transdermal, or intraperitoneal).
- Administration forms suitable for parenteral administration include formulations for injection and infusion in the form of solutions, suspensions, emulsions, lyophilized bodies or sterile powders.
- suitable examples are inhaled drug forms (including powder inhalers, sprays), nasal drops, solutions or sprays, tablets for tongue, sublingual or buccal administration, films/ flakes or capsules, suppositories, ear or eye formulations, vaginal capsules, aqueous suspensions (lotions, shock mixtures), lipophilic suspensions, ointments, creams, transdermal therapeutic systems ( e.g. patches), emulsions (milch), paste, foam, spray powder, implant or stent.
- inhaled drug forms including powder inhalers, sprays), nasal drops, solutions or sprays, tablets for tongue, sublingual or buccal administration, films/ flakes or capsules, suppositories, ear or eye formulations, vaginal capsules, aqueous suspensions (lotions, shock mixtures), lipophilic suspensions, ointments, creams, transdermal therapeutic systems ( e.g. patches), emulsions (milch), paste, foam, spray powder, implant or
- the therapeutically effective amount of the compounds provided herein should be present in the above-mentioned pharmaceutical formulations at a concentration of about 0.1 to 99.5%, preferably about 0.5 to 95% by weight of the entire mixture.
- the above-mentioned pharmaceutical formulations may also contain other pharmaceutical active ingredients.
- the therapeutically effective amount can be estimated using various methods well known in the art.
- the initial dosage for animal studies can be based on the effective concentration established in the cell culture assay.
- the dosage range suitable for a human individual can be determined, for example, using data obtained from animal studies and cell culture assays.
- the compounds of the present invention can be prepared as a medicament for oral administration.
- An exemplary dosage of the compounds of the present invention in a medicament for oral administration is about 0.01 to about 100 mg/kg (wherein kg refers to the body weight of the subject).
- the dosing regimen for medicaments for oral administration is three times a week, twice a week, once a week, three times a day, twice a day, or once a day.
- the compounds of the present invention are administered as active ingredient in a total amount of about 0.001 to about 50 mg/kg body weight every 24 hours. In order to obtain the desired result, it may optionally be administered in the form of multiple single doses.
- the effective amount or therapeutically effective amount or dosage of an agent refers to the amount of an agent or compound that causes improvement in individual symptoms or prolonged survival
- the toxicity and therapeutic efficacy of the molecule can be determined by standard medical procedures in cell cultures or laboratory animals, for example, by measuring LD 50 (the dosage that makes 50% of the population lethal) and ED 50 (the dosage that is therapeutically effective for 50% of the population).
- the dosage ratio of toxic effect to therapeutic effect is the therapeutic index, which can be expressed as LD 50 /ED 50 .
- a drug showing a high therapeutic index is preferred.
- the effective amount or therapeutically effective amount is the amount of a compound or pharmaceutical composition that will elicit the biological or medical response in a tissue, system, animal, or human that is being sought by researchers, veterinarians, doctors, or other clinicians.
- the dosage is preferably within a range of circulating concentrations that include the ED 50 with little or no toxicity.
- the dosage can vary within this range, depending on the dosage form and/or the route of administration used.
- the correct formulation, route of administration, dosage, and interval between administrations should be selected according to the methods known in the art, considering the particularity of individual conditions.
- the dosage and interval can be adjusted individually to provide a plasma level of the active part sufficient to achieve the desired effect; that is, the minimal effective concentration (MEC).
- MEC minimal effective concentration
- the MEC of each compound will be different, but it can be estimated, for example, from in vitro data and animal experiments.
- the dosage necessary to obtain MEC will depend on individual characteristics and route of administration. In the case of local administration or selective uptake, the effective local concentration of the drug may not be related to plasma concentration.
- the amount of the medicament or composition administered can be determined by various factors, including the sex, age and weight of the individual to be treated, the severity of the pain, the manner of administration, and the judgment of the prescribing physician.
- the composition of the present invention can be provided by a packaging or a dispensing device containing one or more unit dosage forms (containing the active ingredient).
- the packaging or dispensing device may include metal or plastic foil (such as foam packaging) or glass and rubber stoppers.
- the packaging or dispensing device may be accompanied by instructions for medicines. It is also possible to prepare a composition containing the compound of the present invention formulated in a compatible pharmaceutical carrier, which is placed in an appropriate container, and labeled for the treatment of a specified condition.
- the compound of the present invention can be used alone or, if necessary, in combination with other active compounds.
- the present invention also provides the combined use of drugs including at least one compound and one or more further active substances, especially the drugs for treating and/or preventing the diseases of the present invention.
- the compounds of the present invention act as mineralocorticoid receptor antagonists and show an unexpected and valuable range of pharmacological effects. Therefore, the compounds are suitable for use as drugs for treating and/or preventing human and animal diseases.
- the compounds of the present invention are suitable for preventing and/or treating various diseases and related diseases, especially the diseases characterized by increased plasma aldosterone concentration or changes in plasma aldosterone concentration relative to plasma renin concentration, or diseases related to these changes.
- diseases and related diseases especially the diseases characterized by increased plasma aldosterone concentration or changes in plasma aldosterone concentration relative to plasma renin concentration, or diseases related to these changes.
- spontaneous primary aldosteronism hyperaldosteronism associated with adrenal hyperplasia, adrenal adenoma and/or adrenal cancer
- hyperaldosteronism associated with cirrhosis hyperaldosteronism associated with heart failure
- hyperaldosteronism associated with essential hypertension (relative) etc.
- the compounds of the present invention are also suitable for preventing sudden cardiac death in patients with an increased risk of death from sudden cardiac death.
- patients are especially suffering from one of the following conditions: primary and secondary hypertension, hypertensive heart disease with or without congestive heart failure, refractory hypertension, acute and chronic heart failure, coronary heart disease, stable and unstable angina pectoris, myocardial ischemia, myocardial infarction, dilated cardiomyopathy, congenital primary cardiomyopathy (such as Bmgada syndrome), cardiomyopathy caused by Chagas disease, shock, arteriosclerosis, atrial and ventricular arrhythmias, transient and ischemic attacks, stroke, inflammatory cardiovascular disorders, peripheral and cardiovascular disorders, peripheral blood flow disorders, arterial occlusive diseases (such as intermittent claudication), asymptomatic left ventricle dysfunction, myocarditis, cardiac hypertrophy, pulmonary hypertension, coronary and peripheral artery spasms, thrombosis, thromboembolic disorders and
- the compounds of the present invention can additionally be suitable for preventing and/or treating the formation of edema, such as pulmonary edema, nephrogenic edema, or swelling lungs associated with heart failure, and restenosis after thrombolytic therapy, percutaneous transluminal angioplasty (PTA) and coronary angioplasty (PTCA), heart transplantation and bypass surgery.
- edema such as pulmonary edema, nephrogenic edema, or swelling lungs associated with heart failure
- thrombolytic therapy percutaneous transluminal angioplasty (PTA) and coronary angioplasty (PTCA), heart transplantation and bypass surgery.
- PTA percutaneous transluminal angioplasty
- PTCA coronary angioplasty
- the compounds of the present invention are also suitable for using as potassium-sparing diuretics and for treating electrolyte disorders, such as hypercalcemia, hypernatremia or hypokalemia.
- the compounds of the present invention are also suitable for treating nephropathy, such as acute or chronic renal failure, hypertensive nephropathy, arteriosclerotic nephritis (chronic and interstitial), nephrosclerosis, chronic renal failure and cystic nephropathy, and for preventing kidney damage (e.g ., kidney damage caused by immunosuppressive agents related to organ transplantation (for example, cyclosporin A) and for kidney cancer.
- nephropathy such as acute or chronic renal failure, hypertensive nephropathy, arteriosclerotic nephritis (chronic and interstitial), nephrosclerosis, chronic renal failure and cystic nephropathy, and for preventing kidney damage (e.g ., kidney damage caused by immunosuppressive agents related to organ transplantation (for example, cyclosporin A) and for kidney cancer.
- the compounds of the present invention can additionally be suitable for preventing and/or treating diabetes and diabetic sequelae, such as neuropathy and diabetic nephropathy.
- the compounds of the present invention can be further used to prevent and/or treat microalbuminuria and proteinuria caused by diabetes or hypertension.
- the compounds of the present invention can be further used to prevent and/or treat fibrotic diseases, e.g. , renal fibrosis, pulmonary fibrosis (including idiopathic pulmonary fibrosis), liver fibrosis, etc.
- fibrotic diseases e.g. , renal fibrosis, pulmonary fibrosis (including idiopathic pulmonary fibrosis), liver fibrosis, etc.
- the compounds of the present invention are also suitable for preventing and/or treating conditions associated with an increase in plasma glucocorticoid concentration or with a local increase in glucocorticoid concentration in tissues (such as the heart).
- adrenal dysfunction Cushing's syndrome
- adrenal tumor that leads to excessive production of glucocorticoids
- pituitary tumor which autonomously produce ACTH (corticotropin) leading to adrenal hyperplasia and Cushing's disease.
- the compounds of the present invention can additionally be used to prevent and/or treat obesity, metabolic syndrome and obstructive sleep apnea.
- the compounds of the present invention can be further used to prevent and/or treat inflammatory disorders caused by viruses, spirochetes, fungi, bacteria or mycobacteria, and inflammatory disorders of unknown etiology, such as polyarthritis, lupus erythematosus, periarthritis or polyarteritis, dermatomyositis, scleroderma and sarcoidosis.
- inflammatory disorders caused by viruses, spirochetes, fungi, bacteria or mycobacteria
- inflammatory disorders of unknown etiology such as polyarthritis, lupus erythematosus, periarthritis or polyarteritis, dermatomyositis, scleroderma and sarcoidosis.
- the compounds of the present invention can be further used to treat central nervous disorders, such as depression, anxiety and chronic pain, especially migraine, and neurodegenerative disorders, such as Alzheimer's disease and Parkinson's syndrome.
- central nervous disorders such as depression, anxiety and chronic pain, especially migraine
- neurodegenerative disorders such as Alzheimer's disease and Parkinson's syndrome.
- the compounds of the present invention are also suitable for preventing and/or treating vascular damage, such as vascular damage caused by reocclusion or restenosis after percutaneous transluminal coronary angioplasty (PTCA), stent implantation, coronary angioscopy and bypass surgery, and endothelial dysfunction, Raynaud's disease, thromboangiitis obliterans (Buerger's syndrome) and tinnitus syndrome.
- vascular damage such as vascular damage caused by reocclusion or restenosis after percutaneous transluminal coronary angioplasty (PTCA), stent implantation, coronary angioscopy and bypass surgery, and endothelial dysfunction, Raynaud's disease, thromboangiitis obliterans (Buerger's syndrome) and tinnitus syndrome.
- the compound of the present invention can be used alone, or if necessary, can be used in combination with other active ingredients.
- the present invention further relates to a medicament comprising at least one compound provided herein and one or more other active ingredients (especially for treating and/or preventing the aforementioned conditions).
- the other active ingredients include, but are not limited to: active ingredients that lower blood pressure, for example, preferably selected from calcium antagonists, angiotensin II receptor antagonists, ACE inhibitors, endothelin antagonists, renin inhibitors, ⁇ -receptor blockers, ⁇ -receptor blockers and Rho kinase inhibitors; diuretics, especially loop diuretics, and thiazides and thiazide diuretics; agents with antithrombotic effect, for example, preferably selected from platelet aggregation inhibitors, anticoagulants or fibrinolytic substances; active ingredients that alter lipid metabolism, for example, preferably selected from thyroid receptor agonists, cholesterol synthesis inhibitors, such as HMG-coenzyme A reductase inhibitors or squalene synthesis inhibitors, ACAT inhibitors, CETP inhibitors agents, MTP inhibitors, PPAR- ⁇ , PPAR- ⁇ and/or PPAR- ⁇ agonists, cholesterol absorption inhibitors, lipase inhibitors,
- the compound of the present invention can also be administered in combination with other active ingredients other than the above-mentioned active ingredients.
- the compound of the present invention is administered in combination with a diuretic, such as furosemide, bumetanide, torsemide, benzflurazine, kurose, hydrochlorothiazide, hydrofluoromethiazine, mechlorothiazide, polithiazide, trichlorothiazide, chlorthalidone, indapamide, metolazone, quetzol, acetazolamide, dichlorobenzenesulfonamide, methazolamide, glycerol, isosorbide, mannitol, amiloride or triamterene.
- a diuretic such as furosemide, bumetanide, torsemide, benzflurazine, kurose, hydrochlorothiazide, hydrofluoromethiazine, mechlorothiazide,
- the compound is characterized by the corresponding structure.
- the compounds of the invention can be prepared by the methods described herein.
- the following non-limiting schemes and examples are presented to further exemplify the invention.
- Anhydrous THF, dioxane, toluene, and ether were obtained by refluxing the solvent with sodium.
- Anhydrous CH 2 Cl 2 and CHCl 3 were obtained by refluxing the solvent with CaH 2 .
- EtOAc, PE, hexane, DMAC and DMF were treated with anhydrous Na 2 SO 4 prior use.
- reaction flasks were typically fitted with rubber septa for the introduction of substrates and reagents via syringe. Glassware was oven dried and/or heat dried.
- MS data were determined by an Agilent 6320 Series LC-MS spectrometer equipped with a G1312A binary pump and a G1316A TCC (column was operated at 30 °C). G1329A autosampler and G1315B DAD detector were applied in the analysis, and an ESI source was used in the LC-MS spectrometer.
- MS data were determined by an Agilent 6120 Series LC-MS spectrometer equipped with a G1311A quaternary pump and a G1316A TCC (column was operated at 30 °C). G1329A autosampler and G1315D DAD detector were applied in the analysis, and an ESI source was used on the LC-MS spectrometer.
- Both LC-MS spectrometers were equipped with an Agilent Zorbax SB-C18, 2.1 ⁇ 30 mm, 5 ⁇ m column. Injection volume was decided by the sample concentration. The flow rate was 0.6 mL/min. The HPLC peaks were recorded by UV-Vis wavelength at 210 nm and 254 nm. The mobile phase was 0.1 % formic acid in acetonitrile (phase A) and 0.1% formic acid in ultrapure water (phase B).
- Table 1 The gradient condition of the mobile phase in Low-resolution mass spectrum analysis Time (min) A (CH 3 CN, 0.1% HCOOH) B (H 2 O, 0.1% HCOOH) 0-3 5 - 100 95 - 0 3-6 100 0 6 - 6.1 100-5 0-95 6.1 - 8 5 95
- the HPLC method for testing the atropisomer excess (% ee) is as follows: chromatographic column: CHIRALPAK AS-H 4.6 ⁇ 250 mm 5 ⁇ m; flow rate: 1.0 mL/min; column temperature: 30°C; detection wavelength: 290 nm; diluent: ethanol; mobile phase A: 0.1% TFA: ETOH; mobile phase B: n-hexane; running time: 30 min.
- the gradient elution conditions were showed in Table 2: Table 2 Time (min) A% B% 0 20 80 30 20 80
- the peak area ratio of the S configuration and the R configuration is used to calculate the corresponding enantiomeric excess (% ee).
- DMSO- d 6 deuterated dimethyl sulfoxide; g grams; mg milligrams; mol moles; mmol millimoles; mL milliliters; ⁇ L microliters
- reaction schemes describe the steps for preparing the compounds disclosed herein.
- R 1 , R 2a , R 2b , R 2c , R 2d and R 2e all have the meanings as described herein;
- L 1 is a leaving group such as Cl, Br, I, methylsulfonyl or p -toluenesulfonyl.
- the reaction in each step of the reaction scheme is carried out in a solvent inert to the reaction.
- the solvents inert to the reaction includes, but are not limited to, the solvents involved in the embodiments or their substitutes.
- the intermediate compound S5 can be prepared by the following method: compound S1 undergoes substitution reaction with bromine to obtain compound S2 ; compound S2 undergoes substitution reaction with ethyl cyanoacetate to obtain compound S3 ; compound S3 reacts under acidic conditions to obtain compound S4 , and finally, compound S4 undergoes dechlorination reaction under the action of a suitable hydrogen transfer reagent to obtain intermediate compound S5 .
- the intermediate compound S5 can also be prepared by the following method: compound S6 undergoes substitution reaction with N -bromosuccinimide (NBS) to obtain compound S7 ; compound S7 undergoes a coupling reaction with phenylboronic acid compound S-a to obtain intermediate compound S5 .
- NBS N -bromosuccinimide
- the intermediate compound S11 can be prepared according to one of the following methods:
- Compound S15 can be prepared according to the method as described in Scheme 1 .
- the reaction process is as follows: compound S11 reacts with a suitable acylating reagent (such as oxalyl chloride) to obtain compound S14 ; S14 undergoes an acylation reaction with 3-fluoro-4-methylsulfonyl aniline to obtain compound S15 .
- a suitable acylating reagent such as oxalyl chloride
- Compound S15 can also be prepared according to the method as described in Scheme 2 .
- the reaction process is as follows: Compound S11 undergoes a condensation reaction with 3-fluoro-4-methylsulfonyl aniline under the action of a suitable reagent (such as a condensation reagent) to obtain compound S15 .
- a suitable reagent such as a condensation reagent
- Compound S16 can be prepared according to the method as described in Scheme 3 .
- the reaction process is as follows: Compound S14 undergoes an acylation reaction with the corresponding aromatic amine substrate to obtain compound S16 .
- Potassium carbonate (166.6 g, 1205 mmol) was weighed and added into a 2000 mL flask, to the flask was added ethyl cyanoacetate (128 mL, 1203 mmol). The mixture was heated to 50°C and stirred for 2 h. The flask was removed and cooled to room temperature, a solution of 2-bromo-1-(2-(trifluoromethyl)phenyl)propan-1-one (188 g, 668.9 mmol) in acetone (1000 mL) was added dropwise. The mixture was stirred at room temperature overnight after addition. The reaction solution was filtered with diatomite, and the filter cake was washed with acetone (50 mL ⁇ 3).
- Ethyl 2-chloro-4-methyl-5-(2-(trifluoromethyl)phenyl)-1 H -pyrrole-3-carboxylate (93.1 g, 281 mmol) was weighed and added into a 2000 mL flask, to the flask were added ethanol (635 mL), tetrahydrofuran (115 mL), water (47 mL), sodium formate (25.17 g, 370.1 mmol) and palladium on carbon (9.79 g, 10 mass%). The mixture was heated to 65°C and stirred for 4.5 h after addition. The reaction solution was cooled to room temperature, to the reaction solution was added tetrahydrofuran (93 mL).
- Step 2) Ethyl 4-methyl-5-(2-(trifluoromethyl)phenyl)-1 H -pyrrole-3-carboxylate
- Ethyl 5-bromo-4-methyl-1 H -pyrrole-3-carboxylate (15.8 g, 68.1 mmol) was weighed and added into a 500 mL flask, to the flask were added 2-(trifluoromethyl)phenyl boronic acid (20.9 g, 110 mmol), lithium chloride (289.3 mg, 6.83 mmol), sodium carbonate solution (68 mL, 136 mmol, 2 mol/L), 1,4-dioxane (200 mL) and (1,1'-bis(diphenylphosphine)ferrocene)dichloride palladium dichloromethane complex (3.49 g, 4.19 mmol).
- Step 2) 1-(2-(Benzyloxy)ethyl)-4-methyl-5-(2-(trifluoromethyl)phenyl)-1 H -pyrrole-3-carboxylic acid
- N -(3-Fluoro-4-(methylsulfonyl)phenyl)-1-(2-hydroxyethyl)-4-methyl-5-(2-(trifluoro methyl)phenyl)-1 H -pyrrole-3-carboxamide (3.4 g, 7.02 mmol) was weighed and added into a 25 mL flask, and anhydrous acetonitrile (8 mL) was added to dissolve all the samples.
- High performance liquid chromatography (instrument: Waters SFC; column: Daicel AS-H 10 mm ⁇ 250 mm 5 ⁇ m; conditions: isocratic 20% MeOH + 80% CO 2 ; flow rate: 8 mL/min; column temperature: 35°C; back pressure: 100 bar; 10 ⁇ L samples per injection) was used for chiral resolution.
- the mixture was rotary evaporated under reduced pressure, and the solvent was removed to obtain the title compound as a white solid (1.43 g, 42.1%; HPLC retention time 8.627 min; purity 99.85%; ee value 99.80%).
- Methyl 1-hydroxy-1-cyclopropanecarboxylate (1.02 g, 8.78 mmol) was weighed and added into a 100 mL flask, to the flask N,N -dimethylformamide (30 mL)was added. The mixture was cooled to 0°C, and sodium hydride (521.6 mg, 13.04 mmol, 60 mass%) was added. The reaction solution was stirred at 0°C for 20 min and then benzyl bromide (1.1 mL, 9.3 mmol) was added. The mixture was reacted at room temperature for 3 h after addition.
- the organic phase was dried with anhydrous sodium sulfate, then filtered and concentrated directly to obtain a pale yellow solid (523.1 mg, 90.33%).
- Step 7) 1-((1-(Benzyloxy)cyclopropyl)methyl)- N -(3-fluoro-4-(methylsulfonyl)phenyl)-4-methyl-5-(2-(trifluoro (methyl)phenyl)-1 H -pyrrole-3-carboxamide
- Step 8) N- (3-Fluoro-4-(methylsulfonyl)phenyl)-1-((1-hydroxycyclopropyl)methyl)-4-methyl-5-(2-(tr ifluoromethyl)phenyl)-1 H -pyrrole-3-carboxamide
- Ethyl 4-methyl-5-(2-(trifluoromethyl)phenyl)-1 H -pyrrole-3-carboxylate (30 g, 100.9 mmol) was weighed and added into a 1000 mL flask, then sodium hydroxide solution (60 mL, 1020 mmol, 17 mol/L) and ethanol (300 mL) were added. The mixture was heated to 70°C and stirred for 12 h. The solvent was removed by rotary evaporation under reduced pressure. Water (1000 mL) was added to the residue and stirred at room temperature for 30 min.
- Step 2) Benzyl 4-methyl-5-(2-(trifluoromethyl)phenyl)-1 H -pyrrole-3-carboxylate
- Benzyl 4-methyl-5-(2-(trifluoromethyl)phenyl)-1 H -pyrrole-3-carboxylate (1.0 g, 2.8 mmol) was weighed and added into a 100 mL flask, then N , N- dimethylformamide (25 mL) and sodium hydride (334.6 mg, 8.37 mmol, 60 mass%) were added. The mixture was stirred at room temperature for 10 min, and then bromocyclobutane (1.0 mL, 11 mmol) was added. After addition, the mixture was heated to 100°C and stirred for 15 h. The reaction solution was cooled to room temperature and extracted with ethyl acetate (60 mL ⁇ 3).
- Step 1) Benzyl 4-methyl-1-(oxetan-2-ylmethyl)-5-(2-(trifluoromethyl)phenyl)-1 H- pyrrole-3-carboxylate
- Step 2 4-Methyl-1-(oxetan-2-ylmethyl)-5-(2-(trifluoromethyl)phenyl)-1 H- pyrrole-3-carboxylic acid
- Step 1) Ethyl 4-methyl-1-(oxetan-3-yl)-5-(2-(trifluoromethyl)phenyl)-1 H -pyrrole-3-carboxylate
- Step 2) 4-Methyl-1-(oxetan-3-yl)-5-(2-(trifluoromethyl)phenyl)-1 H- pyrrole-3-carboxylic acid
- Ethyl 4-methyl-1-(oxetan-3-yl)-5-(2-(trifluoromethyl)phenyl)-1 H -pyrrole-3-carboxylate (365 mg, 1.03 mmol ) was weighed and added into a 50 mL flask, to the flask were added ethanol (10 mL) and sodium hydroxide solution (3.0 mL, 12 mmol, 4 mol/L). The mixture was heated to 70°C and stirred overnight.
- Step 1) Benzyl 4-methyl-1-(pyridin-3-yl)-5-(2-(trifluoromethyl)phenyl)-1 H- pyrrole-3-carboxylate
- Step 2) 4-Methyl-1-(pyridin-3-yl)-5-(2-(trifluoromethyl)phenyl)-1 H- pyrrole-3-carboxylic acid
- Step 2 4-fluoro-3-methyl-6-nitrobenzo[ d ]thiazole-2(3 H )-one
- reaction solution was extracted with ethyl acetate (50 mL ⁇ 3), and the organic phases were combined and washed with 1 M HCl solution (50 mL) and saturated brine (50 mL), and then dried with anhydrous sodium sulfate.
- reaction solution was suction filtered with diatomite, the filtrate was concentrated under reduced pressure.
- the resulting mixture was filtered with suction, and the filter cake was collected and dried at 50°C to obtain a white solid (100 mg, 39.42%).
- the plasmid containing mineralocorticoid receptor (MR) ligand binding domain (LBD) fused with Gal4 DNA binding domain (DBD) and the firefly luciferase reporter gene plasmid under the control of Gal4 UAS (upstream activation sequence) are transfected into human embryonic kidney cells (HEK293).
- MR mineralocorticoid receptor
- BBD Gal4 DNA binding domain
- HEK293 human embryonic kidney cells
- the plasmid with Renilla luciferase gene is used as a control plasmid to transfect cells to provide an internal control for transcriptional activity, so that the test results are not interfered by changes in experimental conditions.
- Example B The pharmacokinetics test of the compounds of the present invention
- test compound solution The test compound was formulated into a solution with 5% dimethyl sulfoxide, 60% PEG400 and 35% normal saline for oral or intravenous administration.
- Beagle dogs 8-10 kg were randomly divided into two groups, and the test compound was administered orally at a dosage of 5.0 mg/kg; after administration, blood was collected at the time points of 0.0833, 0.25, 0.5, 1.0, 2.0, 4.0, 6.0, 8.0, 24.0, 32.0 and 48.0 hours.
- a standard curve was established within a suitable range according to the sample concentration, and AB SCIEX API4000 LC-MS/MS was used to determine the concentration of the test compounds in the plasma sample in the MRM mode.
- the WinNonLin 6.3 software non-compartmental model method was used to calculate the pharmacokinetic parameters.
- Three female cynomolgus monkeys of 3.0-3.5 kg were taken and orally administered with the test compound at a dosage of 3 mg/kg; after the administration, blood was collected at the time points of 0.083, 0.25, 0.5, 1, 2, 4, 6, 8, 24, 32 and 48 hours.
- a standard curve was established within an appropriate range based on the sample concentration, and AB SCIEX API 5000 LC-MS/MS was used to determine the concentration of the test compounds in the plasma sample in the MRM mode.
- WinNnonlin 6.3 software non-compartmental model method was used to calculate the pharmacokinetic parameters.
- the compounds of the present invention have good pharmacokinetic properties in cynomolgus monkeys. Specifically, compared to the control compound CS-3150, the compound of Example 2 has more excellent pharmacokinetic properties, such as higher exposure, blood concentration and bioavailability.
- test compound solution The test compound was dissolved in dimethyl sulfoxide to obtain a 10 mg/mL solution, and then diluted with dimethyl sulfoxide in multiples of 2.15 times into solutions of different concentrations.
- Balb/c 3T3 cells were seeded on 96-well culture plates. After 24 hours of culture, the culture medium was discarded, different concentrations of test compounds or balanced salts (HBSS) solution containing positive control substance (chlorpromazine hydrochloride, CPZ) and vehicle control substance were added. Two culture plates of each concentration of the test compound and the positive control substance are a light (+UV) plate and a non-light (-UV) plate, respectively. After incubating for 1 hour, the light plate was placed under UVA with a light intensity of about 1.7 mw/cm 2 until the light dose reached 5.0 J/cm 2 . The non-light plate was placed at room temperature and protected from light for the same time.
- HBSS balanced salts
- the culture medium was replaced with fresh one and continuously cultured for 18-22 hours. About 3 hours before the culture was complete, the culture medium was replaced with a medium containing neutral red and serum-free. After incubation, neutral red eluent was added, the absorbance value (OD540) of each well at 540 nm was measured after shaking. The cell 50% inhibitory concentration (IC50), light stimulating factor (PIF) and/or average light effect (MPE) were calculated.
- IC50 inhibitory concentration
- PIF light stimulating factor
- MPE average light effect
Abstract
Description
- The present invention belongs to the field of pharmaceuticals, and specifically relates to a pyrrole amide compound and the use thereof. It further relates to a pharmaceutical composition comprising the compound. The compound or the pharmaceutical composition can be used as a mineralocorticoid receptor antagonist.
- Mineralocorticoid Receptor (MR) is a nuclear hormone receptor activated by aldosterone, which regulates the expression of many genes involved in electrolyte homeostasis and cardiovascular diseases. The increase in circulating aldosterone increases blood pressure through its effect on urinary sodium excretion, and potentially affects the brain, heart, and vascular system at the same time. In addition, hyperaldosteronism is related to many physiological processes that lead to kidney and cardiovascular diseases. Although hyperaldosteronism is usually caused by aldosterone-producing adenomas, patients with refractory hypertension often have elevated aldosterone levels, commonly referred to as "aldosterone escape", which is due to increased serum potassium levels or residual AT1R activity. Hyperaldosteronism and aldosterone escape typically lead to increased MR activity. It has been proven that MR antagonists can be effective antihypertensive agents and can also be effective in the treatment of heart failure and primary aldosteronism.
- Aldosterone is a steroid hormone formed in the adrenal cortex. Its production greatly depends on renal blood flow and is indirectly regulated. Any reduction in renal blood flow causes the enzyme renin in the kidney to be released and enter the circulating blood. This in turn activates the formation of angiotensin II, which on the one hand has a constrictive effect on arterial blood vessels, but on the other hand also stimulates the formation of aldosterone in the adrenal cortex. Thus, the kidney is used as a blood pressure sensor in the blood circulation, and thus indirectly as a volume sensor, and the serious loss of volume is offset by the renin-angiotensin-aldosterone system. This is achieved on the one hand by increasing blood pressure (angiotensin II effect), on the other hand by increasing the reabsorption of sodium and water in the kidney to rebalance the filling state of the vascular system (aldosterone effect).
- The control system can be damaged in various ways. For example, a chronic decrease in renal blood flow (eg, due to heart failure and the resulting blood blockage in the venous system) results in chronic excess release of aldosterone. This is followed by the expansion of blood volume and thereby increasing the weakness of the heart by increasing the supply of blood volume to the heart. The obstruction of blood in the lungs, along with shortness of breath and the formation of edema of the limbs, and ascites and pleural effusion may result from this; renal blood flow decreases further. In addition, excessive aldosterone leads to a decrease in the potassium concentration in the blood and extracellular fluid. In myocardium that has been damaged in other ways before, if there is a deviation below the critical minimum level, it may induce fatal cardiac arrhythmia. This is likely to be one of the main causes of sudden cardiac death that often occurs in patients with heart failure.
- In addition, it has also been reported that aldosterone determines many of the myocardial remodeling processes that are typically observed in heart failure. Thus, hyperaldosteronism is a decisive component of the pathogenesis and prognosis of heart failure, which can be initially induced by various types of injury, such as myocardial infarction, myocardial inflammation, or hypertension. This hypothesis is supported by the fact that in an extensive clinical study of patients with chronic heart failure and post-acute myocardial infarction through the use of aldosterone antagonists, overall mortality was significantly reduced (B. Pitt, F. Zannad, WJ Remme et al., N. Engl. J. Med. ML 709-717 (1999); B. Pitt, W. Remme, F. Zannad et al., N. Engl. J. Med 1309-1321 (2003)).
- In addition, in visceral tissues, such as kidneys and intestines, MR regulates sodium retention, potassium excretion, and water balance in response to aldosterone. The expression of MR in the brain also seems to play a role in controlling neuronal excitability, negative feedback regulation of the hypothalamic-pituitary adrenal axis, and cognitive aspects of behavioral performance (Castren et al., J. of Neuroendocrinology, 3, 461-66 (1993)).
- Increased levels of aldosterone or excessive stimulation of mineralocorticoid receptors are related to some physiological disorders or pathological conditions, including Conen's syndrome, primary and secondary hyperaldosteronism, and increased sodium retention, increased excretion of magnesium and potassium (polyuria), increased water retention, hypertension (isolated systolic hypertension and combined systolic/diastolic hypertension), arrhythmia, myocardial fibrosis, myocardial infarction, Bart's syndrome, and disorders related to excessive catecholamine levels (Hadley, ME, ENDOCRINOLOGY, 2nd Ed., pp366-81, (1988); and Brilla et al., Journal of Molecular and Cellular Cardiology, 25(5), pp563-75 (1993)). Compounds and/or pharmaceutical compositions with MR antagonism have therapeutic value for any of the above-mentioned conditions.
- International application
WO 2006012642 A2 discloses a pyrrole derivative - a racemate of Esaxerenone (CS-3150, whose chemical structure is shown below), which is used to modulate the activity of one or more steroid nuclear receptors. Patent applicationWO 2008126831 A1 discloses Esaxerenone with a stereo-configuration, which can be used to treat diseases such as hypertension. According to the "Examination Report" (January 8, 2019) published by PMDA, Japan's Pharmaceuticals and Medical Devices Agency, the compound has phototoxicity. For example, in vitro Balb/c 3T3 fibroblast neutral red uptake test results show the compound is phototoxic (light stimulus factor PIF> 17). - Although mineralocorticoid receptor antagonists have made significant progress in the treatment of hypertension and heart failure, the current standard of care is only close to the best, and there are still obvious unmet medical needs for other treatments/pharmacological interventions. The present invention addresses those needs by providing compounds and compositions that can be used to treat or prevent hypertension, heart failure, other cardiovascular disorders, and other aldosterone disorders.
- The present invention provides a pyrrole amide compound with mineralocorticoid receptor (MR) antagonism and a pharmaceutical composition thereof, as well as the use of the compound or the pharmaceutical composition in the manufacture of a medicament for treating, preventing or alleviating hyperaldosteronism, hypertension, chronic heart failure, sequelae of myocardial infarction, liver cirrhosis, non-alcoholic steatohepatitis, chronic kidney disease, diabetic nephropathy, renal failure, fibrosis and/or stroke, and the like in patients.
-
- wherein, R1 is C1-6 alkyl, C3-6 cycloalkyl, C6-10 aryl, 3-6 membered heterocyclyl or 5-10 membered heteroaryl, wherein, the C1-6 alkyl, C3-6 cycloalkyl, C6-10 aryl, 3-6 membered heterocyclyl and 5-10 membered heteroaryl are independently and optionally substituted with 1, 2, 3 or 4 Ra;
- each Ra is independently D, F, Cl, Br, OH, NH2, SH, CN, NO2, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C1-6 haloalkyl, C3-6 cycloalkyl, C6-10 aryl, 3-6 membered heterocyclyl or 5-10 membered heteroaryl; wherein, the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C1-6 haloalkyl, C3-6 cycloalkyl, C6-10 aryl, 3-6 membered heterocyclyl and 5-10 membered heteroaryl are independently unsubstituted or substituted with 1, 2, 3 or 4 substituents selected from D, F, Cl, Br, OH, NH2, SH, CN, NO2, C1-6 alkyl, C2 -6 alkenyl, C2-6 alkynyl, C1-6 alkoxy and C1-6 haloalkyl;
- each of R2a, R2b, R2c, R2d and R2e is independently H, D, F, Cl, Br, OH, NH2, SH, CN, NO2, -C(=O)C1-6 alkyl, -C(=O)OC1-6 alkyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C1-6 alkylamino , C3-6 cycloalkyl, C6-10 aryl, 3-6 membered heterocyclyl or 5-10 membered heteroaryl;
- each of R2 and R3 is independently H, D, F, Cl, Br, OH, NH2, SH, CN, NO2, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl or C1-6 haloalkyl;
- each of R4, R5, R6 and R7 is independently H, D, F, Cl, Br, OH, NH2, SH, CN, NO2, -C(=O)C1-6 alkyl, -C(=O)OC1-6 alkyl, -S-C1-6 alkyl, -S(=O)C1-6 alkyl, -S(=O)2C1-6 alkyl, -S(=O)2NRbRc, -S(=O)2OC1-6 alkyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C1-6 alkylamino, C3-6 cycloalkyl, C6-10 aryl, 3-6 membered heterocyclyl or 5-10 membered heteroaryl; or
- R5 and R6 together with the carbon atom to which they are attached, form a C3-6 carbocyclic ring, a C6-10 aromatic ring, a 3-6 membered heterocyclic ring or a 5-10 membered heteroaromatic ring, wherein each of the C3-6 carbocyclic ring, C6-10 aromatic ring, 3-6 membered heterocyclic ring and the 5-10 membered heteroaromatic ring is independently unsubstituted or substituted with 1, 2, 3, 4 or 5 substituents independently selected from =O, D, F, Cl, Br, OH, NH2, SH, CN, NO2, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy and C1-6 alkylamino;
- each of R8, Rb and Rc is independently H, D, C1-6 alkyl or C1-6 haloalkyl.
- In some embodiments, each of R2 and R3 is independently H, D, F, Cl, Br, OH, NH2, SH, CN, NO2, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl or difluoromethyl;
- each of R4, R5, R6 and R7 is independently H, D, F, Cl, Br, OH, NH2, SH, CN, NO2, -C(=O)CH3, -C(=O)OCH3, -S-CH3, -S(=O)CH3, -S(=O)2CH3, -S(=O)2CH2CH3, -S(=O)2NRbRc, -S(=O)2OCH3, methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, vinyl, ethynyl, methoxy, ethoxy, isopropoxy, tert-butoxy, trifluoromethyl, difluoromethyl, monofluoromethyl, 2,2-difluoroethyl, trifluoromethoxy, methylamino, dimethylamino, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, oxiranyl, azetidinyl, oxetanyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, morpholinyl, pyrrolyl, pyridyl, pyrimidinyl or quinolinyl; or
- R5 and R6 together with the carbon atom to which they are attached, form cyclobutene, cyclopentene, cyclohexene, benzene, dihydrofuran, dihydrothiazole, dihydroimidazole, dihydropyrazole, dihydrooxazole, dihydropyrrole, tetrahydropyridine, dihydro-1,4-oxazine, pyrrole, pyridine, pyrimidine or quinoline, wherein each of the cyclobutene, cyclopentene, cyclohexene, benzene ring, dihydrofuran, dihydrothiazole, dihydroimidazole, dihydropyrazole, dihydrooxazole, dihydropyrrole, tetrahydropyridine, dihydro-1,4-oxazine, pyrrole, pyridine, pyrimidine and quinoline is independently unsubstituted or substituted with 1, 2, 3, 4 or 5 substituents independently selected from =O, D, F, Cl, Br, OH, NH2, SH, CN, NO2, methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, vinyl, ethynyl, methoxy, ethoxy, isopropoxy, tert-butoxy, trifluoromethyl, difluoromethyl, monofluoromethyl, 2,2-difluoroethyl, trifluoromethoxy, methylamino and dimethylamino;
- each of R8, Rb and Rc is independently H, D, methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, trifluoromethyl, difluoromethyl, monofluoromethyl or 2,2-difluoroethyl.
- In some embodiments, the compound having Formula (I) provided herein is preferably a compound having Formula (Ia) or a stereoisomer, a geometric isomer, a tautomer, an atropisomer, an N-oxide, a hydrate, a solvate, a metabolite, an ester, a pharmaceutically acceptable salt or a prodrug thereof,
- In some embodiments, each of R2a, R2b, R2c, R2d and R2e is independently H, D, F, Cl, Br, OH, NH2, SH, CN, NO2, -C(=O)CH3, -C(=O)OCH3, methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, vinyl, ethynyl, methoxy, ethoxy, isopropoxy, tert-butoxy, trifluoromethyl, difluoromethyl, monofluoromethyl, 2,2-difluoroethyl, trifluoromethoxy, methylamino, dimethylamino, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, oxiranyl, azetidinyl, oxetanyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, morpholinyl, pyrrolyl, pyridyl, pyrimidinyl or quinolinyl.
- In some embodiments, the compound having Formula (I) provided herein is preferably a compound having Formula (IIa) or a stereoisomer, a geometric isomer, a tautomer, an atropisomer, an N-oxide, a hydrate, a solvate, a metabolite, an ester, a pharmaceutically acceptable salt or a prodrug thereof,
- In some embodiments, R1 is C1-4 alkyl, C3-6 cycloalkyl, phenyl, 3-6 membered heterocyclyl or 5-6 membered heteroaryl, wherein the C1-4 alkyl, C3-6 cycloalkyl, phenyl, 3-6 membered heterocyclyl and the 5-6 membered heteroaryl are independently and optionally substituted by 1, 2, 3 or 4 Ra;
each Ra is independently D, F, Cl, Br, OH, NH2, SH, CN, NO2, methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, vinyl, ethynyl, methoxy, ethoxy, isopropoxy, tert-butoxy, trifluoromethyl, difluoromethyl, monofluoromethyl, 2,2-difluoroethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, oxiranyl, azetidinyl, oxetanyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, morpholinyl, pyrrolyl, pyridyl, pyrimidinyl or quinolinyl; wherein the methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, vinyl, ethynyl, methoxy, ethoxy, isopropoxy, tert-butoxy, difluoromethyl, monofluoromethyl, 2,2-difluoroethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, oxiranyl, azetidinyl, oxetanyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, morpholinyl, pyrrolyl, pyridyl, pyrimidinyl and quinolinyl are independently unsubstituted or substituted with 1, 2, 3 or 4 substituents independently selected from D, F, Cl, Br, OH, NH2, SH, CN, NO2, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C1-4 alkoxy and C1-4 haloalkyl. - In some embodiments, R1 is methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, oxiranyl, azetidinyl, oxetanyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, morpholinyl, pyrrolyl, pyridyl or pyrimidine, wherein the methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, oxiranyl, azetidinyl, oxetanyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, morpholinyl, pyrrolyl, pyridyl and pyrimidinyl are independently and optionally substituted by 1, 2, 3 or 4 Ra;
each Ra is independently D, F, Cl, Br, OH, NH2, SH, CN, NO2, methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, vinyl, ethynyl, methoxy, ethoxy, isopropoxy, tert-butoxy, trifluoromethyl, difluoromethyl, monofluoromethyl, 2,2-difluoroethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, oxiranyl, azetidinyl, oxetanyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, morpholinyl, pyrrolyl, pyridyl, pyrimidinyl or quinolinyl; wherein the methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, vinyl, ethynyl, methoxy, ethoxy, isopropoxy, tert-butoxy, difluoromethyl, monofluoromethyl, 2,2-difluoroethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, oxiranyl, azetidinyl, oxetanyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, morpholinyl, pyrrolyl, pyridyl, pyrimidinyl and quinolinyl are independently unsubstituted or substituted with 1, 2, 3 or 4 substituents independently selected from D, F, Cl, Br, OH, NH2, SH, CN, NO2, methyl, ethyl, n-propyl, isopropyl, C2-4 alkenyl, C2-4 alkynyl, methoxy, ethoxy, isopropoxy, trifluoromethyl, difluoromethyl, monofluoromethyl and 2,2-difluoroethyl. - In another aspect, the present invention relates to a pharmaceutical composition comprising the compound of the present invention; optionally, the pharmaceutical composition further comprises at least one of pharmaceutically acceptable carriers, excipients, diluents, adjuvants and vehicles.
- In some embodiments, the pharmaceutical composition provided herein further comprises one or more other active ingredients, and the other active ingredient is an ACE inhibitor, a renin inhibitor, an angiotensin II receptor antagonist, a β-receptor blocker, acetylsalicylic acid, a diuretic, a calcium antagonist, a statin, a digitalis derivative, a calcium sensitizer, a nitrate or an antithrombotic agent.
- In one aspect, the present invention relates to the use of the compound or the pharmaceutical composition in the manufacture of a medicament for treating, preventing or alleviating the following diseases in patients: hyperaldosteronism, hypertension, chronic heart failure, sequelae of myocardial infarction, liver cirrhosis, non-alcoholic steatohepatitis, chronic kidney disease, diabetic nephropathy, renal failure, fibrosis and/or stroke.
- In another aspect, the present invention relates to the use of the compound or the pharmaceutical composition in the manufacture of a medicament, wherein the medicament is used as a mineralocorticoid receptor antagonist.
- Reference will now be made in detail to certain embodiments of the invention, examples of which are illustrated in the accompanying structures and formulas. The invention is intended to cover all alternatives, modifications, and equivalents which may be included within the scope of the present invention as defined by the claims. One skilled in the art will recognize many methods and materials similar or equivalent to those described herein, which could be used in the practice of the present invention. The present invention is in no way limited to the methods and materials described herein. In the event that one or more of the incorporated literature, patents, and similar materials differs from or contradicts this application, including but not limited to defined terms, term usage, described techniques, or the like, this application controls.
- It is further appreciated that certain features of the invention, which are, for clarity, described in the context of separate embodiments, can also be provided in combination in a single embodiment. Conversely, various features of the invention which are, for brevity, described in the context of a single embodiment, can also be provided separately or in any suitable subcombination.
- Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one skilled in the art to which this invention belongs. All patents and publications referred to herein are incorporated by reference in their entirety.
- As used herein, the following definitions shall apply unless otherwise indicated. For purposes of this invention, the chemical elements are identified in accordance with the Periodic Table of the Elements, CAS version, and the Handbook of Chemistry and Physics, 75th Ed. 1994. Additionally, general principles of organic chemistry are described in "Organic Chemistry", Thomas Sorrell, University Science Books, Sausalito: 1999, and Smith et al., "March's Advanced Organic Chemistry", John Wiley & Sons, New York: 2007, the entire contents of which are hereby incorporated by reference.
- The grammatical articles "a", "an" and "the", as used herein, are intended to include "at least one" or "one or more" unless otherwise indicated herein or clearly contradicted by the context. Thus, the articles used herein refer to one or more than one (i.e. at least one) articles of the grammatical objects. By way of example, "a component" means one or more components, and thus, possibly, more than one component is contemplated and may be employed or used in an implementation of the described embodiments.
- As used herein, "patient" refers to a human (including adults and children) or other animal. In some embodiments, "patient" refers to a human.
- The term "comprise" is an open expression, it means comprising the contents disclosed herein, but don't exclude other contents.
- "Stereoisomers" refers to compounds which have identical chemical constitution, but differ with regard to the arrangement of the atoms or groups in space. Stereoisomers include enantiomer, diastereomers, conformer (rotamer), geometric (cis/trans) isomer, atropisomer, etc.
- "Enantiomers" refers to two stereoisomers of a compound which are non-superimposable mirror images of one another.
- "Diastereomer" refers to a stereoisomer with two or more centers of chirality and whose molecules are not mirror images of one another. Diastereomers have different physical properties, e.g., melting points, boling points, spectral properties or biological activities. Mixture of diastereomers may separate under high resolution analytical procedures such as electrophoresis and chromatography such as HPLC.
- "Atropisomers" refer to structural isomers based on axial or planar chirality due to restricted intramolecular rotation. The compound of the present invention has two atropisomers. For example, the compound having formula (II) has two atropisomers, which is resulting from the axial chirality derived from the restriction of the rotation due to steric hindrance of the bond between the phenyl substituted by trifluoromethyl at the ortho position and the substituted pyrrole ring. The "atropisomer" of the present invention is any one of the two atropisomers of the compound provided herein. However, an atropisomer having more excellent pharmacological activity, stability, in vivo kinetic properties, safety, etc., and thus having advantageous properties as a drug is preferred. The separation of atropisomers can be accomplished by chiral resolution techniques, such as selective crystallization or high performance liquid chromatography.
- Stereochemical definitions and conventions used herein generally follow S. P. Parker, Ed., McGraw-Hill Dictionary of Chemical Terms (1984) McGraw-Hill Book Company, New York; and Eliel, E. and Wilen, S., "Stereochemistry of Organic Compounds", John Wiley & Sons, Inc., New York, 1994.
- Any asymmetric atom (e.g., carbon or the like) of the compound(s) disclosed herein can be present in racemic or enantiomerically enriched, for example the (R)-, (S)- or (R, S)-configuration. In certain embodiments, each asymmetric atom has at least 50 % enantiomeric excess, at least 60 % enantiomeric excess, at least 70 % enantiomeric excess, at least 80 % enantiomeric excess, at least 90 % enantiomeric excess, at least 95 % enantiomeric excess, or at least 99 % enantiomeric excess in the (R)- or (S)- configuration.
- Any resulting mixtures of stereoisomers can be separated on the basis of the physicochemical differences of the constituents, into the pure or substantially pure geometric isomers, enantiomers, diastereomers, for example, by chromatography and/or fractional crystallization. Cis and trans isomers are diastereomer.
- The term "tautomer" or "tautomeric form" refers to structural isomers of different energies which are interconvertible via a low energy barrier. Where tautomerization is possible (e.g. in solution), a chemical equilibrium of tautomers can be reached. For example, protontautomers (also known as prototropic tautomers) include interconversions via migration of a proton, such as keto-enol and imine-enamine isomerizations. Valence tautomers include interconversions by reorganization of some of the bonding electrons. A specific example of keto-enol tautomerization is the interconversion of pentane-2,4-dione and 4-hydroxypent-3-en-2-one tautomers. Another example of tautomerization is phenol-keto tautomerization. The specific example of phenol-keto tautomerisms is pyridin-4-ol and pyridin-4(1H)-one tautomerism. Unless otherwise stated, all tautomeric forms of the compounds disclosed herein are within the scope of the invention.
- As described herein, compounds disclosed herein may optionally be substituted with one or more substituents, such as are illustrated generally below, or as exemplified by particular classes, subclasses, and species of the invention.
- Furthermore, what need to be explained is that the phrases "each...is independently" and "each of...and...is independently", unless otherwise stated, should be broadly understood, which can mean that the specific options expressed by the same symbol are independent of each other in different groups; or the specific options expressed by the same symbol are independent of each other in same groups. Similarly, the "independently" in the phrase "...independently and optionally" should be broadly understood.
- The term "optional" or "optionally" refers to that a subsequently described event or circumstance may but need not occur, and that the description includes instances where the event or circumstance occurs and instances in which it does not. For example, "independently and optionally substituted by one or more...substituents" means that the group is unsubstituted or substituted by one or more identical or different substituents.
- At each part of the present specification, substitutes of compounds disclosed herein are disclosed in groups or in ranges. It is specifically intended that the invention includes each and every individual subcombination of the members of such groups and ranges. For example, the term "C1-C6 alkyl" or "C1-6 alkyl" specifically refers to independently disclosed methyl, ethyl, C3 alkyl, C4 alkyl, C5 alkyl and C6 alkyl; "C1-4 alkyl" specifically refers to independently disclosed methyl, ethyl, C3 alkyl (i.e. propyl, including n-propyl and isopropyl) and C4 alkyl (i.e. butyl, including n-butyl, isobutyl, sec-butyl and tert-butyl).
- At various places in the present specification, linking substituents are described. Where the structure clearly requires a linking group, the Markush variables listed for that group are understood to be linking groups. For example, if the structure requires a linking group and the Markush group definition for that variable lists "alkyl" or "aryl" then it is understood that the "alkyl" or "aryl" represents a linking alkylene group or arylene group, respectively.
- The term "alkyl" or "alkyl group" refers to a saturated linear or branched-chain monovalent hydrocarbon group of 1-20 carbon atoms, wherein the alkyl group is optionally substituted with one or more substituents described herein. In some embodiments, the alkyl group contains 1-12 carbon atoms. In other embodiments, the alkyl group contains 1-6 carbon atoms, i.e. C1-6 alkyl. In still other embodiments, the alkyl group contains 1-4 carbon atoms, i.e. C1-4 alkyl. In yet other embodiments, the alkyl group contains 1-3 carbon atoms, i.e. C1-3 alkyl. In some embodiments, the C1-6 alkyl group described herein includes C1-4 alkyl; in other embodiments, the C1-6 alkyl described herein includes C1-3 alkyl.
- Some non-limiting examples of the alkyl group include methyl, ethyl, propyl (including n-propyl and isopropyl), butyl (including n-butyl, isobutyl, sec-butyl, tert-butyl), n-pentyl, 2-pentyl, 3-pentyl, 2-methyl-2-butyl, 3-methyl-2-butyl, 3-methyl-1-butyl, 2-methyl-1-butyl, n-hexyl, 2-hexyl, 3-hexyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 3-methyl-3-pentyl, 2-methyl- 3-pentyl, 2,3-dimethyl-2-butyl, 3,3-dimethyl-2-butyl, n-heptyl, n-octyl, etc.
- The term "alkoxy" refers to an alkyl group, as previously defined, attached to parent molecular moiety via an oxygen atom. Some non-limiting examples of the alkoxy group include methoxy, ethoxy, propoxy (including 1-propoxy or 2-propoxy), butoxy (including n-butoxy, isobutoxy, sec-butoxy, tert-butoxy), etc.
- The term "haloalkyl" or "haloalkoxy" refer to an alkyl or alkoxy group is substituted by one or more halogen atoms. Some non-limiting examples of this include trifluoromethyl, difluoromethyl, monofluoromethyl, trifluoromethoxy, chloroethyl (for example, 2-chloroethyl), trifluoroethyl (including but not limited to, 2,2,2-trifluoroethyl), 2,2-difluoroethyl, 2-chloro-1-methylethyl, etc.
- The term "amino" refers to the group -NH2. The term "carboxy" refers to the group -COOH. The terms "hydroxyl", "cyano", "nitro" and "mercapto" represent the groups -OH, -CN, -NO2, -SH, respectively. The term "oxo" represents the group =O.
- The term "alkylamino" refers to the group -NH2 is substituted by one or two alkyl groups, wherein the alkyl group has the meaning as described herein. Some non-limiting examples of the alkyl group include methylamino, ethylamino, methylethylamino, dimethylamino, etc.
- The term "carbocyclyl" refers to a saturated or partially unsaturated ring having 3 to 14 ring carbon atoms as a monocyclic, bicyclic, or tricyclic ring system, which has one or more attachments attaching to the rest of the molecule, wherein the carbocyclyl is optionally substituted with the substituents described herein. The term "carbocyclic ring" can be used interchangeably with the term "carbocyclyl". Some non-limiting examples of the carbocyclic ring include cyclopropane, cyclobutane, cyclopentane, cyclohexane, cyclopentene, cyclohexene, cyclopentadiene, etc.
- The term "cycloalkyl" refers to a saturated monocyclic, bicyclic or tricyclic ring system containing 3-12 ring carbon atoms. In some embodiments, cycloalkyl contains 3-10 ring carbon atoms, such as C3-10 cycloalkyl; in other embodiments, cycloalkyl contains 3-8 ring carbon atoms, such as C3-8 cycloalkyl; in still other embodiments, the cycloalkyl contains 3-6 ring carbon atoms, such as C3-6 cycloalkyl. Examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, and the like. Wherein, as described in the present invention, C3-8 cycloalkyl includes C3-6 cycloalkyl; the C3-6 cycloalkyl includes cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. The cycloalkyl group may be optionally substituted with one or more substituents disclosed herein.
- The term "heterocyclyl" refers to a saturated or partially unsaturated monocyclic, bicyclic or tricyclic ring system containing 3-12 ring atoms, in which at least one ring member is selected from nitrogen, sulfur and oxygen. Wherein, the heterocyclyl is non-aromatic and does not contain any aromatic ring. Unless otherwise specified, the heterocyclyl group may be carbon or nitrogen linked, and a -CH2- group can be optionally replaced by a -C(=O)- group. In which, the sulfur can be optionally oxygenized to S-oxide, and the nitrogen can be optionally oxygenized to N-oxide. The term "heterocyclic ring" can be used interchangeably with the term "heterocyclic". Some non-limiting examples of the heterocyclic include oxiranyl, azetidinyl, oxetanyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydrothienyl, thiazolidinyl, pyrazolidinyl, oxazolidinyl, imidazolidinyl, isoxanyl oxazolidinyl, piperidinyl, piperazinyl or morpholinyl, etc. As described herein, the heterocyclic can be composed of 3-8 members or 3-6 members, the members are optionally selected from C, N, O or S and at least one member is N, O or S. Wherein the 3-8 membered heterocyclyl includes a heterocyclyl composed of 3-6 members; the 3-6 membered heterocyclyl includes a heterocyclyl composed of 3-5 members. Specifically, the 3-6 membered heterocyclyl includes, but is not limited to, oxiranyl(
- The term "halogen" refers to fluorine(F), chlorine(Cl), bromine(Br) or iodine(I).
- The term "aryl" refers to monocyclic, bicyclic and tricyclic carbocyclic ring systems having a total of 6 to 14 ring members, or 6 to 12 ring members, or 6 to 10 ring members, wherein at least one ring is aromatic and that has a single point or multipoint of attachment to the rest of the molecule. The term "aryl" and "aromatic ring" can be used interchangeably herein. Some non-limiting examples of the aryl group include phenyl, 2,3-dihydro-1H-indenyl, naphthalenyl and anthracenyl. The aryl group may be optionally substituted with one or more substituents disclosed herein. Unless otherwise specified, the group "C6-10 aryl" refers to an aryl group containing 6-10 ring carbon atoms.
- The term "heteroaryl" refers to monocyclic, bicyclic and tricyclic ring systems having a total of 5 to 12 ring members, 5 to 10 ring members, or 5 to 6 ring atoms, wherein at least one ring is aromatic, and in which at least one ring contains 1, 2, 3 or 4 ring heteroatoms selected from nitrogen, oxygen, and sulfur, and the heteroaryl has a single point or multipoint of attachment to the rest of the molecule. When a -CH2- group is present in the heteroaryl, the -CH2- group may be optionally replaced by -C(=O)-. Unless otherwise stated, the heteroaryl group may be connected to the rest of the molecule (such as the parent nucleus structure in the general formula) through any reasonable position (which may be C in CH or N in NH). The term "heteroaryl" and "heteroaromatic ring" or "heteroaromatic compound" can be used interchangeably herein. Some non-limiting examples of the heteroaryl include furyl, imidazolyl, pyrrolyl, pyrazolyl, pyridyl, pyrimidinyl, pyrazinyl, etc. The heteroaryl group may be optionally substituted with one or more substituents disclosed herein. In some embodiments, the heteroaryl is composed of 5-10 members, which refers to the heteroaryl containing 1-9 ring carbon atoms and 1, 2, 3 or 4 ring heteroatoms selected from O, S and N. In some embodiments, the heteroaryl is composed of 5-6 members, which refers to the heteroaryl containing 1-5 ring carbon atoms and 1, 2, 3 or 4 ring heteroatoms selected from O, S and N. Some non-limiting examples of the 5-6 membered heteroaryl include furyl, imidazolyl, isoxazolyl, oxazolyl, pyrrolyl, pyrazolyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, thienyl, thiazolyl, etc.
- The term "j-k membered" refers to the ring group consisted of j to k ring atoms, the ring atoms include carbon atom and/or heteroatoms such as O, N, S, P, and so on; the j and k are each independently any non-zero natural number, and k > j; the "j-k" includes j, k and any natural number between them. For example, "3-8 membered", "5-10 membered" or "5-6 membered" refers to the ring group consisted of 3-8, 5-10 or 5-6 ring atoms, the ring atoms include carbon atom and/or heteroatoms such as O, N, S, P, and so on.
- The phrase "pharmaceutically acceptable" refers to molecular entities and compositions that are physiologically tolerable and do not typically produce an allergic or similar untoward reaction, such as gastric upset, dizziness and the like, when administered to a human. Preferably, as used herein, the term "pharmaceutically acceptable" means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans.
- The term "carrier" refers to a diluent, adjuvant, excipient, or matrix with which the compound is administered. Such pharmaceutical carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. Water and aqueous solutions (e.g., saline solution, dextrose solution, glycerol solution) are preferably employed as carriers, especially injectable solutions. Suitable pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences" by E. W. Martin.
- The term "prodrug" refers to a compound that is transformed in vivo into a compound of Formula (I). Such a transformation can be affected, for example, by hydrolysis of the prodrug form in blood or enzymatic transformation to the parent form in blood or tissue. Prodrugs of the compounds disclosed herein may be, for example, esters. Some common esters which have been utilized as prodrugs are phenyl esters, aliphatic (C1-24) esters, acyloxymethyl esters, carbonates, carbamates and amino acid esters. For example, a compound disclosed herein that contains a hydroxy group may be acylated at this position in its prodrug form. Other prodrug forms include phosphates, such as, those phosphate compounds are derived from the phosphonation of a hydroxy group on the parent compound. A thorough discussion of prodrugs is provided in T. Higuchi and V. Stella, Pro-drugs as Novel Delivery Systems, Vol. 14 of the A.C.S. Symposium Series, Edward B. Roche, ed., Bioreversible Carriers in Drug Design, American Pharmaceutical Association and Pergamon Press, 1987, J. Rautio et al., Prodrugs: Design and Clinical Applications, Nature Review Drug Discovery, 2008, 7, 255-270, and S. J. Hecker et al., Prodrugs of Phosphates and Phosphonates, Journal of Medicinal Chemistry, 2008, 51 , 2328-2345, all of which are incorporated herein by reference in their entireties.
- A "metabolite" is a product produced through metabolism in the body of a specified compound or salt thereof. The metabolites of a compound may be identified using routine techniques known in the art and their activities determined using tests such as those described herein. Such products may result for example from oxidation, reduction, hydrolysis, amidation, deamidation, esterification, deesterification, enzyme cleavage, and the like, of the administered compound. Accordingly, the invention includes metabolites of compounds disclosed herein, including metabolites produced by contacting a compound disclosed herein with a mammal for a sufficient time period.
- A "pharmaceutically acceptable salts" refers to organic or inorganic salts of a compound disclosed herein. Pharmaceutically acceptable salts are well known in the art. For example, S. M. Berge et al., describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 1977, 66: 1-19, which is incorporated herein by reference. Some non-limiting examples of pharmaceutically acceptable and nontoxic salts include salts formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid, malonic acid, etc. or by using other methods used in the art such as ion exchange. Other pharmaceutically acceptable salts include those obtained by reacting with an appropriate base, including alkali metal, alkaline earth metal, ammonium and N+(C1-4 alkyl)4 salts. This invention also envisions the quaternization of any basic nitrogen-containing groups of the compounds disclosed herein. Water or oil soluble or dispersable products may be obtained by such quaternization. Alkali metals or alkaline earth metals that can form salts include sodium, lithium, potassium, calcium, magnesium, and the like. Further pharmaceutically acceptable salts include appropriate and nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions, such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, C1-8 sulfonate or aryl sulfonate.
- The term "solvate" refers to an association or complex of one or more solvent molecules and a compound disclosed herein. Examples of solvents that form solvates include, but are not limited to, water, isopropanol, ethanol, methanol, DMSO, ethyl acetate, acetic acid and ethanolamine. The term "hydrate" refers to the complex where the solvent molecule is water.
- An "ester" refers to an in vivo hydrolysable ester of a compound containing a hydroxyl group or a carboxyl group. for example, a pharmaceutically acceptable ester which is hydrolysed in the human or animal body to produce the parent alcohol or acid. The compound having Formula (I) of the present invention contains carboxyl group, which can form a hydrolyzable ester in vivo with an appropriate group. Such groups include, but are not limited to, alkyl, arylalkyl and the like.
- An "N-oxide" refers to one or more than one nitrogen atoms oxidised to form an N-oxide, where a compound contains several amine functions. Particular examples of N-oxides are the N-oxides of a tertiary amine or a nitrogen atom of a nitrogen-containing heterocycle. N-oxides can be formed by treatment of the corresponding amine with an oxidizing agent such as hydrogen peroxide or a per-acid (e.g., a peroxycarboxylic acid) (See, Advanced Organic Chemistiy, by Jerry March, 4th Edition, Wiley Interscience, pages). More particularly, N-oxides can be made by the procedure of L. W. Deady (Syn. Comm. 1977, 7, 509-514) in which the amine compound is reacted with m-chloroperoxybenzoic acid (MCPBA), for example, in an inert solvent such as dichloromethane.
- The "compounds provided herein", "compounds of the present invention", "compounds described herein", "compounds described in the present invention" or similar expressions used herein refer to compounds represented by any general structure of the present invention. For example, the compound provided herein may refer to a compound having Formula (I) or Formula (Ia) or Formula (II) or Formula (IIa) in the present invention. The compound of the present invention also includes the specific compound in any one of the examples.
- As used herein, the term "treat", "treating" or "treatment" of any disease or disorder refers in one embodiment, to ameliorating the disease or disorder (i.e., slowing or arresting or reducing the development of the disease or at least one of the clinical symptoms thereof). In another embodiment "treat", "treating" or "treatment" refers to alleviating or ameliorating at least one physical parameter including those which may not be discernible by the patient. In yet another embodiment, "treat", "treating" or "treatment" refers to modulating the disease or disorder, either physically, (e.g., stabilization of a discernible symptom), physiologically, (e.g., stabilization of a physical parameter), or both. In yet another embodiment, "treat", "treating" or "treatment" refers to preventing or delaying the onset or development or progression of the disease or disorder.
- Any formula given herein is also intended to represent isotopically unenriched forms as well as isotopically enriched forms of the compounds. Isotopically enriched compounds have the structure depicted by the general formula given herein, except that one or more atoms are replaced by the atom having a selected atomic mass or mass number. Examples of isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, and chlorine, such as 2H (deuterium, D), 3H, 11C, 13C, 14C, 15N, 17O, 18O, 18F, 31P, 32P, 35S, 36Cl 125I, respectively.
- In another aspect, the compounds of the invention include isotopically enriched compounds as defined herein, for example those into which radioactive isotopes, such as 3H, 14C and 18F, or those into which non-radioactive isotopes, such as 2H and 13C are present. Such isotopically enriched compounds are useful in metabolic studies (with 14C), reaction kinetic studies (with, for example 2H or 3H), detection or imaging techniques, such as positron emission tomography (PET) or single-photon emission computed tomography (SPECT) including drug or substrate tissue distribution assays, or in radioactive treatment of patients. In particular, an 18F-enriched compound may be particularly desirable for PET or SPECT studies. Isotopically-enriched compounds of Formula (I) can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the accompanying Examples and Preparations using an appropriate isotopically-labeled reagent in place of the non-labeled reagent previously employed.
- Further, substitution with heavier isotopes, particularly deuterium (i.e.,2H or D) may afford certain therapeutic advantages resulting from greater metabolic stability. For example, increased in vivo half-life or reduced dosage requirements or an improvement in therapeutic index. It is understood that deuterium in this context is regarded as a substituent of a compound of Formula (I). The concentration of such a heavier isotope, specifically deuterium, may be defined by the isotopic enrichment factor. The term "isotopic enrichment factor" as used herein means the ratio between the isotopic abundance and the natural abundance of a specified isotope. If a substituent in a compound of this invention is denoted deuterium, such compound has an isotopic enrichment factor for each designated deuterium atom of at least 3500 (52.5% deuterium incorporation at each designated deuterium atom), at least 4000 (60% deuterium incorporation), at least 4500 (67.5% deuterium incorporation), at least 5000 (75% deuterium incorporation), at least 5500 (82.5% deuterium incorporation), at least 6000 (90% deuterium incorporation), at least 6333.3 (95% deuterium incorporation), at least 6466.7 (97% deuterium incorporation), at least 6600 (99% deuterium incorporation), or at least 6633.3 (99.5% deuterium incorporation). Pharmaceutically acceptable solvates in accordance with the invention include those wherein the solvent of crystallization may be isotopically substituted, e.g. D2O, d6-acetone, DMSO-d6.
- Unless otherwise stated, all tautomeric forms of the compounds disclosed herein are within the scope of the invention. Additionally, unless otherwise stated, structures depicted herein are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms.
- As used herein, the abbreviations for any protective groups, amino acids and other compounds are, unless otherwise indicated, in accord with their common usage, recognized abbreviations, or the IUPAC-IUB Commission on Biochemical Nomenclature (See, Biochem. 1972, 11: 942-944).
- The present invention provides a pyrrole amide compound that can competitively antagonize the mineralocorticoid receptor (MR) and the use thereof, as well as a pharmaceutical composition containing the compound and the compound or the pharmaceutical composition in the manufacture of a medicament for treating, preventing or alleviating hyperaldosteronism, hypertension, chronic heart failure, sequelae of myocardial infarction, liver cirrhosis, non-alcoholic steatohepatitis, chronic kidney disease, diabetic nephropathy, renal failure, fibrosis and/or stroke, and the like in patients. It was unexpectedly discovered through research that the change of the substitution position of F on the benzene ring connected to the amide has a greater impact on the properties of the compound; for example, when F is in the meta position of the acyl group, the activity of the compound (i.e., the compound provided herein) is the highest. In general, the compound provided herein has excellent mineralocorticoid receptor antagonistic activity and excellent pharmacokinetic properties; furthermore, the compound has substantially no phototoxicity.
- In one aspect, provided herein is a compound having Formula (I) or a stereoisomer, a geometric isomer, a tautomer, an atropisomer, an N-oxide, a hydrate, a solvate, a metabolite, an ester, a pharmaceutically acceptable salt or a prodrug thereof,
- In some embodiments, each of R2 and R3 is independently H, D, F, Cl, Br, OH, NH2, SH, CN, NO2, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl or C1-6 haloalkyl.
- In some embodiments, each of R2 and R3 is independently H, D, F, Cl, Br, OH, NH2, SH, CN, NO2, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl or C1-4 haloalkyl.
- In some embodiments, each of R2 and R3 is independently H, D, F, Cl, Br, OH, NH2, SH, CN, NO2, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl or difluoromethyl.
- In some embodiments, each of R4, R5, R6 and R7 is independently H, D, F, Cl, Br, OH, NH2, SH, CN, NO2, -C(=O)C1-6 alkyl, -C(=O)OC1-6 alkyl, -S-C1-6 alkyl, -S(=O)C1-6 alkyl, -S(=O)2C1-6 alkyl, -S(=O)2NRbRc, -S(=O)2OC1-6 alkyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C1-6 alkylamino, C3-6 cycloalkyl, C6-10 aryl, 3-6 membered heterocyclyl or 5-10 membered heteroaryl, wherein Rb and Rc have the meanings described in the present invention; or
R5 and R6 together with the carbon atom to which they are attached, form a C3-6 carbocyclic ring, a C6-10 aromatic ring, a 3-6 membered heterocyclic ring or a 5-10 membered heteroaromatic ring, wherein each of the C3-6 carbocyclic ring, C6-10 aromatic ring, 3-6 membered heterocyclic ring and the 5-10 membered heteroaromatic ring is independently unsubstituted or substituted with 1, 2, 3, 4 or 5 substituents independently selected from =O, D, F, Cl, Br, OH, NH2, SH, CN, NO2, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy and C1-6 alkylamino. - In some embodiments, each of R4, R5, R6 and R7 is independently H, D, F, Cl, Br, OH, NH2, SH, CN, NO2, -C(=O)C1-4 alkyl, -C(=O)OC1-4 alkyl, -S-C1-4 alkyl, -S(=O)C1-4 alkyl, -S(=O)2C1-4 alkyl, -S(=O)2NRbRc, -S(=O)2OC1-4 alkyl, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C1-4 alkoxy, C1-4 haloalkyl, C1-4 haloalkoxy, C1-4 alkylamino, C3-6 cycloalkyl, C6-10 aryl, 3-6 membered heterocyclyl or 5-6 membered heteroaryl, wherein Rb and Rc have the meanings described in the present invention; or
R5 and R6 together with the carbon atom to which they are attached, form a C3-6 carbocyclic ring, a benzene ring, a 3-6 membered heterocyclic ring or a 5-6 membered heteroaromatic ring, wherein each of the C3-6 carbocyclic ring, benzene ring, 3-6 membered heterocyclic ring and 5-6 membered heteroaromatic ring is independently unsubstituted or substituted with 1, 2, 3, 4 or 5 substituents independently selected from =O, D, F, Cl, Br, OH, NH2, SH, CN, NO2, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C1-4 alkoxy, C1-4 haloalkyl, C1-4 haloalkoxy and C1-4 alkylamino. - In some embodiments, each of R4, R5, R6, and R7 is independently H, D, F, Cl, Br, OH, NH2, SH, CN, NO2, -C(=O)CH3, -C(=O)OCH3, -S-CH3, -S(=O)CH3, -S(=O)2CH3, -S(=O)2CH2CH3, -S(=O)2NRbRc, -S(=O)2OCH3, methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, vinyl, ethynyl, methoxy, ethoxy, isopropoxy, tert-butoxy, trifluoromethyl, difluoromethyl, monofluoromethyl, 2,2-difluoroethyl, trifluoromethoxy, methylamino, dimethylamino, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, oxiranyl, azetidinyl, oxetanyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, morpholinyl, pyrrolyl, pyridyl, pyrimidinyl or quinolinyl, wherein, Rb and Rc have the meanings described in the present invention; or
R5 and R6 together with the carbon atom to which they are attached, form cyclobutene, cyclopentene, cyclohexene, benzene, dihydrofuran, dihydrothiazole, dihydroimidazole, dihydropyrazole, dihydrooxazole, dihydropyrrole, tetrahydropyridine, dihydro-1,4-oxazine, pyrrole, pyridine, pyrimidine or quinoline, wherein each of the cyclobutene, cyclopentene, cyclohexene, benzene, dihydrofuran, dihydrothiazole, dihydroimidazole, dihydropyrazole, dihydrooxazole, dihydropyrrole, tetrahydropyridine, dihydro-1,4-oxazine, pyrrole, pyridine, pyrimidine and the quinoline is independently unsubstituted or substituted with 1, 2, 3, 4 or 5 substituents independently selected from =O, D, F, Cl, Br, OH, NH2, SH, CN, NO2, methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, vinyl, ethynyl, methoxy, ethoxy, isopropoxy, tert-butoxy, trifluoromethyl, difluoromethyl, monofluoromethyl, 2,2-difluoroethyl, trifluoromethoxy, methylamino and dimethylamino. - Preferably, each of R4, R5 and R7 is independently H or D, and R6 is -S(=O)2CH3 or -S(=O)2CH2CH3.
- In some embodiments, each of R8, Rb and Rc is independently H, D, C1-6 alkyl or C1-6 haloalkyl. In some embodiments, each of R8, Rb and Rc is independently H, D, C1-4 alkyl or C1-4 haloalkyl.
- In some embodiments, each of R8, Rb and Rc is independently H, D, methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, trifluoromethyl, difluoromethyl, monofluoromethyl or 2,2-difluoroethyl.
- In some embodiments, the compound having Formula (I) provided herein is preferably a compound having Formula (Ia) or a stereoisomer, a geometric isomer, a tautomer, an atropisomer, an N-oxide, a hydrate, a solvate, a metabolite, an ester, a pharmaceutically acceptable salt or a prodrug thereof,
- In some embodiments, each of R2a, R2b, R2c, R2d and R2e is independently H, D, F, Cl, Br, OH, NH2, SH, CN, NO2, -C(=O)C1-6 alkyl, -C(=O)OC1-6 alkyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C1-6 alkylamino , C3-6 cycloalkyl, C6-10 aryl, 3-6 membered heterocyclyl or 5-10 membered heteroaryl.
- In some embodiments, each of R2a, R2b, R2c, R2d and R2e is independently H, D, F, Cl, Br, OH, NH2, SH, CN, NO2, -C(=O)C1-4 alkyl, -C(=O)OC1-4 alkyl, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C1-4 alkoxy, C1-4 haloalkyl, C1-4 haloalkoxy, C1-4 alkylamino , C3-4 cycloalkyl, C6-10 aryl, 3-6 membered heterocyclyl or 5-6 membered heteroaryl.
- In some embodiments, each of R2a, R2b, R2c, R2d and R2e is independently H, D, F, Cl, Br, OH, NH2, SH, CN, NO2, -C(=O)CH3, -C(=O)OCH3, methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, vinyl, ethynyl, methoxy, ethoxy, isopropoxy, tert-butoxy, trifluoromethyl, difluoromethyl, monofluoromethyl, 2,2-difluoroethyl, trifluoromethoxy, methylamino, dimethylamino, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, oxiranyl, azetidinyl, oxetanyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, morpholinyl, pyrrolyl, pyridyl, pyrimidinyl or quinolinyl.
- In some embodiments, the compound having Formula (I) provided herein is preferably a compound having Formula (II) or a stereoisomer, a geometric isomer, a tautomer, an atropisomer, an N-oxide, a hydrate, a solvate, a metabolite, an ester, a pharmaceutically acceptable salt or a prodrug thereof,
- In some embodiments, the compound having Formula (I) provided herein is preferably a compound having Formula (IIa) or a stereoisomer, a geometric isomer, a tautomer, an atropisomer, an N-oxide, a hydrate, a solvate, a metabolite, an ester, a pharmaceutically acceptable salt or a prodrug thereof,
- In some embodiments, R1 is C1-6 alkyl, C3-6 cycloalkyl, C6-10 aryl, 3-6 membered heterocyclyl or 5-10 membered heteroaryl, wherein the C1-6 alkyl, C3-6 cycloalkyl, C6-10 aryl, 3-6 membered heterocyclyl or 5-10 membered heteroaryl are independently and optionally substituted with 1, 2, 3 or 4 Ra; wherein Ra has the meaning described herein.
- In some embodiments, R1 is C1-4 alkyl, C3-6 cycloalkyl, phenyl, 3-6 membered heterocyclyl or 5-6 membered heteroaryl, wherein the C1-4 alkyl, C3-6 cycloalkyl, phenyl, 3-6 membered heterocyclyl and 5-6 membered heteroaryl are independently and optionally substituted with 1, 2, 3 or 4 Ra; wherein Ra has the meaning described herein.
- In some embodiments, R1 is methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, oxiranyl, azetidinyl, oxetanyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, morpholinyl, pyrrolyl, pyridyl or pyrimidinyl, wherein the methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, oxiranyl, azetidinyl, oxetanyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, morpholinyl, pyrrolyl, pyridyl and pyrimidinyl are independently and optionally substituted by 1, 2, 3 or 4 Ra; wherein Ra has the meaning described herein.
- In some embodiments, each Ra is independently D, F, Cl, Br, OH, NH2, SH, CN, NO2, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C1-6 haloalkyl, C3-6 cycloalkyl, C6-10 aryl, 3-6 membered heterocyclyl or 5-10 membered heteroaryl; wherein, the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C1-6 haloalkyl, C3-6 cycloalkyl, C6-10 aryl, 3-6 membered heterocyclyl and 5-10 membered heteroaryl are independently unsubstituted or substituted with 1, 2, 3 or 4 substituents independently selected from D, F, Cl, Br, OH, NH2, SH, CN, NO2, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C3-6 cycloalkyl, C6-10 aryl, 3-6 membered heterocyclyl or 5-10 membered heteroaryl.
- In some embodiments, each Ra is independently D, F, Cl, Br, OH, NH2, SH, CN, NO2, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C1-4 alkoxy, C1-4 haloalkyl, C3-4 cycloalkyl, C6-10 aryl, 3-6 membered heterocyclyl or 5-6 membered heteroaryl; wherein, the C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C1-4 alkoxy, C1-4 haloalkyl, C3-6 cycloalkyl, C6-10 aryl, 3-6 membered heterocyclyl and 5-6 membered heteroaryl are independently unsubstituted or substituted with 1, 2, 3 or 4 substituents independently selected from D, F, Cl, Br, OH, NH2, SH, CN, NO2, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C1-4 alkoxy, C1-4 haloalkyl, C1-4 haloalkoxy, C3-6 cycloalkyl, C6-10 aryl, 3-6 membered heterocyclyl or 5-6 membered heteroaryl.
- In some embodiments, each Ra is independently D, F, Cl, Br, OH, NH2, SH, CN, NO2, methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, vinyl, ethynyl, methoxy, ethoxy, isopropoxy, tert-butoxy, trifluoromethyl, difluoromethyl, monofluoromethyl, 2,2-difluoroethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, oxiranyl, azetidinyl, oxetanyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, morpholinyl, pyrrolyl, pyridyl, pyrimidinyl or quinolinyl; wherein the methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, vinyl, ethynyl, methoxy, ethoxy, isopropoxy, tert-butoxy, difluoromethyl, monofluoromethyl, 2,2-difluoroethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, oxiranyl, azetidinyl, oxetanyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, morpholinyl, pyrrolyl, pyridyl, pyrimidinyl and quinolinyl are independently unsubstituted or substituted with 1, 2, 3 or 4 substituents independently selected from D, F, Cl, Br, OH, NH2, SH, CN, NO2, methyl, ethyl, n-propyl, isopropyl, C2-4 alkenyl, C2-4 alkynyl, methoxy, ethoxy, isopropoxy, trifluoromethyl, difluoromethyl, monofluoromethyl, 2,2-difluoroethyl, C3-6 cycloalkyl, phenyl, 3-6 membered heterocyclyl or 5-6 membered heteroaryl.
-
- In other aspect, provided herein is a pharmaceutical composition comprising the compound disclosed herein.
- In some embodiments, the pharmaceutical composition provided herein optionally comprises at least one of pharmaceutically acceptable carriers, excipients, diluents, adjuvants and vehicles.
- In some other embodiments, the pharmaceutical composition provided herein further comprises one or more other active ingredients, wherein the other active ingredient is a ACE inhibitor, a renin inhibitor, an angiotensin II receptor antagonist, a β-receptor blocker, acetylsalicylic acid, a diuretic, a calcium antagonist, a statin, a digitalis derivative, a calcium sensitizer, a nitrate and/or an antithrombotic agent.
- In one aspect, provided herein is use of the compound or the pharmaceutical composition disclosed herein in the manufacture of a medicament for treating, preventing or alleviating the following diseases in patients: hyperaldosteronism, hypertension, chronic heart failure, sequelae of myocardial infarction, liver cirrhosis, non-alcoholic steatohepatitis, chronic kidney disease, diabetic nephropathy, renal failure, fibrosis or stroke.
- In other aspect, provided herein is use of the compound or the pharmaceutical composition disclosed herein in the manufacture of a medicament, wherein the medicament is used as a mineralocorticoid receptor antagonist.
- In one aspect, provided herein is the compound or the pharmaceutical composition disclosed herein for use in treating, preventing or alleviating the following diseases in patients: hyperaldosteronism, hypertension, chronic heart failure, sequelae of myocardial infarction, liver cirrhosis, non-alcoholic steatohepatitis, chronic kidney disease, diabetic nephropathy, renal failure, fibrosis or stroke.
- In other aspect, the compound or the pharmaceutical composition disclosed herein can be used as a mineralocorticoid receptor antagonist.
- In one aspect, provided herein is a method for treating, preventing or alleviating the following diseases in patients: hyperaldosteronism, hypertension, chronic heart failure, sequelae of myocardial infarction, liver cirrhosis, non-alcoholic steatohepatitis, chronic kidney disease, diabetic nephropathy, renal failure, fibrosis or stroke, comprising administering to the subject a therapeutically effective amount of the compound or the the pharmaceutical composition disclosed herein.
- In other aspect, provided herein is a method for using the compound or pharmaceutical composition disclosed herein to antagonize the mineralocorticoid receptor, comprising contacting an organism (including in vivo or in vitro) with the compound or pharmaceutical composition disclosed herein in an effective dosage.
- The compounds or pharmaceutical compositions disclosed herein competitively antagonize the mineralocorticoid receptor (MR), and therefore they can be useful agents for treating and preventing conditions associated with increased aldosterone levels.
- The compound or pharmaceutical composition disclosed herein can be used to treat or prevent aldosterone receptor-mediated diseases. The present invention also provides a method for treating or reducing aldosterone receptor-mediated diseases, or sensitiving to these diseases in a patient comprising administering to the patient a therapeutically effective amount of the compound or pharmaceutical composition disclosed herein.
- The present invention also comprises uses of the compound and pharmaceutically acceptable salts thereof in the manufacture of a medicine for treating mineralocorticoid receptor or aldosterone related diseases in patients, including those diseases described herein. The present invention provides a pharmaceutical composition comprising an effective therapeutic amount of the compound having Formula (I) required for combining with at least one pharmaceutically acceptable carrier, excipient, diluent, adjuvant, vehicle.
- Unless otherwise stated, all hydrates, solvates and pharmaceutically acceptable salts of the compounds disclosed herein are within the scope of the invention.
- Specifically, the salt is a pharmaceutically acceptable salt. The phrase "pharmaceutically acceptable" refers to that the substance or composition must be compatible chemically and/or toxicologically, with the other ingredients comprising a formulation, and/or the mammal being treated therewith.
- The slats of the compounds disclosed herein also include salts of intermediates used for preparing and/or purifying compounds of Formula (I), or the salts of the isolated enantiomers of the compounds of Formula (I), but not necessarily pharmaceutically acceptable salts.
- The salts of the compounds disclosed herein may be prepared by any suitable method available in the art, for example, treatment of the free base with an inorganic acid, such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like. or with an organic acid, such as acetic acid, maleic acid, succinic acid, mandelic acid, fumaric acid, malonic acid, pyruvic acid, oxalic acid, glycolic acid and salicylic acid; a pyranosidyl acid, such as glucuronic acid and galacturonic acid; an alpha-hydroxy acid, such as citric acid and tartaric acid; an amino acid, such as aspartic acid and glutamic acid; an aromatic acid, such as benzoic acid and cinnamic acid; a sulfonic acid, such as p-toluenesulfonic acid, ethanesulfonic acid and the like.
- The biological activity of the compounds disclosed herein may be assessed by using any conventionally known methods. Appropriate detection methods are well known in the art. For example, the MR antagonistic activity, pharmacokinetic activity, and/or liver microsomal stability of the compounds disclosed herein can be tested by appropriate conventional methods. The detection method provided herein is presented only as an example and does not limit the present invention. The compounds disclosed herein have activity in at least one of the detection methods provided herein. For example, the compounds disclosed herein have good antagonistic activity against mineralocorticoid receptors and good in vivo pharmacokinetic properties, such as better absorption and exposure, and high bioavailability; in another example, the compounds disclosed herein have low toxic side effects.
- In other aspect, the pharmaceutical composition of the invention comprises pyrrole amide compounds having Formula (I), Formula (Ia), Formula (II) or Formula (IIa), the compounds listed herein, or the compounds of Examples 1-8, and a pharmaceutically acceptable carrier, adjuvant, or excipient. The amount of the compound in the composition of the present invention can effectively treat or lessen mineralocorticoid receptor or aldosterone-related diseases in a subject.
- As described above, the pharmaceutical compositions disclosed herein further comprise a pharmaceutically acceptable carrier, an adjuvant, or a vehicle, which, as used herein, includes any and all solvents, diluents, or other liquid vehicle, dispersion or suspension aids, surface active agents, isotonic agents, thickening or emulsifying agents, preservatives, solid binders, lubricants and the like, as suited to the particular dosage form desired. As described in the following: In Remington: Troy et al., Remington: The Science and Practice of Pharmacy, 21st ed., 2005, Lippincott Williams & Wilkins, Philadelphia, and Swarbrick et al., Encyclopedia of Pharmaceutical Technology, eds. 1988-1999, Marcel Dekker, New York, both of which are herein incorporated by reference in their entireties, discloses various carriers used in formulating pharmaceutically acceptable compositions and known techniques for the preparation thereof. Except insofar as any conventional carrier medium incompatible with the compounds disclosed herein, such as by producing any undesirable biological effect or otherwise interacting in a deleterious manner with any other components of the pharmaceutically acceptable composition, its use is contemplated to be within the scope of this invention.
- Some non-limiting examples of materials which can serve as pharmaceutically acceptable carriers include ion exchangers; aluminium; aluminum stearate; lecithin; serum proteins such as human serum albumin; buffer substances such as phosphates; glycine; sorbic acid; potassium sorbate; partial glyceride mixtures of saturated vegetable fatty acids; water; salts or electrolytes such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride and zinc salts; colloidal silica; magnesium trisilicate; polyvinyl pyrrolidone; polyacrylates; waxes; polyethylene-polyoxypropylene-block polymers; wool fat; sugars such as lactose, glucose and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients such as cocoa butter and suppository waxes; oils such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols such as propylene glycol and polyethylene glycol; esters such as ethyl oleate and ethyl laurate; agar; buffering agents such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethyl alcohol; and phosphate buffer solutions, as well as other non-toxic compatible lubricants such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, releasing agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants.
- The pharmaceutical composition of the present invention can be administered directly or in a pharmaceutical composition or pharmaceutical form along with a suitable carrier or excipient, which is well known in the art. The treatment method of the present invention may comprise administering an effective compound of the present invention to an individual in need. In some embodiments, the individual is a mammalian individual, and in other preferred embodiments, the individual is a human individual.
- The effective amount of the compound, pharmaceutical composition or drug of the present invention can be easily determined by routine test, and the most effective and convenient route of administration and the most suitable formulation can also be determined by routine test.
- The pharmaceutical dosage form of the compound of the present invention can be provided in the form of an immediate release, controlled release, sustained release or target drug release system. For example, commonly used dosage forms include solutions and suspensions, (micro) emulsions, ointments, gels and patches, liposomes, tablets, dragees, soft or hard shell capsules, suppositories, ovules, implants, amorphous or crystalline powder, aerosol and freeze-dried formulations. Depending on the route of administration, special devices may be required to administer the drug, such as syringes and needles, inhalers, pumps, injection pens, applicators or special flask. Pharmaceutical dosage forms often consist of drugs, excipients, and container/sealing systems. One or more excipients (also known as inactive ingredients) can be added to the compounds of the present invention to improve or promote the manufacture, stability, administration and safety of the drug, and can provide a method to obtain the desired drug release curve. Therefore, the type of excipients added to the drugs may depend on various factors, such as the physical and chemical properties of the drugs, the route of administration, and the preparation steps. Pharmaceutical excipients exist in this field and include those listed in various pharmacopoeias. (Refer to U.S. Pharmacopeia (USP), Japanese Pharmacopoeia (JP), European Pharmacopoeia (EP) and British Pharmacopoeia (BP); publications of the Center for Drug Evaluation and Research (CEDR) of the U.S. Food and Drug Administration(www.fda.gov), such as Inactive Ingredient Guide, 1996; Handbook of Pharmaceutical Additives by Ash and Ash, 2002; Synapse Information Resources, Inc., Endicott NY; etc.)
- The pharmaceutical dosage form of the compound of the present invention can be manufactured by any method well known in the art, for example, by conventional mixing, sieving, dissolving, melting, granulating, making sugar-coated pills, pressing, suspending, squeezing, spray drying, grinding, emulsification, (nano/micron) encapsulation, encapsulation or freeze-drying process. As mentioned above, the composition of the present invention may include one or more physiologically acceptable inactive ingredients, which can promote the processing of active molecules into formulations for medical use.
- The appropriate formulation depends on the desired route of administration. For example, for intravenous injection, the composition can be formulated in an aqueous solution, if necessary, using physiologically compatible buffers, including, for example, phosphate, histidine or citrate used to adjust the pH of the formulation, and tonicity agents such as sodium chloride or dextrose. For transmucosal or nasal administration, semi-solid, liquid preparations or patches may be preferred, and may contain penetration enhancers; such penetration enhancers are generally known in the art. For oral administration, the compounds can be formulated into liquid or solid dosage forms and used as immediate release or controlled release/sustained release formulations. Suitable dosage forms for oral administration by individuals include tablets, pills, dragees, hard and soft shell capsules, liquids, gels, syrups, ointments, suspensions and emulsions. The compounds also be formulated in rectal compositions such as suppositories or retention enemas, which, for example, contain conventional suppository matrix, such as cocoa butter or other glycerides.
- Solid oral dosage forms can be obtained by using excipients, which include fillers, disintegrants, binders (dry and wet), dissolution retardants, lubricants, glidants, anti-adherents, cation exchange resins, humectants, antioxidants, preservatives, coloring agents and flavoring agents. These excipients can be synthetic or natural. Examples of the excipients include cellulose derivatives, citric acid, dicalcium phosphate, gelatin, magnesium carbonate, magnesium lauryl sulfate/sodium lauryl sulfate, mannitol, polyethylene glycol, polyvinylpyrrolidone, silicic acid salt, silicon dioxide, sodium benzoate, sorbitol, starch, stearic acid or its salt, sugar (i.e. dextrose, sucrose, lactose, etc.), talc, tragacanth mucilage, vegetable oil (hydrogenated) and wax. Ethanol and water can be used as granulation additives. In some cases, it is necessary to coat the tablet with, for example, a taste-masked film, a gastric acid resistant film, or a delayed release film. Natural and synthetic polymers are usually combined with colorants, sugar and organic solvents or water to coat tablets to produce dragees. When the capsule is superior to the tablet, the drug powder, suspension or solution can be delivered in a compatible hard-shell or soft-shell capsule form.
- Compositions formulated for parenteral administration by injection are generally sterile and can be provided in unit dosage forms, such as ampoules, syringes, injection pens, or multi-dose containers., The latter usually contains a preservative. The composition can be the form of a suspension, solution or emulsion in an oily or aqueous carrier, and can contain preparation agents, such as buffers, tonicity agents, viscosity enhancers, surfactants, suspending and dispersing agents, antioxidants, biocompatible polymers, chelating agents and preservatives. Depending on the injection site, the carrier may contain water, vegetable oils, and/or organic co-solvents. In some cases, for lyophilized products or concentrates, parenteral formulations will be reconstituted or diluted before administration. The controlled release or sustained release depot formulation of the compound of the present invention may include injectable suspensions of nano/micro particles or nano/micro or non-micronized crystals. Other well-known matrices in the art, polymers, such as poly (lactic acid), poly (glycolic acid) or copolymers thereof, can be used as a controlled release/sustained release matrix. Other depot delivery systems can be provided in the form of implants and pumps that require incisions.
- Suitable carriers for the compound of the present invention for intravenous injection are well known in the art and include water-based solutions containing alkalis (such as sodium hydroxide) for the formation of ionic compounds; sucrose or sodium chloride as tonicity agents; buffers containing phosphate or histidine. Co-solvents of polyethylene glycol can be added. These water-based systems can effectively dissolve the compounds of the present invention and produce low toxicity after systemic administration. Without destroying the solubility and toxicity characteristics, the ratio of the components of the solution system can be greatly changed. In addition, the characteristics of the components can be changed. For example, low-toxicity surfactants such as polysorbate or poloxamer can be used, polyethylene glycol or other co-solvents can also be used. Biocompatible polymer such as polyvinylpyrrolidone can be added, and dextrose can be replaced by other sugars or polyols.
- The compounds of the invention can be used systemically and/or locally. They can be administered in a suitable manner, for example, oral administration, gastrointestinal administration, pulmonary administration, nasal administration, sublingual administration, translingual administration, buccal administration, rectal administration, dermal administration, transdermal administration, conjunctival administration, ear canal administration, or administration as a graft or stent. The compounds of the present invention are preferably administered orally or parenterally.
- Suitable administration manner for oral administration are as follows: according to the prior art, the manners of administration that release the compounds of the present invention by rapid release and/or modified methods include crystalline and/or amorphous and/or dissolved forms of the compounds, such as tablet (an uncoated tablet or a tablet coated with a gastric tolerant or delayed dissolution or insoluble coating that controls the release of the compounds), tablet or film/flake that quickly shatter in the mouth, film/lyophilized body, capsule (e.g., hard or soft capsule), sugar-coated tablet, granule, pill, powder, emulsion, suspension, aerosol or solution.
- Parenteral administration can bypass the absorption step (e.g., intravenous, intraarterial, intracardia, intraspine, or lumbar) or include absorption (e.g., intramuscular, subcutaneous, intradermal, transdermal, or intraperitoneal). Administration forms suitable for parenteral administration include formulations for injection and infusion in the form of solutions, suspensions, emulsions, lyophilized bodies or sterile powders.
- For other routes of administration, suitable examples are inhaled drug forms (including powder inhalers, sprays), nasal drops, solutions or sprays, tablets for tongue, sublingual or buccal administration, films/ flakes or capsules, suppositories, ear or eye formulations, vaginal capsules, aqueous suspensions (lotions, shock mixtures), lipophilic suspensions, ointments, creams, transdermal therapeutic systems (e.g. patches), emulsions (milch), paste, foam, spray powder, implant or stent.
- The therapeutically effective amount of the compounds provided herein should be present in the above-mentioned pharmaceutical formulations at a concentration of about 0.1 to 99.5%, preferably about 0.5 to 95% by weight of the entire mixture.
- In addition to the compounds of the present invention, the above-mentioned pharmaceutical formulations may also contain other pharmaceutical active ingredients.
- The therapeutically effective amount can be estimated using various methods well known in the art. The initial dosage for animal studies can be based on the effective concentration established in the cell culture assay. The dosage range suitable for a human individual can be determined, for example, using data obtained from animal studies and cell culture assays. In some embodiments, the compounds of the present invention can be prepared as a medicament for oral administration. An exemplary dosage of the compounds of the present invention in a medicament for oral administration is about 0.01 to about 100 mg/kg (wherein kg refers to the body weight of the subject).
- Usually the dosing regimen for medicaments for oral administration is three times a week, twice a week, once a week, three times a day, twice a day, or once a day. In some embodiments, the compounds of the present invention are administered as active ingredient in a total amount of about 0.001 to about 50 mg/kg body weight every 24 hours. In order to obtain the desired result, it may optionally be administered in the form of multiple single doses.
- The effective amount or therapeutically effective amount or dosage of an agent (such as the compound of the present invention) refers to the amount of an agent or compound that causes improvement in individual symptoms or prolonged survival The toxicity and therapeutic efficacy of the molecule can be determined by standard medical procedures in cell cultures or laboratory animals, for example, by measuring LD50 (the dosage that makes 50% of the population lethal) and ED50 (the dosage that is therapeutically effective for 50% of the population). The dosage ratio of toxic effect to therapeutic effect is the therapeutic index, which can be expressed as LD50/ED50. A drug showing a high therapeutic index is preferred.
- The effective amount or therapeutically effective amount is the amount of a compound or pharmaceutical composition that will elicit the biological or medical response in a tissue, system, animal, or human that is being sought by researchers, veterinarians, doctors, or other clinicians. The dosage is preferably within a range of circulating concentrations that include the ED50 with little or no toxicity. The dosage can vary within this range, depending on the dosage form and/or the route of administration used. The correct formulation, route of administration, dosage, and interval between administrations should be selected according to the methods known in the art, considering the particularity of individual conditions.
- The dosage and interval can be adjusted individually to provide a plasma level of the active part sufficient to achieve the desired effect; that is, the minimal effective concentration (MEC). The MEC of each compound will be different, but it can be estimated, for example, from in vitro data and animal experiments. The dosage necessary to obtain MEC will depend on individual characteristics and route of administration. In the case of local administration or selective uptake, the effective local concentration of the drug may not be related to plasma concentration.
- The amount of the medicament or composition administered can be determined by various factors, including the sex, age and weight of the individual to be treated, the severity of the pain, the manner of administration, and the judgment of the prescribing physician.
- When necessary, the composition of the present invention can be provided by a packaging or a dispensing device containing one or more unit dosage forms (containing the active ingredient). For example, the packaging or dispensing device may include metal or plastic foil (such as foam packaging) or glass and rubber stoppers. The packaging or dispensing device may be accompanied by instructions for medicines. It is also possible to prepare a composition containing the compound of the present invention formulated in a compatible pharmaceutical carrier, which is placed in an appropriate container, and labeled for the treatment of a specified condition.
- The compound of the present invention can be used alone or, if necessary, in combination with other active compounds. The present invention also provides the combined use of drugs including at least one compound and one or more further active substances, especially the drugs for treating and/or preventing the diseases of the present invention.
- The compounds of the present invention act as mineralocorticoid receptor antagonists and show an unexpected and valuable range of pharmacological effects. Therefore, the compounds are suitable for use as drugs for treating and/or preventing human and animal diseases.
- The compounds of the present invention are suitable for preventing and/or treating various diseases and related diseases, especially the diseases characterized by increased plasma aldosterone concentration or changes in plasma aldosterone concentration relative to plasma renin concentration, or diseases related to these changes. For example, spontaneous primary aldosteronism, hyperaldosteronism associated with adrenal hyperplasia, adrenal adenoma and/or adrenal cancer, hyperaldosteronism associated with cirrhosis, hyperaldosteronism associated with heart failure, and hyperaldosteronism associated with essential hypertension (relative), etc.
- Due to its mechanism of action, the compounds of the present invention are also suitable for preventing sudden cardiac death in patients with an increased risk of death from sudden cardiac death. These patients are especially suffering from one of the following conditions: primary and secondary hypertension, hypertensive heart disease with or without congestive heart failure, refractory hypertension, acute and chronic heart failure, coronary heart disease, stable and unstable angina pectoris, myocardial ischemia, myocardial infarction, dilated cardiomyopathy, congenital primary cardiomyopathy (such as Bmgada syndrome), cardiomyopathy caused by Chagas disease, shock, arteriosclerosis, atrial and ventricular arrhythmias, transient and ischemic attacks, stroke, inflammatory cardiovascular disorders, peripheral and cardiovascular disorders, peripheral blood flow disorders, arterial occlusive diseases (such as intermittent claudication), asymptomatic left ventricle dysfunction, myocarditis, cardiac hypertrophy, pulmonary hypertension, coronary and peripheral artery spasms, thrombosis, thromboembolic disorders and vasculitis.
- The compounds of the present invention can additionally be suitable for preventing and/or treating the formation of edema, such as pulmonary edema, nephrogenic edema, or swelling lungs associated with heart failure, and restenosis after thrombolytic therapy, percutaneous transluminal angioplasty (PTA) and coronary angioplasty (PTCA), heart transplantation and bypass surgery.
- The compounds of the present invention are also suitable for using as potassium-sparing diuretics and for treating electrolyte disorders, such as hypercalcemia, hypernatremia or hypokalemia.
- The compounds of the present invention are also suitable for treating nephropathy, such as acute or chronic renal failure, hypertensive nephropathy, arteriosclerotic nephritis (chronic and interstitial), nephrosclerosis, chronic renal failure and cystic nephropathy, and for preventing kidney damage (e.g., kidney damage caused by immunosuppressive agents related to organ transplantation (for example, cyclosporin A) and for kidney cancer.
- The compounds of the present invention can additionally be suitable for preventing and/or treating diabetes and diabetic sequelae, such as neuropathy and diabetic nephropathy.
- The compounds of the present invention can be further used to prevent and/or treat microalbuminuria and proteinuria caused by diabetes or hypertension.
- The compounds of the present invention can be further used to prevent and/or treat fibrotic diseases, e.g., renal fibrosis, pulmonary fibrosis (including idiopathic pulmonary fibrosis), liver fibrosis, etc.
- The compounds of the present invention are also suitable for preventing and/or treating conditions associated with an increase in plasma glucocorticoid concentration or with a local increase in glucocorticoid concentration in tissues (such as the heart). For example, adrenal dysfunction (Cushing's syndrome) that leads to excessive production of glucocorticoids, adrenal tumor that leads to excessive production of glucocorticoids, and pituitary tumor, which autonomously produce ACTH (corticotropin) leading to adrenal hyperplasia and Cushing's disease.
- The compounds of the present invention can additionally be used to prevent and/or treat obesity, metabolic syndrome and obstructive sleep apnea.
- The compounds of the present invention can be further used to prevent and/or treat inflammatory disorders caused by viruses, spirochetes, fungi, bacteria or mycobacteria, and inflammatory disorders of unknown etiology, such as polyarthritis, lupus erythematosus, periarthritis or polyarteritis, dermatomyositis, scleroderma and sarcoidosis.
- The compounds of the present invention can be further used to treat central nervous disorders, such as depression, anxiety and chronic pain, especially migraine, and neurodegenerative disorders, such as Alzheimer's disease and Parkinson's syndrome.
- The compounds of the present invention are also suitable for preventing and/or treating vascular damage, such as vascular damage caused by reocclusion or restenosis after percutaneous transluminal coronary angioplasty (PTCA), stent implantation, coronary angioscopy and bypass surgery, and endothelial dysfunction, Raynaud's disease, thromboangiitis obliterans (Buerger's syndrome) and tinnitus syndrome.
- The compound of the present invention can be used alone, or if necessary, can be used in combination with other active ingredients. The present invention further relates to a medicament comprising at least one compound provided herein and one or more other active ingredients (especially for treating and/or preventing the aforementioned conditions). The other active ingredients include, but are not limited to: active ingredients that lower blood pressure, for example, preferably selected from calcium antagonists, angiotensin II receptor antagonists, ACE inhibitors, endothelin antagonists, renin inhibitors, α-receptor blockers, β-receptor blockers and Rho kinase inhibitors; diuretics, especially loop diuretics, and thiazides and thiazide diuretics; agents with antithrombotic effect, for example, preferably selected from platelet aggregation inhibitors, anticoagulants or fibrinolytic substances; active ingredients that alter lipid metabolism, for example, preferably selected from thyroid receptor agonists, cholesterol synthesis inhibitors, such as HMG-coenzyme A reductase inhibitors or squalene synthesis inhibitors, ACAT inhibitors, CETP inhibitors agents, MTP inhibitors, PPAR-α, PPAR-γ and/or PPAR-δ agonists, cholesterol absorption inhibitors, lipase inhibitors, polymeric bile adsorbents, bile acid reabsorption inhibitors and lipoprotein (a) antagonist; organic nitrates and NO donors, for example, sodium nitroprusside, nitroglycerin, isosorbide mononitrate, isosorbide dinitrate, doramine or SIN-1, and inhaled NO; compounds with positive inotropic effects, for example, cardiac glycosides (digoxin), β-adrenergic and dopaminergic agonists, such as isoproterenol, epinephrine, norepinephrine, dopamine and dobutamine; compounds that inhibit the breakdown of cyclic-guanosine phosphate (cGMP) and/or cyclic-adenosine phosphate (cAMP), for example, phosphodiesterase (PDE) 1, 2, 3, 4 and/or 5 inhibitors, especially PDE5 inhibitors, such as sildenafil, vardena fife and tadalafil, and PDE3 inhibitors, such as aminone and milrinone; natriuretic peptides, for example, atrial natriuretic peptide (ANP, anaritide), B-type natriuretic peptide or brain natriuretic peptide (BNP, nesiritide), C-type natriuretic peptide (CNP) and uroexpandin; calcium sensitizers, for example, preferably levosimendan; NO-independent but heme-dependent guanylate cyclase stimulator, especially the compounds described in
WO 00/06568 WO00/06569 WO02/42301 WO03/ 095451 (for example, Riociguat WO 01/19355 WO 01/19776 WO 01/19778 WO 02/ 070462 WO 02/070510 - The compound of the present invention can also be administered in combination with other active ingredients other than the above-mentioned active ingredients. For example, in the preferred embodiments, the compound of the present invention is administered in combination with a diuretic, such as furosemide, bumetanide, torsemide, benzflurazine, kurose, hydrochlorothiazide, hydrofluoromethiazine, mechlorothiazide, polithiazide, trichlorothiazide, chlorthalidone, indapamide, metolazone, quetzol, acetazolamide, dichlorobenzenesulfonamide, methazolamide, glycerol, isosorbide, mannitol, amiloride or triamterene.
- In the present invention, if the chemical name of the compound doesn't match the corresponding structure, the compound is characterized by the corresponding structure.
- Generally, the compounds of the invention can be prepared by the methods described herein. The following non-limiting schemes and examples are presented to further exemplify the invention.
- Persons skilled in the art will recognize that the chemical reactions described may be readily adapted to prepare a number of other compounds disclosed herein, and alternative methods for preparing the compounds disclosed herein are deemed to be within the scope disclosed herein. For example, the synthesis of non-exemplified compounds according to the invention may be successfully performed by modifications apparent to those skilled in the art, e.g., by appropriately protecting interfering groups, by utilizing other suitable reagents known in the art other than those described, and/or by making routine modifications of reaction conditions. Alternatively, other reactions disclosed herein or known in the art will be recognized as having applicability for preparing other compounds disclosed herein.
- In the examples described below, unless otherwise indicated all temperatures are set forth in degrees Celsius. Unless otherwise stated, the reagents were purchased from commercial suppliers, such as Aldrich Chemical Company, Arco Chemical Company and Alfa Chemical Company, and the reagents have not been further purified when used. Common solvents were purchased from commercial suppliers such as Shantou XiLong Chemical Factory, Guangdong Guanghua Reagent Chemical Factory Co. Ltd., Guangzhou Reagent Chemical Factory, Tianjin YuYu Fine Chemical Ltd., Qingdao Tenglong Reagent Chemical Ltd., and Qingdao Ocean Chemical Factory.
- Anhydrous THF, dioxane, toluene, and ether were obtained by refluxing the solvent with sodium. Anhydrous CH2Cl2 and CHCl3 were obtained by refluxing the solvent with CaH2. EtOAc, PE, hexane, DMAC and DMF were treated with anhydrous Na2SO4 prior use.
- The reactions set forth below were done generally under a positive pressure of nitrogen or argon or with a drying tube (unless otherwise stated) in anhydrous solvents, and the reaction flasks were typically fitted with rubber septa for the introduction of substrates and reagents via syringe. Glassware was oven dried and/or heat dried.
- Column chromatography was conducted using a silica gel column. Silica gel (300-400 mesh) was purchased from Qingdao Ocean Chemical Factory. 1H NMR spectra were recorded by a Bruker Avance 400 MHz spectrometer or Bruker Avance III HD 600 spectrometer, using CDCl3, DMSO-d6 , CD3OD or acetone-d6 (reported in ppm) as solvent, and using TMS (0 ppm) or chloroform (7.26 ppm) as the reference standard. When peak multiplicities are reported, the following abbreviations are used: s (singlet), d (doublet), t (triplet), m (multiplet), q (quartet), br (broadened), dd (doublet of doublets), dt (doublet of triplets), dq (doublet of quartets),ddd (doublet of doublet of doublets), ddt (doublet of doublet of triplets), dddd (doublet of doublet of doublet of doublets). Coupling constants, when given, were reported in Hertz (Hz).
- Low-resolution mass spectral (MS) data were determined by an Agilent 6320 Series LC-MS spectrometer equipped with a G1312A binary pump and a G1316A TCC (column was operated at 30 °C). G1329A autosampler and G1315B DAD detector were applied in the analysis, and an ESI source was used in the LC-MS spectrometer.
- Low-resolution mass spectral (MS) data were determined by an Agilent 6120 Series LC-MS spectrometer equipped with a G1311A quaternary pump and a G1316A TCC (column was operated at 30 °C). G1329A autosampler and G1315D DAD detector were applied in the analysis, and an ESI source was used on the LC-MS spectrometer.
- Both LC-MS spectrometers were equipped with an Agilent Zorbax SB-C18, 2.1 × 30 mm, 5 µm column. Injection volume was decided by the sample concentration. The flow rate was 0.6 mL/min. The HPLC peaks were recorded by UV-Vis wavelength at 210 nm and 254 nm. The mobile phase was 0.1 % formic acid in acetonitrile (phase A) and 0.1% formic acid in ultrapure water (phase B). The gradient elution conditions were showed in Table 1:
Table 1 The gradient condition of the mobile phase in Low-resolution mass spectrum analysis Time (min) A (CH3CN, 0.1% HCOOH) B (H2O, 0.1% HCOOH) 0-3 5 - 100 95 - 0 3-6 100 0 6 - 6.1 100-5 0-95 6.1 - 8 5 95 - The HPLC method for testing the atropisomer excess (% ee) is as follows: chromatographic column: CHIRALPAK AS-H 4.6 × 250 mm 5 µm; flow rate: 1.0 mL/min; column temperature: 30°C; detection wavelength: 290 nm; diluent: ethanol; mobile phase A: 0.1% TFA: ETOH; mobile phase B: n-hexane; running time: 30 min. The gradient elution conditions were showed in Table 2:
Table 2 Time (min) A% B% 0 20 80 30 20 80 -
- The following abbreviations are used throughout the specification:
DMSO-d6 deuterated dimethyl sulfoxide; g grams; mg milligrams; mol moles; mmol millimoles; mL milliliters; µL microliters - The following reaction schemes describe the steps for preparing the compounds disclosed herein. Wherein, unless otherwise stated, R1, R2a, R2b, R2c, R2d and R2e all have the meanings as described herein; L1 is a leaving group such as Cl, Br, I, methylsulfonyl or p-toluenesulfonyl. Unless otherwise stated, the reaction in each step of the reaction scheme is carried out in a solvent inert to the reaction. The solvents inert to the reaction includes, but are not limited to, the solvents involved in the embodiments or their substitutes.
-
- The intermediate compound S5 can be prepared by the following method: compound S1 undergoes substitution reaction with bromine to obtain compound S2; compound S2 undergoes substitution reaction with ethyl cyanoacetate to obtain compound S3; compound S3 reacts under acidic conditions to obtain compound S4, and finally, compound S4 undergoes dechlorination reaction under the action of a suitable hydrogen transfer reagent to obtain intermediate compound S5.
- The intermediate compound S5 can also be prepared by the following method: compound S6 undergoes substitution reaction with N-bromosuccinimide (NBS) to obtain compound S7; compound S7 undergoes a coupling reaction with phenylboronic acid compound S-a to obtain intermediate compound S5.
-
- The intermediate compound S11 can be prepared according to one of the following methods:
- (1) compound S5 undergoes saponification reaction to obtain compound S8; compound S8 undergoes a substitution reaction with benzyl bromide under alkaline conditions to obtain intermediate compound S9; compound S9 reacts with appropriate reagent L1-R1 to obtain compound S12; compound S12 undergoes saponification reaction to obtain compound S11. or
- (2) compound S5 reacts with appropriate reagents L1-R1 to obtain compound S10; compound S10 undergoes saponification reaction to obtain compound S11.
- Compound S15 can be prepared according to the method as described in Scheme 1. The reaction process is as follows: compound S11 reacts with a suitable acylating reagent (such as oxalyl chloride) to obtain compound S14; S14 undergoes an acylation reaction with 3-fluoro-4-methylsulfonyl aniline to obtain compound S15.
- Compound S15 can also be prepared according to the method as described in Scheme 2. The reaction process is as follows: Compound S11 undergoes a condensation reaction with 3-fluoro-4-methylsulfonyl aniline under the action of a suitable reagent (such as a condensation reagent) to obtain compound S15.
- Compound S16 can be prepared according to the method as described in Scheme 3. The reaction process is as follows: Compound S14 undergoes an acylation reaction with the corresponding aromatic amine substrate to obtain compound S16.
- The following examples disclosed herein are presented to further describe the invention. However, these examples should not be used to limit the scope of the invention.
-
- 2'-(Trifluoromethyl)propiophenone (139 g, 687.5 mmol) was weighed and added into a 2000 mL four-necked flask, to the flask was added dichloromethane (800 mL), and then 1 drop of hydrobromic acid (content 48%) and 1 drop of liquid bromine were added. The color of bromine was found to fade under stirring, and then liquid bromine (121.5 g, 760.3 mmol) was added dropwise to the mixture. The mixture was stirred at room temperature for 0.5 h after addition. Saturated sodium sulfite solution (300 mL) was added to the flask, and the dichloromethane was removed by rotary evaporation under reduced pressure. Water (600 mL) and ethyl acetate (1000 mL) were added to the residue, and the organic phase was separated and washed with saturated brine (500 mL), dried with anhydrous sodium sulfate, filtered, and concentrated directly to obtain a pale yellow solid (193 g, 99.9%).
- Potassium carbonate (166.6 g, 1205 mmol) was weighed and added into a 2000 mL flask, to the flask was added ethyl cyanoacetate (128 mL, 1203 mmol). The mixture was heated to 50°C and stirred for 2 h. The flask was removed and cooled to room temperature, a solution of 2-bromo-1-(2-(trifluoromethyl)phenyl)propan-1-one (188 g, 668.9 mmol) in acetone (1000 mL) was added dropwise. The mixture was stirred at room temperature overnight after addition. The reaction solution was filtered with diatomite, and the filter cake was washed with acetone (50 mL × 3). The filtrate was concentrated, extracted with ethyl acetate (200 mL × 4). The organic phase was dried with anhydrous sodium sulfate, then filtered, and concentrated. The residue was separated by silica gel column chromatography (petroleum ether/ethyl acetate (v/v) = 5/1) to obtain a beige solid (180.4 g, 86.09%).
- MS (ESI, pos. ion) m/z: 314.2 (M+1).
- Ethyl 2-cyano-3-methyl-4-oxo-4-(2-(trifluoromethyl)phenyl)butyrate (30 g, 95.8 mmol) was weighed and added into a 200 mL sealed tube, and to the sealed tube was added a solution of hydrogen chloride in ethyl acetate (120 mL, 480 mmol, 4 mol/L). The mixture was heated to 65°C and reacted for 48 h after addition. The solvent was removed by rotary evaporation under reduced pressure, and the residue was separated by silica gel column chromatography (petroleum ether/ethyl acetate (v/v) = 10/1) to obtain a beige solid (31.7 g, 99.8%).
- MS (ESI, pos. ion) m/z: 332.0 (M+1).
- Ethyl 2-chloro-4-methyl-5-(2-(trifluoromethyl)phenyl)-1H-pyrrole-3-carboxylate (93.1 g, 281 mmol) was weighed and added into a 2000 mL flask, to the flask were added ethanol (635 mL), tetrahydrofuran (115 mL), water (47 mL), sodium formate (25.17 g, 370.1 mmol) and palladium on carbon (9.79 g, 10 mass%). The mixture was heated to 65°C and stirred for 4.5 h after addition. The reaction solution was cooled to room temperature, to the reaction solution was added tetrahydrofuran (93 mL). The mixture was filtered with suction, the filter cake was washed with ethanol (93 mL × 4), and the filtrate was concentrated. Water (750 mL) was added into the filtrate, and the resulting mixture stirred at room temperature overnight. The mixture was filtered with suction, and the filter cake was washed with a mixed solution of ethanol/water (280 mL, v/v = 7/8). The filter cake was collected and dried under reduced pressure at 40°C to obtain an off-white solid (71.3 g, 85.4%).
- MS (ESI, pos. ion) m/z: 298.3 (M+1).
- Ethyl 4-methylpyrrole-3-carboxylate (6.0 g, 39 mmol) was weighed and added into a 100 mL flask, to the flask was added tetrahydrofuran (50 mL), then the mixture was cooled to -78°C. To the mixture was added N-Bromosuccinimide (6.99 g, 39.3 mmol), and the mixture was stirred at -78°C for 15 min, then 6 drops of pyridine was added, and the resulting mixture was slowly heated to 5°C and stirred overnight. The reaction solution was extracted with ethyl acetate (100 mL × 3). The organic phase was dried with anhydrous sodium sulfate, then filtered and concentrated. The residue was separated by silica gel column chromatography (petroleum ether/ethyl acetate (v/v) = 10/1) to obtain a white solid (7.41 g, 82%).
- MS (ESI, pos. ion) m/z: 232.1 (M+1).
- 1H NMR (400 MHz, DMSO-d 6) δ (ppm) 11.97 (s, 1H), 7.40 (s, 1H), 4.15 (q, J = 7.1 Hz, 2H), 2.11 (s, 3H), 1.24 (t, J = 7.1 Hz, 3H).
- Ethyl 5-bromo-4-methyl-1H-pyrrole-3-carboxylate (15.8 g, 68.1 mmol) was weighed and added into a 500 mL flask, to the flask were added 2-(trifluoromethyl)phenyl boronic acid (20.9 g, 110 mmol), lithium chloride (289.3 mg, 6.83 mmol), sodium carbonate solution (68 mL, 136 mmol, 2 mol/L), 1,4-dioxane (200 mL) and (1,1'-bis(diphenylphosphine)ferrocene)dichloride palladium dichloromethane complex (3.49 g, 4.19 mmol). The mixture was heated to 90°C and reacted for 22 h after addition. The solvent was removed by rotary evaporation under reduced pressure, and the resulting mixture was extracted with ethyl acetate (80 mL × 4) The organic phase was dried with anhydrous sodium sulfate, then filtered and concentrated. The residue was separated by silica gel column chromatography (petroleum ether/dichloromethane (v/v) = 5/1) to obtain a white solid (6.9 g, 34%).
- MS (ESI, pos. ion) m/z: 298.2 (M+1).
-
- Ethyl 4-methyl-5-(2-(trifluoromethyl)phenyl)-1H-pyrrole-3-carboxylate (25 g, 84.1 mmol) was weighed and added into a 500 mL flask, to the flask were added N,N-dimethylformamide (160 mL), cesium carbonate (41.7 g, 128 mmol) and benzyl 2-bromoethyl ether (16 mL, 101 mmol). The mixture was heated to 70°C and stirred for 12 h after addition. The reaction solution was extracted with ethyl acetate (150 mL × 3), the organic phases were combined and washed with saturated brine (150 mL × 3). The resulting mixture was dried with anhydrous sodium sulfate, then filtered and concentrated. The residue was separated by silica gel column chromatography (petroleum ether/ethyl acetate (v/v) = 10/1) to obtain a brown-yellow solid (36.2 g, 99.8%).
- MS (ESI, pos. ion) m/z: 432.4 (M+1).
- Ethyl 1-(2-(benzyloxy)ethyl)-4-methyl-5-(2-(trifluoromethyl)phenyl)-1H-pyrrole-3-carboxylate (36.2 g, 83.9 mmol) was weighed and added into a 1000 mL flask, to the flask were added sodium hydroxide solution (60 mL, 960 mmol, 16 mol/L) and ethanol (200 mL). The mixture was heated to 70°C and stirred overnight after addition. The ethanol was removed by rotary evaporation under reduced pressure, water (1000 mL) was added to the residue and then the mixture was stirred at room temperature for 30 min. The resulting mixture was washed with methyl tert-butyl ether (200 mL × 3), and the aqueous phase was adjusted to pH = 2 with 6 M HCl solution, then extracted with ethyl acetate (200 mL × 3). The organic layer was dried over anhydrous sodium sulfate, then filtered and concentrated to obtain a brown-yellow solid (33.4 g, 98.7%).
- MS (ESI, pos. ion) m/z: 404.2 (M+1).
- 1-(2-(benzyloxy)ethyl)-4-methyl-5-(2-(trifluoromethyl)phenyl)-1H-pyrrole-3-carbo xylic acid (401 mg, 0.994 mmol) was weighed and added into a 100 mL flask, to the flask were added dichloromethane (15 mL) and 2 drops of N,N-dimethylformamide. Then oxalyl chloride (0.40 mL, 4.7 mmol) was added dropwise under ice bath conditions. The mixture was reacted at room temperature for 2.5 h after addition. The solvent was removed by rotary evaporation under reduced pressure to obtain a brown-yellow solid (400 mg, 95.40%).
- 1-(2-(Benzyloxy)ethyl)-4-methyl-5-(2-(trifluoromethyl)phenyl)-1H-pyrrole-3-carbo nyl chloride (400 mg, 0.948 mmol ) was weighed and added into a 50 mL sealed tube, to the sealed tube were added tetrahydrofuran (10 mL), pyridine (0.14 mL, 1.7 mmol), 3-fluoro-4-methylsulfonylaniline (160 mg, 0.846 mmol) and 4-dimethylaminopyridine (10.7 mg, 0.0876 mmol). The mixture was heated to 80°C and stirred overnight after addition. The solvent was removed by rotary evaporation under reduced pressure, and the residue was separated by silica gel column chromatography (petroleum ether/ethyl acetate (v/v) = 2/1) to obtain a pale yellow solid (337 mg, 69.36%).
- MS (ESI, pos. ion) m/z: 575.2 (M+1).
- 1-(2-(benzyloxy)ethyl)-N-(3-fluoro-4-(methylsulfonyl)phenyl)-4-methyl-5-(2-(triflu oromethyl)phenyl)-1H-pyrrole-3-carboxamide (337 mg, 0.587 mmol) was weighed and added into a 100 mL flask, to the flask were added methanol (10 mL) and palladium on carbon (66.7 mg, 10 mass%). The mixture was stirred at room temperature for 1.5 h under H2. The reaction solution was suction filtered by diatomite, the filter cake was washed with methanol (10 mL × 3), the filtrate was concentrated, and the residue was separated by silica gel column chromatography (petroleum ether/ethyl acetate (v/v) = 1/2) to obtain a white solid (220.5 mg, 77.60%).
- MS (ESI, pos. ion) m/z: 485.3 (M+1);
- 1H NMR (400 MHz, DMSO-d 6) δ (ppm): 10.15 (s, 1H), 7.99 (dd, J = 13.4, 1.1 Hz, 1H), 7.90 (d, J= 7.7 Hz, 1H), 7.83 - 7.76 (m, 3H), 7.74 - 7.69 (m, 2H), 7.47 (d, J= 7.4 Hz, 1H), 4.94 (t, J= 4.8 Hz, 1H), 3.73 - 3.64 (m, 1H), 3.55 - 3.44 (m, 3H), 3.28 (s, 3H), 1.93 (s, 3H).
-
- N-(3-Fluoro-4-(methylsulfonyl)phenyl)-1-(2-hydroxyethyl)-4-methyl-5-(2-(trifluoro methyl)phenyl)-1H-pyrrole-3-carboxamide (3.4 g, 7.02 mmol) was weighed and added into a 25 mL flask, and anhydrous acetonitrile (8 mL) was added to dissolve all the samples. High performance liquid chromatography (instrument: Waters SFC; column: Daicel AS-H 10 mm × 250 mm 5 µm; conditions: isocratic 20% MeOH + 80% CO2; flow rate: 8 mL/min; column temperature: 35°C; back pressure: 100 bar; 10 µL samples per injection) was used for chiral resolution. The mixture was rotary evaporated under reduced pressure, and the solvent was removed to obtain the title compound as a white solid (1.43 g, 42.1%; HPLC retention time 8.627 min; purity 99.85%; ee value 99.80%).
- MS (ESI, pos. ion) m/z: 485.1 (M+1);
- 1H NMR (400 MHz, DMSO-d 6) δ (ppm): 10.15 (s, 1H), 7.98 (dd, J = 13.5, 1.3 Hz, 1H), 7.90 (d, J= 7.8 Hz, 1H), 7.82 - 7.76 (m, 3H), 7.75 - 7.68 (m, 2H), 7.47 (d, J= 7.4 Hz, 1H), 4.94 (t, J= 4.9 Hz, 1H), 3.73 - 3.64 (m, 1H), 3.56 - 3.45 (m, 3H), 3.28 (s, 3H), 1.92 (s, 3H).
-
- Methyl 1-hydroxy-1-cyclopropanecarboxylate (1.02 g, 8.78 mmol) was weighed and added into a 100 mL flask, to the flask N,N-dimethylformamide (30 mL)was added. The mixture was cooled to 0°C, and sodium hydride (521.6 mg, 13.04 mmol, 60 mass%) was added. The reaction solution was stirred at 0°C for 20 min and then benzyl bromide (1.1 mL, 9.3 mmol) was added. The mixture was reacted at room temperature for 3 h after addition. The reaction solution was extracted with ethyl acetate (80 mL × 3), the organic phases were combined and washed with saturated brine (50 mL × 2), dried over anhydrous sodium sulfate, then filtered and concentrated. The residue was separated by silica gel column chromatography (petroleum ether/ethyl acetate (v/v) = 5/1) to obtain brown-yellow liquid (1.465 g, 80.9%).
- MS (ESI, pos. ion) m/z: 207.2 (M+1).
- Tetrahydroaluminum lithium (233.1 mg, 6.14 mmol) was weighed and added into a 100 mL flask, tetrahydrofuran (15 mL) was added. A solution of methyl 1-(benzyloxy)cyclopropanecarboxylate (1.40 g, 6.79 mmol) in tetrahydrofuran (15 mL) was added dropwise. The mixture was stirred at room temperature for 3 h after addition. To the flask was added sodium sulfate decahydrate until the solution was clarified, the solution was suction filtered by diatomite, the filter cake was washed with ethyl acetate (20 mL × 3) and the filtrate was concentrated. The residue was separate by silica gel column chromatography (petroleum ether/ethyl acetate (v/v) = 5/1) to obtain yellow liquid (871.9 mg, 72.1%).
- MS (ESI, pos. ion) m/z: 196.2 (M+NH4).
- (1-(Benzyloxy)cyclopropyl)methanol (511 mg, 2.87 mmol) was weighed and added into a 50 mL flask, dichloromethane (15 mL) was added. The mixture was cooled to 0°C, triethylamine (0.80 mL, 5.8 mmol) was added, and methanesulfonyl chloride (0.29 mL, 3.7 mmol) was added dropwise. The mixture was reacted at room temperature for 2 h after addition. The reaction solution was extracted with dichloromethane (40 mL × 3). The organic phase was dried with anhydrous sodium sulfate, then filtered and concentrated to obtain yellow liquid (730 mg, 99.34%).
- MS (ESI, pos. ion) m/z: 279.0 (M+Na).
- Ethyl 4-methyl-5-(2-(trifluoromethyl)phenyl)-1H-pyrrole-3-carboxylate (450 mg, 1.51 mmol) was weighed and added into a 50 mL flask, N,N-dimethylformamide (15 mL) and sodium hydride (186.3 mg, 4.66 mmol, 60 mass%) were added. The mixture was stirred at room temperature for 10 min, then a solution of (1-(benzyloxy)cyclopropyl)methyl methanesulfonate (730 mg, 2.85 mmol) in N,N-dimethylformamide (5 mL) was added dropwise. The mixture was stirred at room temperature overnight after addition. The reaction solution was extracted with ethyl acetate (80 mL × 3), the organic phases were combined and washed with saturated brine (50 mL × 2), dried with anhydrous sodium sulfate, then filtered and concentrated. The residue was separated by silica gel column chromatography (petroleum ether/ethyl acetate (v/v) = 10/1), light yellow oily liquid (617 mg, 89.10%) was obtained.
- MS (ESI, pos. ion) m/z: 458.1 (M+1).
- Ethyl 1-((1-(benzyloxy)cyclopropyl)methyl)-4-methyl-5-(2-(trifluoromethyl)phenyl)-1H-pyrrole-3-car boxylate (617 mg, 1.35 mmol) was weighed and added into a 50 mL flask, to the flask were added ethanol (10 mL) and sodium hydroxide solution (2.0 mL, 12 mmol, 6 mol/L). The mixture was heated to 70°C and stirred overnight after addition. The solvent was removed by rotary evaporation under reduced pressure, water (50 mL) was added to the residue, and the resulting mixture was washed with methyl tert-butyl ether (30 mL × 2). The aqueous phase was adjusted to pH = 2 with 1 M HCl solution and extracted with ethyl acetate (60 mL× 4). The organic phase was dried with anhydrous sodium sulfate, then filtered and concentrated directly to obtain a pale yellow solid (523.1 mg, 90.33%).
- MS (ESI, pos. ion) m/z: 430.3 (M+1).
- 1-((1-(Benzyloxy)cyclopropyl)methyl)-4-methyl-5-(2-(trifluoromethyl)phenyl)-1H-pyrrole-3-formic acid (300 mg, 0.699 mmol) and dichloromethane (20 mL) were added into a flask, then oxalyl chloride (0.30 mL, 3.5 mmol) and N,N-dimethylformamide (5 mg, 0.0684 mmol) were added dropwise. The mixture was stirred at room temperature for 22 h. The solvent was evaporated under reduced pressure to obtain a yellow solid (312 mg, 99.70%).
- 3-Fluoro-4-methylsulfonylaniline (110 mg, 0.581 mmol), 1-((1-(benzyloxy)cyclopropyl)methyl)-4-methyl-5-(2-(trifluoromethyl)phenyl)-1H-pyrrole-3-car bonyl chloride (312 mg, 0.697 mmol) and pyridine (10 mL) were added into a sealed tube, the reaction system was heated to 100°C and stirred for 29 h. The reaction solution was cooled to room temperature, 1 M HCl solution was added to adjust pH = 3, the mixture was extracted with ethyl acetate (80 mL). The organic phase was adjusted to pH = 8 with saturated sodium bicarbonate aqueous solution, then washed with saturated brine (60 mL), and dried with anhydrous sodium sulfate. The resulting mixture was filtered, the solvent was evaporated under reduced pressure, and the residue was separated by silica gel column chromatography (petroleum ether/ethyl acetate (v/v) = 10/1-4/1) to obtain a pale yellow solid (140 mg, 40.10%).
- MS (ESI, pos.ion) m/z: 601.0 (M+1).
- 1-((1-(Benzyloxy)cyclopropyl)methyl)-N-(3-fluoro-4-(methylsulfonyl)phenyl)-4-m ethyl-5-(2-(trifluoromethyl)phenyl)-1H-pyrrole-3-carboxamide (140 mg, 0.233 mmol), methanol (10 mL) and palladium on carbon (30 mg, 10 mass%) were added into a flask, the reaction system was stirred at room temperature under H2 for 3 h. The reaction solution was filtered, the filtrate was concentrated under reduced pressure The residue was separated by silica gel column chromatography (petroleum ether/ethyl acetate (v/v) = 10/1-4/1), and then stirred with petroleum ether/ethyl acetate (10 mL /1 mL) for 1 h, then filtered and dried to obtain a white solid (80 mg, 67.23%).
- MS (ESI, pos.ion) m/z: 511.1 (M+1).
- 1H NMR (400 MHz, CDCl3) δ (ppm): 8.00 (d, J = 12.1 Hz, 1H), 7.94 - 7.79 (m, 3H), 7.72 - 7.56 (m, 3H), 7.41 (d, J = 7.6 Hz, 1H), 3.73 - 3.69 (m, 2H), 3.24 (s, 3H), 2.11 (s, 3H),0.92 - 0.87 (m, 2H), 0.54 - 0.48 (m, 1H), 0.44 - 0.40 (m, 1H).
- 19F NMR (376 MHz, CDCl3) δ (ppm): -60.95, -107.35.
-
- Ethyl 4-methyl-5-(2-(trifluoromethyl)phenyl)-1H-pyrrole-3-carboxylate (30 g, 100.9 mmol) was weighed and added into a 1000 mL flask, then sodium hydroxide solution (60 mL, 1020 mmol, 17 mol/L) and ethanol (300 mL) were added. The mixture was heated to 70°C and stirred for 12 h. The solvent was removed by rotary evaporation under reduced pressure. Water (1000 mL) was added to the residue and stirred at room temperature for 30 min. The resulting mixture was washed with methyl tert-butyl ether (100 mL × 3), and the aqueous phase was adjusted to pH = 2 with 6 M HCl solution. The resulting solution was extracted with ethyl acetate (200 mL × 3). The organic phase was dried with anhydrous sodium sulfate, then filtered and concentrated directly to obtain a brown-yellow solid (27.1 g, 99.8%).
- MS (ESI, pos. ion) m/z: 270.2 (M+1).
- 4-Methyl-5-(2-(trifluoromethyl)phenyl)-1H-pyrrole-3-carboxylic acid (27.3 g, 101 mmol) was weighed and added into a 500 mL flask, then N,N-dimethylformamide (250 mL) was added. The mixture was cooled to 0°C, and cesium carbonate (33.09 g, 101.6 mmol) and benzyl bromide (12 mL, 101 mmol) were added. The mixture was reacted at 0°C for 7 h after addition. Cesium carbonate (3.31 g, 10.16 mmol) and benzyl bromide (1.2 mL, 10.1 mmol) were added, the mixture was reacted overnight at 0°C. The reaction solution was extracted with ethyl acetate (200 mL × 3), the organic phases were combined and washed with saturated brine (200 mL × 3), dried with anhydrous sodium sulfate, then filtered and concentrated. The residue was separated by silica gel column chromatography (petroleum ether/ethyl acetate (v/v) = 10/1) to obtain a brown-yellow solid (29.7 g, 81.5%).
- MS (ESI, pos. ion) m/z: 360.1 (M+1).
- Benzyl 4-methyl-5-(2-(trifluoromethyl)phenyl)-1H-pyrrole-3-carboxylate (1.0 g, 2.8 mmol) was weighed and added into a 100 mL flask, then N,N-dimethylformamide (25 mL) and sodium hydride (334.6 mg, 8.37 mmol, 60 mass%) were added. The mixture was stirred at room temperature for 10 min, and then bromocyclobutane (1.0 mL, 11 mmol) was added. After addition, the mixture was heated to 100°C and stirred for 15 h. The reaction solution was cooled to room temperature and extracted with ethyl acetate (60 mL × 3). The organic phases were combined and washed with saturated brine (50 mL × 2), dried with anhydrous sodium sulfate, then filtered and concentrated. The residue was separated by silica gel column chromatography (petroleum ether/ethyl acetate (v/v) = 10/1) to obtain pale yellow oily liquid (839 mg, 73%) .
- MS (ESI, pos. ion) m/z: 414.3 (M+1).
- Benzyl 1-cyclobutyl-4-methyl-5-(2-(trifluoromethyl)phenyl)-1H-pyrrole-3-carboxylate (830 mg, 2.01 mmol) was weighed and added into a 100 mL flask, then methanol (25 mL) and palladium on carbon (216.1 mg, 10 mass%) were added. The mixture was stirred at room temperature for 5 h under H2. The reaction solution was suction filtered by diatomite, the filter cake was washed with methanol (10 mL × 3). The filtrate was concentrated, and the residue was separated by silica gel column chromatography (petroleum ether/ethyl acetate (v/v) = 2/1) to obtain a white solid (183.6 mg, 28.29%).
- MS (ESI, pos. ion) m/z: 324.2 (M+1).
- 1-Cyclobutyl-4-methyl-5-(2-(trifluoromethyl)phenyl)-1H-pyrrole-3-carboxylic acid (210 mg, 0.65 mmol) and dichloromethane ( 20 mL) were added a flask, oxalyl chloride (0.27 mL, 3.2 mmol) and N,N-dimethylformamide (5 mg, 0.0684 mmol) were added dropwise. The reaction system was stirred at room temperature for 21 h. The solvent was evaporated under reduced pressure to obtain a yellow solid (222 mg, 99.99%).
- 3-Fluoro-4-methylsulfonylaniline (102 mg, 0.539 mmol), 1-cyclobutyl-4-methyl-5-(2-(trifluoromethyl)phenyl)-1H-pyrrole-3-carbonyl chloride (221 mg, 0.647 mmol) and pyridine (10 mL) were added into a sealed tube. The reaction system was heated to 90°C and stirred for 24 h. The mixture was cooled to room temperature, 1 M HCl solution was added to adjust pH = 3. The mixture was extracted with ethyl acetate (80 mL), the organic phase was adjusted pH = 8 by saturated aqueous sodium bicarbonate solution. The resulting mixture was washed with saturated brine (60 mL), and dried with anhydrous sodium sulfate. The mixture was filteredand the solvent was evaporated under reduced pressure The residue was separated by silica gel column chromatography (petroleum ether/ethyl acetate (v/v) = 10/1-4/1) to obtain a yellow solid (116 mg, 43.51%).
- MS (ESI, pos.ion) m/z: 495.1 (M+1).
- 1H NMR (400 MHz, CDCl3) δ (ppm): 7.99 (d, J = 12.4 Hz, 1H), 7.90 (s, 1H), 7.89 - 7.76 (m, 2H), 7.72 - 7.60 (m, 3H), 7.59 (s, 1H), 7.32 - 7.28 (m, 2H), 4.13 - 4.00 (m, 1H), 3.23 (s, 3H), 2.45 - 2.31 (m, 1H), 2.25 - 2.18 (m, 2H), 2.17 - 2.08 (m, 2H), 2.07 (s, 3H), 1.80 - 1.74 (m, 1H).
- 19F NMR (376 MHz, CDCl3) δ (ppm): -60.91, -107.38, -107.41, -107.43.
-
- Benzyl 4-methyl-5-(2-(trifluoromethyl)phenyl)-1H-pyrrole-3-carboxylate (1.09 g, 3.03 mmol) and N,N-dimethylformamide (20 mL) were added into a flask, sodium hydride (133 mg, 3.33 mmol, 60 mass%) was added under ice bath. The mixture was stirred under N2 for 0.5 h, 2-bromomethyloxetane (687 mg, 4.55 mmol) was added dropwise. The reaction system was stirred at room temperature for 24.5 h. To the flask was added saturated ammonium chloride solution (40 mL) to quench the reaction. The mixture was extracted with ethyl acetate (80 mL × 2). The organic phases were combined, washed with saturated brine (40 mL × 2) and dried with anhydrous sodium sulfate. The mixture was filtered and the solvent was evaporated under reduced pressure The residue was separated by silica gel column chromatography (dichloromethane/ethyl acetate (v/v) = 100/1-50/1) to obtain a pale yellow solid (660 mg, 50.7%).
- MS (ESI, pos.ion) m/z: 430.1 (M+1).
- 1H NMR (400 MHz, CDCl3) δ (ppm): 7.81 (d, J= 7.5 Hz, 1H), 7.67 - 7.51 (m, 3H), 7.46 (d, J = 7.5 Hz, 2H), 7.39 (t, J = 7.4 Hz, 2H), 7.33 (t, J = 7.2 Hz, 2H), 5.35 - 5.25 (m, 2H), 4.94 - 4.74 (m, 1H), 4.67 - 4.57 (m, 1H), 4.43 (ddt, J = 34.0, 9.2, 5.9 Hz, 1H), 3.96 - 3.62 (m, 2H), 2.59 (qd, J = 14.1, 7.0 Hz, 1H), 2.36 - 2.19 (m, 1H), 2.03 (d, J = 4.6 Hz, 3H).
- Benzyl 4-Methyl-1-(oxetan-2-ylmethyl)-5-(2-(trifluoromethyl)phenyl)-1H-pyrrole-3-carboxylate ( 650 mg, 1.51 mmol), methanol (20 mL), and palladium-carbon (130 mg, 10 mass%) were added into a flask. The mixture was stirred at room temperature for 11 h under H2 after addition. The reaction solution was filtered with diatomite, the filtrate was concentrated under reduced pressure, and the residue was separated by silica gel column chromatography (petroleum ether/ethyl acetate (v/v) = 4/1-1/1) to obtain a pale yellow solid (480 mg, 93.46%).
- MS (ESI, pos.ion) m/z: 340.2 (M+1).
- 1H NMR (400 MHz, CDCl3) δ (ppm): 7.81 (d, J= 7.4 Hz, 1H), 7.70 - 7.54 (m, 3H), 7.37 (d, J = 7.3 Hz, 1H), 4.97 - 4.79 (m, 1H), 4.70 - 4.57 (m, 1H), 4.45 (ddt, J = 31.5, 9.2, 5.9 Hz, 1H), 3.88 (ddd, J = 19.1, 14.7, 5.6 Hz, 1H), 3.76 - 3.64 (m, 1H), 2.69 - 2.55 (m, 1H), 2.40 - 2.20 (m, 1H), 2.06 - 2.00 (m, 3H).
- 4-Methyl-1-(oxetan-2-ylmethyl)-5-(2-(trifluoromethyl)phenyl)-1H-pyrrole-3-carbo xylic acid (320 mg, 0.943 mmol), 3-fluoro-4-methylsulfonylaniline (178 mg, 0.941 mmol), pyridine (20 mL) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (365 mg, 1.89 mmol) were added into a flask. The reaction system was stirred at room temperature for 47 h. The solvent was evaporated under reduced pressure, ethyl acetate (60 mL) was added to dissolve, and then the mixture was washed with 1 M HCl solution (20 mL), saturated sodium bicarbonate aqueous solution (20 mL) and saturated brine (20 mL) respectively, dried with anhydrous sodium sulfate. The mixture was filtered, the solvent was evaporated under reduced pressure, and the residue was separated by silica gel column chromatography (dichloromethane/ethyl acetate (v/v) = 50/1-20/1) to obtain a pale yellow solid (90 mg, 18.69%).
- MS (ESI, pos.ion) m/z: 511.2 (M+1).
- 1H NMR (400 MHz, CDCl3) δ (ppm): 8.18 - 8.13 (m, 1H), 7.99 - 7.94 (m, 1H), 7.86 - 7.81 (m, 2H), 7.69 - 7.60 (m, 2H), 7.59 - 7.51 (m, 1H), 7.37 - 7.31 (m, 2H), 5.01 - 4.78 (m, 1H), 4.71 - 4.59 (m, 1H), 4.57 - 4.40 (m, 1H), 3.84 - 3.53 (m, 2H), 3.22 (s, 3H), 2.64 - 2.58 (m, 1H), 2.37 - 2.22 (m, 1H), 2.11 - 2.05 (m, 3H).
- 19F NMR (376 MHz, CDCl3) δ (ppm): -60.99, -61.07, -107.65, -107.68.
-
- Ethyl 4-methyl-5-(2-(trifluoromethyl)phenyl)-1H-pyrrole-3-carboxylate (401 mg, 1.35 mmol) was weighed and added into a 50 mL flask, N,N-dimethylformamide and sodium hydride (168.9 mg, 4.22 mmol, 60 mass%) were added under ice bath conditions. After addition, the mixture was stirred at room temperature for 10 min. Then 3-iodooxetane (0.36 mL, 4.2 mmol) was added and the mixture was heated to 100°C and stirred for 24 h. Sodium hydride (168.9 mg, 4.22 mmol, 60 mass%) and 3-iodooxetane (0.36 mL, 4.2 mmol) were added into the system, the mixture was heated and stirred at 100°C for 24 h. The reaction solution was extracted with ethyl acetate (40 mL × 3), the organic phases were combined and washed with saturated brine (50 mL × 2), dried over anhydrous sodium sulfate, then filtered and concentrated. The residue was separated by silica gel column chromatography (petroleum Ether/ethyl acetate (v/v) = 5/1) to obtain a pale yellow solid (365 mg, 76.59%).
- MS (ESI, pos. ion) m/z: 354.3 (M+1).
- Ethyl 4-methyl-1-(oxetan-3-yl)-5-(2-(trifluoromethyl)phenyl)-1H-pyrrole-3-carboxylate (365 mg, 1.03 mmol ) was weighed and added into a 50 mL flask, to the flask were added ethanol (10 mL) and sodium hydroxide solution (3.0 mL, 12 mmol, 4 mol/L). The mixture was heated to 70°C and stirred overnight. The solvent was removed by rotary evaporation under reduced pressure, the residue was dissolved in water (60 mL), washed with methyl tert-butyl ether (20 mL × 2), the aqueous phase was adjusted to pH = 2 with 1 M HCl solution. The mixture was extracted with ethyl acetate (30 mL × 4). The organic phase was dried with anhydrous sodium sulfate, then filtered and concentrated to obtain an orange solid (319.7 mg, 95.13%).
- MS (ESI, pos. ion) m/z: 326.2 (M+1).
- 4-Methyl-1-(oxetan-3-yl)-5-(2-(trifluoromethyl)phenyl)-1H-pyrrole-3-carboxylic acid (400 mg, 1.23 mmol) and dichloromethane (20 mL) and oxalyl chloride (0.52 mL, 6.1 mmol) were added to a flask, then N,N-dimethylformamide (9 mg, 0.123 mmol) were added dropwise. The reaction system was stirred at room temperature for 16 h. The solvent was evaporated under reduced pressure to obtain a yellow solid (467 mg, 99.89%).
- 3-Fluoro-4-methylsulfonylaniline (193 mg, 1.02 mmol), 1-(1-chloro-3-hydroxypropan-2-yl)-4-methyl-5-(2-(trifluoromethyl)phenyl)-1H-pyrrole-3-carbon yl chloride (465 mg, 1.286 mmol) and pyridine (10 mL) were added into a sealed tube. The reaction system was heated to 90°C and stirred for 29 h. The mixture was cooled to room temperature, 1 M HCl solution was added to adjust pH = 3. The mixture was extracted with ethyl acetate (80 mL), and saturated aqueous sodium bicarbonate solution was added to adjust pH = 8. Then the mixture was washed with saturated brine (60 mL), and dried with anhydrous sodium sulfate. The resulting mixture was filtered, the solvent was evaporated under reduced pressure, and the residue was separated by silica gel column chromatography (petroleum ether/ethyl acetate (v/v) = 10/1-4/1) to obtain a pale yellow solid (100 mg, 18.40%).
- MS (ESI, pos.ion) m/z: 533.0 (M+1).
- 1-(1-Chloro-3-hydroxypropan-2-yl)-N-(3-fluoro-4-(methylsulfonyl)phenyl)-4-meth yl-5-(2-(trifluoromethyl)phenyl)-1H-pyrrole-3-carboxamide (100 mg, 0.188 mmol), sodium hydroxide (22 mg, 0.55 mmol) and tetrahydrofuran (50 mL) were added into a flask, and the reaction system was heated to 70°C and stirred for 4 h. The reaction solution was cooled to room temperature, adjusted to pH = 7 by adding 1 M HCl solution. The resulting mixture was extracted with ethyl acetate (80 mL), the organic phase was washed with saturated brine (60 mL), and dried with anhydrous sodium sulfate. The mixture was filtered, the solvent was evaporated under reduced pressure, and the residue was separated by silica gel column chromatography (petroleum ether/ethyl acetate (v/v) = 10/1-4/1) to obtain a pale yellow solid (40 mg, 42.93%).
- MS (ESI, pos.ion) m/z: 497.1 (M+1).
- 1H NMR (400 MHz, CDCl3) δ (ppm): 8.25 - 7.77 (m, 5H), 7.66 (s, 2H), 7.28 (s, 2H), 4.90 - 4.72 (m, 5H), 3.25 (s, 3H), 2.09 (s, 3H).
- 19F NMR (376 MHz, CDCl3) δ (ppm): -61.26, -107.28.
-
- Benzyl 4-methyl-5-(2-(trifluoromethyl)phenyl)-1H-pyrrole-3-carboxylate (1.00 g, 2.78 mmol), 3-fluoropyridine (1.35 g, 13.9 mmol), cesium carbonate (2.72 g, 8.35 mmol) and N,N-dimethylformamide (20 mL) were added into a sealed tube. The mixture was heated to 100°C for 73 h under N2. The mixture was cooled to room temperature, quenched with water (40 mL), extracted with ethyl acetate (80 mL), the organic phase was washed with saturated brine (40 mL × 2), and dried with anhydrous sodium sulfate. The resulting mixture was filtered. The solvent was evaporated under reduced pressure to give a yellow solid (1.10 g, 90.6%).
- Benzyl 4-methyl-1-(pyridin-3-yl)-5-(2-(trifluoromethyl)phenyl)-1H-pyrrole-3-carboxylate (1.10 g, 2.52 mmol ), methanol (20 mL) and palladium on carbon (110 mg, 10 mass%) were added into a flask, the mixture was stirred at room temperature for 17 h under H2. The reaction solution was suction filtered with diatomite, the filtrate was concentrated under reduced pressure, and the residue was separated by silica gel column chromatography (petroleum ether/ethyl acetate (v/v) = 4/1-1/1) to obtain a pale yellow solid (340 mg, 39.0%).
- MS (ESI, pos.ion) m/z: 347.1 (M+1).
- 1H NMR (400 MHz, CDCl3) δ (ppm): 8.49 (d, J= 4.1 Hz, 1H), 8.44 (s, 1H), 7.70 (d, J= 7.7 Hz, 2H), 7.54 (dd, J = 18.7, 7.4 Hz, 2H), 7.41 (dd, J = 16.2, 7.8 Hz, 2H), 7.22 (dd, J = 8.1, 4.8 Hz, 1H), 2.15 (s, 3H).
- 4-Methyl-1-(pyridin-3-yl)-5-(2-(trifluoromethyl)phenyl)-1H-pyrrole-3-carboxylic acid (340 mg, 0.982 mmol) and dichloromethane (20 mL) were added into a flask, oxalyl chloride (0.42 mL, 5.0 mmol) and N,N-dimethylformamide (7 mg, 0.0958 mmol) were added dropwise. The mixture was stirred at room temperature for 14.5 h. The solvent was evaporated under reduced pressure to obtain a yellow solid (358 mg, 99.95%).
- 3-Fluoro-4-methylsulfonylaniline (131 mg, 0.692 mmol), 4-methyl-1-(pyridin-3-yl)-5-(2-(trifluoromethyl)phenyl)-1H-pyrrole-3-carbonyl chloride (358 mg, 0.981 mmol), pyridine (0.17 mL, 2.1 mmol) and tetrahydrofuran (20 mL) were added to a sealed tube. The mixture was heated to 90°C and stirred for 49 h. The reaction solution was cooled to room temperature, 1 M HCl solution was added to adjust pH = 3, the mixture was extracted with ethyl acetate (80 mL). Saturated sodium bicarbonate aqueous solution was added to the organic phase to adjust pH = 8, then the organic phase was washed with saturated brine (60 mL), dried with anhydrous sodium sulfate. The resulting mixture was filtered, the solvent was evaporated under reduced pressure, and the residue was separated by silica gel column chromatography (petroleum ether/ethyl acetate (v/v) = 2/1-1/1) to obtain a pale yellow solid (100 mg, 27.91%).
- MS (ESI, pos.ion) m/z: 518.1 (M+1);
- 1H NMR (400 MHz, CDCl3) δ (ppm): 8.46 (d, J = 17.9 Hz, 2H), 8.22 (s, 1H), 7.97 (d, J = 12.2 Hz, 1H), 7.85 (t, J = 8.1 Hz, 1H), 7.71 (d, J = 7.3 Hz, 1H), 7.60 (s, 1H), 7.59 - 7.48 (m, 2H), 7.47 - 7.30 (m, 3H), 7.23 (d, J = 4.7 Hz, 1H), 3.23 (s, 3H), 2.18 (s, 3H).
- 19F NMR (376 MHz, CDCl3) δ (ppm): -60.42, -107.35.
-
- At -10°C, 2(3H)-4-fluorobenzothiazolone (5.00 g, 29.6 mmol) and concentrated H2SO4 (50 mL) were added into a flask, concentrated HNO3 (2.03 mL, 29.5 mmol) was slowly added dropwise. The mixture was stirred at -10°C for 1 h. The reaction solution was poured into ice water, stirred for 1 h, and filtered with suction. The filter cake was washed with ice water (20 mL × 2). The filter cake was collected and dried under vacuum at 60°C for 12 h to obtain a pale yellow solid (5.40 g, 85.3%).
- MS (ESI, pos.ion) m/z: 215.0 (M+1).
- 4-Fluoro-6-nitrobenzo[d]thiazole-2(3H)-one (1.00 g, 4.67 mmol), DBU (0.84 mL, 5.6 mmol) and N,N-dimethylformamide (20 mL, 375.2 mmol) were added into a flask, methyl iodide (0.35 mL, 5.6 mmol) was slowly added dropwise. The mixture was heated to 65°C and stirred for 16.5 h. The reaction solution was extracted with ethyl acetate (50 mL × 3), and the organic phases were combined and washed with 1 M HCl solution (50 mL) and saturated brine (50 mL), and then dried with anhydrous sodium sulfate. The mixture was filtered, the solvent was evaporated under reduced pressure, and the residue was separated by silica gel column chromatography (petroleum ether/ethyl acetate (v/v) = 10/1-4/1) to obtain a yellow solid (1.07 g, 100%).
- MS (ESI, pos.ion) m/z: 229.1 (M+1).
- 4-Fluoro-3-methyl-6-nitrobenzo[d]thiazole-2(3H)-one (1.07 g, 4.69 mmol), tetrahydrofuran (50 mL), methanol (50 mL) and palladium on carbon (107 mg, 10 mass%) were added into a flask. The mixture was reacted at room temperature for 9 h under H2. Palladium on carbon (107 mg, 10 mass%) was added to the system, and the mixture was reacted at room temperature for 12 h under H2. The reaction solution was suction filtered with diatomite, and the filtrate was concentrated under reduced pressure. The crude product was stirred with ethyl acetate/methanol (10 mL/2 mL) to obtain a yellow solid (400 mg, 43.0%).
- MS (ESI, pos.ion) m/z: 199.1 (M+1).
- 1H NMR (400 MHz, CDCl3) δ (ppm): 6.53 (s, 1H), 6.41 (d, J = 13.7 Hz, 1H), 3.71 (s, 2H), 3.61 (d, J = 3.2 Hz, 3H).
- 1-(2-(Benzyloxy)ethyl)-4-methyl-5-(2-(trifluoromethyl)phenyl)-1H-pyrrole-3-carbo nyl chloride (312 mg , 0.740 mmol), 6-amino-4-fluoro-3-methylbenzo[d]thiazole-2(3H)-one (122 mg, 0.615 mmol) and pyridine (10 mL) were added into a sealed tube, the reaction system was heated to 90°C and reacted for 30 h. The reaction solution was cooled to room temperature, and saturated sodium bicarbonate aqueous solution was added to adjust the pH = 8. The mixture was extracted with dichloromethane (40 mL × 2), and the organic phases were combined and washed with saturated brine (20 mL), and dried over anhydrous sodium sulfate. The resulting mixture was filtered, the solvent was evaporated under reduced pressure, and the residue was separated by silica gel column chromatography (petroleum ether/ethyl acetate (v/v) = 10/1-5/1) to obtain a pale yellow solid (300 mg, 83.52%).
- MS (ESI, pos.ion) m/z: 584.2 (M+1).
- 1-(2-(Benzyloxy)ethyl)-N-(4-fluoro-3-methyl-2-oxo-2,3-dihydrobenzo[d]thiazol-6-yl)-4-methyl-5-(2-(trifluoromethyl)phenyl)-1H-pyrrole-3-carboxamide (300 mg, 0.514 mmol), methanol (20 mL) and palladium on carbon (60 mg, 10 mass%) were added to a reaction flask. The mixture was reacted at room temperature for 22 h under H2. Palladium on carbon (60 mg, 10 mass%) was added, the reaction solution was heated to 50°C and stirred for 24 h. The reaction solution was suction filtered with diatomite, the filtrate was concentrated under reduced pressure. The residue was separated by silica gel column chromatography (petroleum ether/ethyl acetate (v/v) = 4/1-1/2), then stirred with petroleum ether/ethyl acetate (20 mL/2 mL) for 1 h. The resulting mixture was filtered with suction, and the filter cake was collected and dried at 50°C to obtain a white solid (100 mg, 39.42%).
- MS (ESI, pos.ion) m/z: 494.1 (M+1).
- 1H NMR (400 MHz, CDCl3) δ (ppm): 7.84 (d, J= 7.5 Hz, 1H), 7.70 - 7.60 (m, 2H), 7.58 (d, J = 15.8 Hz, 2H), 7.47 (s, 1H), 7.403-7.38 (m, 2H), 3.85 - 3.67 (m, 4H), 3.67 (d, J = 2.9 Hz, 3H), 2.09 (s, 3H).
- 19F NMR (376 MHz, CDCl3) δ (ppm): -60.97, -131.08.
- Using the characteristics of luciferase binding to the substrate to generate a chemiluminescence reaction, the plasmid containing mineralocorticoid receptor (MR) ligand binding domain (LBD) fused with Gal4 DNA binding domain (DBD) and the firefly luciferase reporter gene plasmid under the control of Gal4 UAS (upstream activation sequence) are transfected into human embryonic kidney cells (HEK293). The changes in mineralocorticoid receptor activity before and after stimulation or the influence of different stimuli on mineralocorticoid receptor activity are judged by the level of firefly luciferase activity. At the same time, in order to reduce the impact of internal change factors on the accuracy of the experiment, the plasmid with Renilla luciferase gene is used as a control plasmid to transfect cells to provide an internal control for transcriptional activity, so that the test results are not interfered by changes in experimental conditions.
-
- 1) The HEK293 cells were collected after trypsinization and the cell density was adjusted to 500,000 cells/mL;
- 2) FuGENE HD transfection reagent was added to the cell suspension;
- 3) The above cell suspension was inoculated into a 96-well cell culture plate of 100 µL/well, and incubated for 24 hours at 37°C, 5% CO2;
- 4) A series of concentrations of the test compound solution and EC80 concentration of agonist aldosterone were added to each well and incubated for 18 hours;
- 5) Firefly and Renilla luciferase signals were detected by Promega dual luciferase reporter gene test system.
- Result processing:
- 1) After obtaining the firefly luciferase signal (F) and the Renilla luciferase signal (R), the Renilla luciferase signal was used for correction, that is, the F/R value was used for subsequent calculation of inhibition rate;
- 2)% inhibition rate = (Max-X) / (Max-Min) × 100%, wherein Max is the F/R value of the positive control well, Min is the F/R value of the negative control well, and X is the test compound well of different concentrations F/R value;
- 3) IC50 was calculated by GraphPrism 5.0 mapping software.
- Results:
Table 3 In vitro activity data of the compounds of the present invention Example No. MR IC50 (nM) Example 1 6.93 Example 2 3.4 Example 3 47.6 Example 5 21.5 Example 6 30.3 Example 7 84.5 Example 8 82.2 - Experimental conclusion: It can be seen from the experimental results in Table 3 that the compounds of the examples of the present invention have good mineralocorticoid receptor (MR) antagonistic activity, and they can be used as effective mineralocorticoid receptor antagonists.
- Preparation of the test compound solution: The test compound was formulated into a solution with 5% dimethyl sulfoxide, 60% PEG400 and 35% normal saline for oral or intravenous administration.
- Beagle dogs 8-10 kg were randomly divided into two groups, and the test compound was administered orally at a dosage of 5.0 mg/kg; after administration, blood was collected at the time points of 0.0833, 0.25, 0.5, 1.0, 2.0, 4.0, 6.0, 8.0, 24.0, 32.0 and 48.0 hours. A standard curve was established within a suitable range according to the sample concentration, and AB SCIEX API4000 LC-MS/MS was used to determine the concentration of the test compounds in the plasma sample in the MRM mode. According to the drug concentration-time curve, the WinNonLin 6.3 software non-compartmental model method was used to calculate the pharmacokinetic parameters.
- Results:
Table 4 Pharmacokinetic data of the compounds of the present invention in Beagle dogs Test compounds Tmax (h) Cmax (ng/mL) AUCINF (h∗ng/mL) T1/2 (h) CS-3150 2.33 1580 45600 20.3 Example 2 3.33 4690 145000 25.3 - Experimental conclusion: It can be seen from the data in Table 4 that the compounds of the present invention have better in vivo pharmacokinetic properties. For example, compared with the control compound CS-3150, the compound of Example 2 shows higher exposure, blood concentration and long half-life in beagle dogs.
- Three female cynomolgus monkeys of 3.0-3.5 kg were taken and orally administered with the test compound at a dosage of 3 mg/kg; after the administration, blood was collected at the time points of 0.083, 0.25, 0.5, 1, 2, 4, 6, 8, 24, 32 and 48 hours. A standard curve was established within an appropriate range based on the sample concentration, and AB SCIEX API 5000 LC-MS/MS was used to determine the concentration of the test compounds in the plasma sample in the MRM mode. According to the drug concentration-time curve, WinNnonlin 6.3 software non-compartmental model method was used to calculate the pharmacokinetic parameters.
- Results:
Table 5 Pharmacokinetic data of the compounds of the present invention in cynomolgus monkeys Test compounds Tmax (h) Cmax (ng/ml) AUCINF (h∗ng/ml) T1/2 (h) CS-3150 1.67 741 8990 9.63 Example 2 5.3 1040 22000 13 - Conclusion: The compounds of the present invention have good pharmacokinetic properties in cynomolgus monkeys. Specifically, compared to the control compound CS-3150, the compound of Example 2 has more excellent pharmacokinetic properties, such as higher exposure, blood concentration and bioavailability.
- Preparation of the test compound solution: The test compound was dissolved in dimethyl sulfoxide to obtain a 10 mg/mL solution, and then diluted with dimethyl sulfoxide in multiples of 2.15 times into solutions of different concentrations.
- Balb/c 3T3 cells were seeded on 96-well culture plates. After 24 hours of culture, the culture medium was discarded, different concentrations of test compounds or balanced salts (HBSS) solution containing positive control substance (chlorpromazine hydrochloride, CPZ) and vehicle control substance were added. Two culture plates of each concentration of the test compound and the positive control substance are a light (+UV) plate and a non-light (-UV) plate, respectively. After incubating for 1 hour, the light plate was placed under UVA with a light intensity of about 1.7 mw/cm2 until the light dose reached 5.0 J/cm2. The non-light plate was placed at room temperature and protected from light for the same time. After the light was over, the culture medium was replaced with fresh one and continuously cultured for 18-22 hours. About 3 hours before the culture was complete, the culture medium was replaced with a medium containing neutral red and serum-free. After incubation, neutral red eluent was added, the absorbance value (OD540) of each well at 540 nm was measured after shaking. The cell 50% inhibitory concentration (IC50), light stimulating factor (PIF) and/or average light effect (MPE) were calculated. The phototoxicity of the compound was determined according to the following criteria: PIF> 5 is judged as positive for phototoxicity; 5> PIF> 2 is judged as possible phototoxicity; 2> PIF is judged as no phototoxicity.
Table 6 Test results of in vitro 3T3 cell neutral red uptake phototoxicity of the compounds of the present invention Test sample/ Control IC50(µg/mL) PIF MPE Phototoxicity IC50 (-UV ) IC50 (+UV ) Example 2 63.815 49.565 1.289 -0.044 - CPZ 36.695 0.982 37.38 0.368 + 1 - Conclusion: The results of the in vitro phototoxicity test of the compound of Example 2 are shown in Table 6. It can be seen from the test results that the compound of Example 2 of the present invention has no in vitro phototoxicity. That is, the compound of Example 2 has low toxicity, high safety and better druggability.
- Reference throughout this specification to "an embodiment," "some embodiments," "one embodiment", "another example," "an example," "a specific example," or "some examples," means that a particular feature, structure, material, or characteristic described in connection with the embodiment or example is included in at least one embodiment or example of the present disclosure. Thus, the appearances of the above terms throughout this specification are not necessarily referring to the same embodiment or example of the present disclosure. Furthermore, the particular features, structures, materials, or characteristics may be combined in any suitable manner in one or more embodiments or examples. In addition, those skilled in the art can integrate and combine different embodiments, examples or the features of them as long as they are not contradictory to one another.
- Although explanatory embodiments have been shown and described, it would be appreciated by those skilled in the art that the above embodiments cannot be construed to limit the present disclosure, and changes, alternatives, and modifications can be made in the embodiments without departing from spirit, principles and scope of the present disclosure.
Claims (12)
- A compound having Formula (I) or a stereoisomer, a geometric isomer, a tautomer, an atropisomer, an N-oxide, a hydrate, a solvate, a metabolite, an ester, a pharmaceutically acceptable salt or a prodrug thereof,wherein, R1 is C1-6 alkyl, C3-6 cycloalkyl, C6-10 aryl, 3-6 membered heterocyclyl or 5-10 membered heteroaryl, wherein, the C1-6 alkyl, C3-6 cycloalkyl, C6-10 aryl, 3-6 membered heterocyclyl and 5-10 membered heteroaryl are independently and optionally substituted with 1, 2, 3 or 4 Ra;each Ra is independently D, F, Cl, Br, OH, NH2, SH, CN, NO2, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C1-6 haloalkyl, C3-6 cycloalkyl, C6-10 aryl, 3-6 membered heterocyclyl or 5-10 membered heteroaryl; wherein, the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C1-6 haloalkyl, C3-6 cycloalkyl, C6-10 aryl, 3-6 membered heterocyclyl or 5-10 membered heteroaryl is independently unsubstituted or substituted with 1, 2, 3 or 4 substituents selected from D, F, Cl, Br, OH, NH2, SH, CN, NO2, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy and C1-6 haloalkyl;each of R2a, R2b, R2c, R2d and R2e is independently H, D, F, Cl, Br, OH, NH2, SH, CN, NO2, -C(=O)C1-6 alkyl, -C(=O)OC1-6 alkyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C1-6 alkylamino , C3-6 cycloalkyl, C6-10 aryl, 3-6 membered heterocyclyl or 5-10 membered heteroaryl;each of R2 and R3 is independently H, D, F, Cl, Br, OH, NH2, SH, CN, NO2, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl or C1-6 haloalkyl;each of R4, R5, R6 and R7 is independently H, D, F, Cl, Br, OH, NH2, SH, CN, NO2, -C(=O)C1-6 alkyl, -C(=O)OC1-6 alkyl, -S-C1-6 alkyl, -S(=O)C1-6 alkyl, -S(=O)2C1-6 alkyl, -S(=O)2NRbRc, -S(=O)2OC1-6 alkyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C1-6 alkylamino, C3-6 cycloalkyl, C6-10 aryl, 3-6 membered heterocyclyl or 5-10 membered heteroaryl; orR5 and R6 together with the carbon atom to which they are attached, form a C3-6 carbocyclic ring, a C6-10 aromatic ring, a 3-6 membered heterocyclic ring or a 5-10 membered heteroaromatic ring, wherein each of the C3-6 carbocyclic ring, C6-10 aromatic ring, 3-6 membered heterocyclic ring and the 5-10 membered heteroaromatic ring is independently unsubstituted or substituted with 1, 2, 3, 4 or 5 substituents selected from =O, D, F, Cl, Br, OH, NH2, SH, CN, NO2, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy and C1-6 alkylamino;each of R8, Rb and Rc is independently H, D, C1-6 alkyl or C1-6 haloalkyl.
- The compound according to claim 1, wherein, each of R2 and R3 is independently H, D, F, Cl, Br, OH, NH2, SH, CN, NO2, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl or difluoromethyl;each of R4, R5, R6 and R7 is independently H, D, F, Cl, Br, OH, NH2, SH, CN, NO2, -C(=O)CH3, -C(=O)OCH3, -S-CH3, -S(=O)CH3, -S(=O)2CH3, -S(=O)2CH2CH3, -S(=O)2NRbRc, -S(=O)2OCH3, methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, vinyl, ethynyl, methoxy, ethoxy, isopropoxy, tert-butoxy, trifluoromethyl, difluoromethyl, monofluoromethyl, 2,2-difluoroethyl, trifluoromethoxy, methylamino, dimethylamino, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, oxiranyl, azetidinyl, oxetanyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, morpholinyl, pyrrolyl, pyridyl, pyrimidinyl or quinolinyl; orR5 and R6 together with the carbon atom to which they are attached, form cyclobutene, cyclopentene, cyclohexene, benzene, dihydrofuran, dihydrothiazole, dihydroimidazole, dihydropyrazole, dihydrooxazole, dihydropyrrole, tetrahydropyridine, dihydro-1,4-oxazine, pyrrole, pyridine, pyrimidine or quinoline, wherein each of the cyclobutene, cyclopentene, cyclohexene, benzene, dihydrofuran, dihydrothiazole, dihydroimidazole, dihydropyrazole, dihydrooxazole, dihydropyrrole, tetrahydropyridine, dihydro-1,4-oxazine, pyrrole, pyridine, pyrimidine and quinoline is independently unsubstituted or substituted with 1, 2, 3, 4 or 5 substituents selected from =O, D, F, Cl, Br, OH, NH2, SH, CN, NO2, methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, vinyl, ethynyl, methoxy, ethoxy, isopropoxy, tert-butoxy, trifluoromethyl, difluoromethyl, monofluoromethyl, 2,2-difluoroethyl, trifluoromethoxy, methylamino and dimethylamino;each of R8, Rb and Rc is independently H, D, methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, trifluoromethyl, difluoromethyl, monofluoromethyl or 2,2-difluoroethyl.
- The compound according to any one of claims 1-3, wherein, each of R2a, R2b, R2c, R2d and R2e is independently H, D, F, Cl, Br, OH, NH2, SH, CN, NO2,-C(=O)CH3, -C(=O)OCH3, methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, vinyl, ethynyl, methoxy, ethoxy, isopropoxy, tert-butoxy, trifluoromethyl, difluoromethyl, monofluoromethyl, 2,2-difluoroethyl, trifluoromethoxy, methylamino, dimethylamino, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, oxiranyl, azetidinyl, oxetanyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, morpholinyl, pyrrolyl, pyridyl, pyrimidinyl or quinolinyl.
- The compound according to any one of claims 1-5, wherein R1 is C1-4 alkyl, C3-6 cycloalkyl, phenyl, 3-6 membered heterocyclyl or 5-6 membered heteroaryl, wherein the C1-4 alkyl, C3-6 cycloalkyl, phenyl, 3-6 membered heterocyclyl and 5-6 membered heteroaryl are independently and optionally substituted by 1, 2, 3 or 4 Ra;
each Ra is independently D, F, Cl, Br, OH, NH2, SH, CN, NO2, methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, vinyl, ethynyl, methoxy, ethoxy, isopropoxy, tert-butoxy, trifluoromethyl, difluoromethyl, monofluoromethyl, 2,2-difluoroethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, oxiranyl, azetidinyl, oxetanyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, morpholinyl, pyrrolyl, pyridyl, pyrimidinyl or quinolinyl; wherein the methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, vinyl, ethynyl, methoxy, ethoxy, isopropoxy, tert-butoxy, difluoromethyl, monofluoromethyl, 2,2-difluoroethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, oxiranyl, azetidinyl, oxetanyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, morpholinyl, pyrrolyl, pyridyl, pyrimidinyl and quinolinyl are independently unsubstituted or substituted with 1, 2, 3 or 4 substituents selected from D, F, Cl, Br, OH, NH2, SH, CN, NO2, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C1-4 alkoxy and C1-4 haloalkyl. - The compound according to any one of claims 1-6, wherein R1 is methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, oxiranyl, azetidinyl, oxetanyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, morpholinyl, pyrrolyl, pyridyl or pyrimidinyl, wherein the methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, oxiranyl, azetidinyl, oxetanyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, morpholinyl, pyrrolyl, pyridyl and pyrimidinyl are independently and optionally substituted by 1, 2, 3 or 4 Ra;
each Ra is independently D, F, Cl, Br, OH, NH2, SH, CN, NO2, methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, vinyl, ethynyl, methoxy, ethoxy, isopropoxy, tert-butoxy, trifluoromethyl, difluoromethyl, monofluoromethyl, 2,2-difluoroethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, oxiranyl, azetidinyl, oxetanyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, morpholinyl, pyrrolyl, pyridyl, pyrimidinyl or quinolinyl; wherein the methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, vinyl, ethynyl, methoxy, ethoxy, isopropoxy, tert-butoxy, difluoromethyl, monofluoromethyl, 2,2-difluoroethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, oxiranyl, azetidinyl, oxetanyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, morpholinyl, pyrrolyl, pyridyl, pyrimidinyl and quinolinyl are independently unsubstituted or substituted with 1, 2, 3 or 4 substituents selected from D, F, Cl, Br, OH, NH2, SH, CN, NO2, methyl, ethyl, n-propyl, isopropyl, C2-4 alkenyl, C2-4 alkynyl, methoxy, ethoxy, isopropoxy, trifluoromethyl, difluoromethyl, monofluoromethyl and 2,2-difluoroethyl. - A pharmaceutical composition comprising the compound of any one of claims 1-8; optionally, the pharmaceutical composition further comprises at least one of pharmaceutically acceptable carriers, excipients, diluents, adjuvants and vehicles.
- The pharmaceutical composition according to claim 9, further comprising one or more other active ingredients, wherein the other active ingredient is an ACE inhibitor, a renin inhibitor, an angiotensin II receptor antagonist, a β-receptor blocker, acetylsalicylic acid, a diuretic, a calcium antagonist, a statin, a digitalis derivative, a calcium sensitizer, a nitrate or an antithrombotic agent.
- Use of the compound of any one of claims 1-8 or the pharmaceutical composition of any one of claims 9-10 in the manufacture of a medicament for treating, preventing or alleviating the following disease in patients: hyperaldosteronism, hypertension, chronic heart failure, sequelae of myocardial infarction, liver cirrhosis, non-alcoholic steatohepatitis, chronic kidney disease, diabetic nephropathy, renal failure, fibrosis or stroke.
- Use of the compound of any one of claims 1-8 or the pharmaceutical composition of any one of claims 9-10 in the manufacture of a medicament, wherein the medicament is used as a mineralocorticoid receptor antagonist.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911021710 | 2019-10-25 | ||
PCT/CN2020/122388 WO2021078135A1 (en) | 2019-10-25 | 2020-10-21 | Pyrrole amide compound and use thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3950674A1 true EP3950674A1 (en) | 2022-02-09 |
EP3950674A4 EP3950674A4 (en) | 2022-12-28 |
Family
ID=75541759
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP20878312.6A Pending EP3950674A4 (en) | 2019-10-25 | 2020-10-21 | Pyrrole amide compound and use thereof |
Country Status (8)
Country | Link |
---|---|
US (1) | US20220211665A1 (en) |
EP (1) | EP3950674A4 (en) |
JP (1) | JP2022553474A (en) |
KR (1) | KR20220088375A (en) |
CN (2) | CN114702427A (en) |
AU (1) | AU2020371836A1 (en) |
CA (1) | CA3136989A1 (en) |
WO (1) | WO2021078135A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4317133A1 (en) | 2021-03-30 | 2024-02-07 | Sunshine Lake Pharma Co., Ltd. | Crystalline form of pyrrole amide compound, preparation method therefor and use thereof |
AU2022264993A1 (en) * | 2021-04-26 | 2023-11-09 | Sunshine Lake Pharma Co., Ltd. | Preparation method for pyrrole amide compound |
CN115784961A (en) * | 2021-09-10 | 2023-03-14 | 上海鼎雅药物化学科技有限公司 | Synthesis method of oxacillin and intermediate thereof |
WO2023134677A1 (en) * | 2022-01-14 | 2023-07-20 | 广东东阳光药业有限公司 | Method for preparing pyrrole compound and intermediate thereof |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19834047A1 (en) | 1998-07-29 | 2000-02-03 | Bayer Ag | Substituted pyrazole derivatives |
DE19943634A1 (en) | 1999-09-13 | 2001-04-12 | Bayer Ag | Novel dicarboxylic acid derivatives with pharmaceutical properties |
DE19943636A1 (en) | 1999-09-13 | 2001-03-15 | Bayer Ag | Novel dicarboxylic acid derivatives with pharmaceutical properties |
DE19943639A1 (en) | 1999-09-13 | 2001-03-15 | Bayer Ag | Dicarboxylic acid derivatives with novel pharmaceutical properties |
AR031176A1 (en) | 2000-11-22 | 2003-09-10 | Bayer Ag | NEW DERIVATIVES OF PIRAZOLPIRIDINA SUBSTITUTED WITH PIRIDINE |
DE10110749A1 (en) | 2001-03-07 | 2002-09-12 | Bayer Ag | Substituted aminodicarboxylic acid derivatives |
DE10110750A1 (en) | 2001-03-07 | 2002-09-12 | Bayer Ag | Novel aminodicarboxylic acid derivatives with pharmaceutical properties |
CN101006052B (en) * | 2004-07-30 | 2013-11-06 | 埃克塞利希斯股份有限公司 | Pyrrole derivatives as pharmaceutical agents |
CA2573426C (en) | 2004-07-30 | 2015-11-17 | Exelixis, Inc. | Pyrrole derivatives as pharmaceutical agents |
WO2006076202A1 (en) * | 2005-01-10 | 2006-07-20 | Exelixis, Inc. | Heterocyclic carboxamide compounds as steroid nuclear receptors ligands |
PL2133330T3 (en) | 2007-04-09 | 2014-06-30 | Daiichi Sankyo Co Ltd | Atropisomer of pyrrole derivative |
WO2010042622A1 (en) * | 2008-10-08 | 2010-04-15 | Exelixis, Inc. | Atropisomers of (hydroxyalkyl) pyrrole derivatives |
JP5971657B2 (en) * | 2011-04-20 | 2016-08-17 | 塩野義製薬株式会社 | Aromatic heterocyclic derivatives having TRPV4 inhibitory activity |
-
2020
- 2020-10-21 CN CN202210162322.0A patent/CN114702427A/en active Pending
- 2020-10-21 US US17/605,934 patent/US20220211665A1/en active Pending
- 2020-10-21 EP EP20878312.6A patent/EP3950674A4/en active Pending
- 2020-10-21 KR KR1020217038554A patent/KR20220088375A/en unknown
- 2020-10-21 WO PCT/CN2020/122388 patent/WO2021078135A1/en unknown
- 2020-10-21 CN CN202011130931.5A patent/CN112707854B/en active Active
- 2020-10-21 JP JP2021562143A patent/JP2022553474A/en active Pending
- 2020-10-21 AU AU2020371836A patent/AU2020371836A1/en active Pending
- 2020-10-21 CA CA3136989A patent/CA3136989A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3950674A4 (en) | 2022-12-28 |
JP2022553474A (en) | 2022-12-23 |
US20220211665A1 (en) | 2022-07-07 |
TW202128618A (en) | 2021-08-01 |
CA3136989A1 (en) | 2021-04-29 |
CN112707854A (en) | 2021-04-27 |
KR20220088375A (en) | 2022-06-27 |
AU2020371836A1 (en) | 2021-11-11 |
CN112707854B (en) | 2022-03-15 |
CN114702427A (en) | 2022-07-05 |
WO2021078135A1 (en) | 2021-04-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110511219B (en) | Phenyl-substituted dihydronaphthyridine compound and application thereof | |
EP3950674A1 (en) | Pyrrole amide compound and use thereof | |
ES2963590T3 (en) | EZH2 inhibitor and its use | |
TW201639828A (en) | 4H-pyrrolo[3,2-c]pyridin-4-one derivatives | |
US10604502B2 (en) | Substituted 5-cyanoindole compounds and uses thereof | |
WO2018086446A1 (en) | Substituted quinazoline compound having blood-brain barrier penetration capability | |
JP2012526107A (en) | Phenoxymethyl heterocyclic compound | |
EP3590941A1 (en) | Urea-substituted aromatic ring-linked dioxane-quinazoline and -linked dioxane-quinoline compounds, preparation method therefor and use thereof | |
TW202024096A (en) | Highly active sting protein agonist | |
ES2927529T3 (en) | condensed heterocyclic compound | |
AU2020336975A1 (en) | Perk inhibiting pyrrolopyrimidine compounds | |
KR102615821B1 (en) | Fluorine-substituted indazole compounds and uses thereof | |
CN109721536B (en) | Phenyl-substituted fused tricyclic compounds and application thereof | |
CN109721596B (en) | Phenyl-substituted dihydropyridines and their use | |
TWI833046B (en) | Pyrrolamide compounds and their uses | |
WO2019196622A1 (en) | 5-substituted difluoropiperidine compound capable of passing through blood-brain barrier | |
EP2448584A1 (en) | Substituted 4-hydroxypyrimidine-5-carboxamides | |
WO2024022481A1 (en) | Phenyl-substituted dihydronaphthyridine compounds, and preparation and use thereof | |
CN112794848B (en) | N-ring-aminopyrimidine derivatives and use thereof | |
WO2016153394A1 (en) | Use of novel chemical compounds (variants) as nuak1 kinase inhibitors for treating oncological diseases | |
TW202333697A (en) | Wnt pathway inhibitor compound | |
EA045207B1 (en) | COMPOUNDS INHIBITING RIP1, AS WELL AS METHODS OF THEIR PREPARATION AND APPLICATION |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20211028 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: ZENG, JUNNAN Inventor name: DING, XIAOHONG Inventor name: HAN, WEI Inventor name: CHI, BO Inventor name: ZHANG, YINGJUN Inventor name: ZHANG, YINGXUN Inventor name: ZUO, YINGLIN Inventor name: WANG, XIAOJUN Inventor name: WANG, JIANCHENG |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R079 Free format text: PREVIOUS MAIN CLASS: C07D0207333000 Ipc: C07D0207340000 |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20221125 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 1/16 20060101ALI20221121BHEP Ipc: A61K 45/06 20060101ALI20221121BHEP Ipc: A61K 31/428 20060101ALI20221121BHEP Ipc: A61K 31/4025 20060101ALI20221121BHEP Ipc: A61K 31/40 20060101ALI20221121BHEP Ipc: C07D 417/12 20060101ALI20221121BHEP Ipc: C07D 405/06 20060101ALI20221121BHEP Ipc: C07D 405/04 20060101ALI20221121BHEP Ipc: C07D 401/04 20060101ALI20221121BHEP Ipc: C07D 207/34 20060101AFI20221121BHEP |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20231228 |